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ABSTRACT
Glasgow suffers one of the highest prevalence rates of congenital 
neural tube defects in the world. There have been reports of a 
long-term decline in the prevalence of neural tube defects 
although the reasons for it are unclear. Anencephaly is always 
fatal while, even with active treatment, spina bifida is 
associated with high rates of early infant mortality and a high 
degree of physical and mental impairment in the survivors. 
Antenatal screening followed by induced abortion is the only 
available means of avoiding such births.
The purpose of the study was to evaluate the effectiveness of 
antenatal screening for neural tube defects in the context of 
changing epidemiological patterns and the growing use of 
ultrasound. The impact of screening on the population frequency 
of the defect during 1976-1986 was investigated. The data were 
obtained from several sources including the Glasgow Register of 
Congenital Malformations and the Department of Medical Genetics 
at the Royal Hospital for Sick Children, Yorkhill, Glasgow.
There was a statistically significant decline in both the birth 
and pregnancy prevalence of anencephaly and a statistically 
significant decline in birth prevalence of spina bifida over the 
study period. Antenatal screening made a considerable impact on 
both anencephaly and spina bifida birth prevalence particularly 
the former.
The effectiveness of antenatal screening was influenced by three 
factors: the proportion of affected pregnancies screened; the
proportion of affected pregnancies detected and the proportion of 
affected pregnancies terminated when detected. The interaction 
of these factors can be expressed arithmetically.
The proportion of pregnancies screened was higher in Glasgow than 
in the west of Scotland as a whole. A high proportion of those 
not screened were women under twenty years of age, multipara and 
those from lower social class. The effectiveness of antenatal 
screening improved with the combined use of maternal serum AFP 
and ultrasound. The combined screening approach had a high 
sensitivity, specificity and efficacy.
In conclusion, antenatal screening for neural tube defects has 
contributed to the reduction of both anencephaly and spina bifida 
birth prevalence but there is substantial scope for improving the 
efficiency and consequently the effectiveness of screening for 
spina bifida. Until primary prevention is possible, antenatal 
screening for neural tube defects in Glasgow will continue to 
play a major role in avoiding affected births.
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DEFINITIONS*
EPIDEMIOLOGY: The study of the distribution and determinants of
health-related states or events in a specified population, and 
the application of this study to the control of health problems
CONGENITAL MALFORMATION: An abnormality of structure
attributable to faulty development (Leek et al. 1968)
INCIDENCE OF A CONGENITAL MALFORMATION: The proportion of
embryos developing the malformation during a specified period of 
time. (In practice this figure is not usually possible to
calculate)
PREVALENCE OF A CONGENITAL MALFORMATION: The proportion of
births (live and still, delivered from 28 weeks gestation) with 
the malformation during a specified period of time. (Some 
studies in the literature refer to this as an "Incidence Rate".)
The term "prevalence" of a congenital malformation is shorthand 
for "prevalence at birth" (Pharoah 1990) usually defined as the 
number of instances of the disorder per 1000 total births. The 
difference between the true incidence of a defect and its 
prevalence is proportional to the (usually unknown) number of
fetuses with the defect which are aborted.
* Definitions from Last, 1983 - unless stated otherwise.
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ASCERTAINMENT OF A CONGENITAL MALFORMATION: The method employed
to identify or count all affected births occurring in a defined 
population during a given time period. One of the commonest 
methods of ascertainment is by means of a register.
REGISTER: A written record or official list regularly kept. It
is usually designed to collect information on one specific topic, 
in contrast to master palient files and record linkage systems, 
which provide the means of collecting, storing and retrieving 
information on many topics not predetermined or limited in scope.
REGISTRY: Place where a register is kept
EVALUATION: Systematic and scientific process of determining the
extent to which an action or set of actions were successful in
the achievement of predetermined objectives
SCREENING: The presumptive identification of unrecognised
disease or defect by the application of tests, examinations or 
other procedures which can be applied rapidly. Screening tests 
sort out apparently well persons who probably have a disease from 
those who probably do not. A screening test is not intended to 
be diagnostic. Persons with positive or suspicious findings must 
be referred to their physicians for diagnosis and necessary 
treatment.
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Screening is an initial examination only and positive responders 
require a second diagnostic examination. The initiative for 
screening usually comes from the investigator or the person or 
agency providing care rather than from a patient with a 
complaint.
There are different types of medical screening each with its own 
aim:
Mass screening simply means the screening of whole populations 
Multiple or multiphasic screening involves the use of a variety 
of screening tests on the same occasion
Prescriptive screening has as its aim the early detection in 
presumptively healthy individuals of disease that can be
controlled better if detected early in its natural history.
SENSITIVITY: Is the proportion of truly diseased persons in the
screened population who are identified as diseased by the
screening test. Sensitivity is a measure of the probability of 
correctly diagnosing a case or the probability that any given 
case will be identified by the test (Syn : true positive rate)
SPECIFICITY: Is the proportion of truly non-diseased persons who
are so identified by the screening test. It is a measure of the
probability of correctly identifying a non-diseased person with a 
screening test. (Syn : true negative rate)
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FALSE POSITIVE: Positive test result in a subject who does not
possess the attribute for which the test is conducted. The 
labelling of a healthy person as diseased when screening in the 
detection of disease.
FALSE NEGATIVE: Negative test result in a subject who possesses
the attribute for which the test is conducted. The labelling of 
a diseased person as healthy when screening in the detection of 
disease.
Predictive value of positive test: the proportion of true
positive (i.e. diseased individuals) among all those who have 
positive tests. (The probability that a person with a positive 
test does have the disease.)
Predictive value of negative test: the proportion of non-
diseased individuals among all those who have negative test 
result. (The probability that a person with a negative test does 
not have the disease.)
EFFICIENCY: The end results achieved in relation to the effort
expended in terms of money, resources and time.
EFFECTIVENESS: The extent to which a specific intervention,
procedure, regimen, or service, when deployed in the field, does 
what it is intended to do for a defined population.
EFFICACY OF ANTENATAL SCREENING: The proportion of those with
the disorder in the study population detected and terminated as a 
consequence of screening procedure. (Roberts et al. 1983.)
PARITY: The number of full term infants previously born to a
woman, excluding miscarriages or abortions in early pregnancy, 
but including still birth
SOCIAL CLASS: A stratum in society composed of individuals and
families of equal standing.
Social class based on Classification of the Registrar General- 
Social Class I: Higher professional and administrative
occupation
Social Class II: Employees in industry and retail
trades
the "lesser" professions (intermediate 
■ j, occupations)
Social Class III: Skilled occupation
Social Class IV: Partly skilled occupation
Social Class V: Unskilled occupation
(Office of Population Censuses and Surveys, 1980)
SECULAR TREND: Changes over a long period of time, generally
years or decades.
COST-BENEFIT ANALYSIS: An economic analysis in which the costs 
of medical care and the loss of net earnings due to death or
21
disability are considered. The general rule for the allocation 
of funds in a cost-benefit analysis is that the ratio of marginal 
benefit (the benefit of preventing an additional case) to 
marginal cost (the cost of preventing an additional case) should 
be equal to or greater than one.
COST-EFFECTIVENESS ANALYSIS: This form of analysis seeks to
determine the cost and effectiveness of an activity or to compare 
similar alternative activities to determine the relative degree 
to which they will obtain the desired objectives or outcomes. 
The preferred action or alternative is one that requires the 
least cost to produce a given level of effectiveness or provides 
the greatest effectiveness for a given level of cost.
SECTION I: INTRODUCTION
23
SECTION I: INTRODUCTION
1.1 HISTORICAL NOTE
Ferembach (1963) reported a prehistoric human skeleton with spina 
bifida occulta excavated in North america. Brothwell and Power 
(1968) found prehistoric skeletons with spina bifida cystica from 
the Roman, Anglo-Saxon and Medieval periods in England.
The teratological record_s of chaldean clay tablets covered with 
cuneiform script, excavated near the River Tigris in the 
nineteenth century, contain descriptions of several types of 
human malformation. Ballantyne (1894) suggested that these 
tablets were a good source of information for congenital 
malformations in the past.
The concept of congenital malformations, including anencephaly 
and spina bifida, has evolved throughout history. From pre­
history to the end of the nineteenth century, the term monsters 
(derived from a Latin verb moneo meaning to warn) was used to 
include all types of congenital malformations. Congenital 
malformations were regarded as an indication of divine warning to 
the parents or society and believed to be a result of 
supernatural intervention. (Warkany 1971)
In medieval Christian societies it was thought that supernatural 
anger at the community frequently led to abnormal infants who 
were regarded as portents of major events.
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Many cultures believed that unions between members of different 
species could produce monstrous offspring, this being linked with 
the centaur of Greek mythology and the Hindu belief in 
transmigration of the soul from man to animal and vice versa. 
The theory of Hippocrates and Aristotle, that the narrowing of 
the womb and excessive pressure are causes of abnormalities, are 
still popularly accepted as explanations of postural deformities. 
The wide acceptance of "maternal impression" as a cause of 
malformed births, due to similarities in appearance between 
malformed infants and real and imaginary animals, gave rise to 
the belief that it was dangerous for a pregnant woman to look at 
monkeys for fear of producing a similar monstrous infant. (Kenen 
1980)
Infanticide was widespread in many ancient cultures. Deformed 
infants were killed as were many normal female children in times 
of hardship. An especially brutal infanticidal eugenic policy 
was that of the Spartans who threw rejected offspring into a deep 
chasm on Mount Taygetus. The Romans drowned unwanted infants in 
the River Tiber. Infanticide was also widespread throughout 
medieval Europe. Christian societies in England during the 
fifteenth century practised infanticide, as is indicated by the 
large excess of male children in parish records of medieval 
England (Russell, 1948). At the end of the seventeenth century, 
London was a centre for exhibiting every variety of unusual human 
form, displayed like circus animals.
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Subsequently, anatomists, surgeons and pathologists began to 
document their experiences of such conditions. In Amsterdam,
Nicholase Tulp (1637), a successful surgeon, gave the first 
detailed description of spina bifida (Brocklehurst, 1976).
The second era of development in teratology came during the late 
nineteenth and early twentieth centuries with the publication of 
Darwin’s "The Origin of the Species" (1859). He argued that 
selective forces produced changes over many generations. This 
led to. renewed interest in congenital malformations in terms of 
their biological importance as a matter of natural variation. 
The science of genetics started to develop during this period and 
some scientists encouraged the more intelligent and successful 
members of society to have large families for eugenic reasons.
During the third era of development (from the middle of the 
twentieth century) it was discovered that specific environmental
factors predisposed to congenital defects (including x-rays and
vitamin deficiencies). During this period experimental work and 
human observational work has gone hand in hand. The dramatic 
change in the pattern of disease, with decreases in the frequency 
and impact of infectious disease as causes of infant deaths, has 
been accompanied by advances in genetics and experimental
teratology. All these disciplines have investigated congenital 
abnormalities which are becoming relatively more important 
clinically with the passage of time. The advances in genetic 
understanding of the most common defects has led to the
development of the concept of multifactori#l inheritance. Most 
congenital defects are probably due to a combination of genetic 
and environmental factors.
Toward the end of the 1970's the fourth era was initiated by 
discovery of methods for examining and analysing maternal serum 
and amniotic fluid to detect and diagnose a number of congenital 
abnormalities prenatally. This is linked with the use of induced 
abortion of the abnormal fetus as a legally and ethically 
accepted procedure in many countries.
1.2 EMBRYOLOGY, ANATOMY AND CLASSIFICATION 
EMBRYOLOGY
Normally the brain and spinal cord develop from the neural plate, 
a thickening of the outer germ layer, the ectoderm of the 
embryonic central nervous system. This runs the length of the 
embryo in the midline dorsally, and rapidly forms a groove called 
the neural groove. The groove deepens and is bounded on either 
side by the neural folds. The edges of the neural folds fuse 
with each other to form the neural tube, when the embryo has six
to seven somites at about twenty-two days.
The fusion commences in the cervical region and extends in both 
cranial and caudal directions leaving temporary canals or 
neuropores connecting the central neural canal to the amniotic 
cavity which is the last point to close. This process is 
normally completed by twenty-six days of gestation which is 
approximately four weeks after conception (Shepard, 1976).
The neural tube consists of a single layer of cells which 
proliferate at the cephalic end to form the various structures of 
the brain, while the remaining cells of the tube proliferate to 
form ependyma, neurones, glial cells and pyramidal cells. The 
mesoderm surrounding the tube segments into somites which develop 
into vertebral bodies and arches. The meninges, the pia, 
arachnoid and dura are also formed from the mesenchyme at the
time of separation of the neural tube from the ectoderm. The
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lesions of anencephalus and spina bifida are believed to be due 
to the failure of some part of the foregoing process.
Marin-Paddilla (1966) suggested that vitamin A excess in hamsters 
acts primarily by retarding mesodermal development and points out 
that the deformity produced is similar to that seen in humans 
with various degrees of neural tube defects. Wilson, Jordan and 
Brent (1954) concluded that radiation-induced anencephalus is due 
to rupture of a necrotic area of the closed tube.
Kallen (1968) and Warkany (1971) agree that the pathogenesis of 
neural tube defects is due to a disturbance of the neural- 
mesodermal interaction and that the cause of this is unknown.
Vogel and McClenahan (1952) and Vogel (1961) demonstrated 
anomalous vasculature in anencephalic specimens and suggested 
that the cerebral vessels never become connected to the systemic 
circulation, preventing adequate nutrition to the cranial neural 
tissue resulting in anencephaly.
Stevenson et al (1987) demonstrated abnormalities of the arterial 
supply to the region of spine defect. Because embryologically 
these arteries develop prior to closure of the neural tube, he 
suggested that vascular disturbance limited nutrition to the 
developing neural tissue and supporting structures, preventing 
appropriate growth and closure.
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In summary, although conflicting hypotheses have been proposed, 
there is a general agreement among embryologists that the key to 
the pathogenesis of N.T.D lies in the disturbance of the neural- 
mesodermal interaction.
ANATOMY
Anencephaly: failure x>f fusion of the neural tube at the
cephalic end prevents development of the fore brain and as a 
consequence the vault of the skull does not develop leading to
anencephaly (Morison, 1970).
In anencephaly the fore brain is replaced by a mass of 
haemorrhagic fibrovascular tissue containing some neural elements 
called cerebrovasculosa (Warkany, 1971). The brain stem is
usually present as eyes and optic nerves which end blindly at
the base of the skull, but the mid-brain and cerebellum may be
normally developed or absent.
There is an abnormality in the shape of the bones at the base of 
the skull particularly the sphenoid and petrous temporal bones. 
The cranial vault bones, the parietal frontal, squamous temporal
and the occipital are present but rudimentary.
The facial bones are normal but look deformed because of their
articulation with an abnormal skull base. In anencephalus the
lesion may extend through the cranium and sometimes through the 
cranium and the spine; this is called craniorachischisis which is
rare in humans (Warkany, 1971).
The abnormality is incompatible with life and most infants are 
stillborn, but if the respiratory centre is intact liveborn 
infants may survive for a few days.
Anencephaly may be associated with other abnormalities, the 
commonest being spina bifida (Elwood and Nevin, 1973). Others 
include exomphalos, congenital heart disease, cleft palate and 
urinary tract defects (David and Nixon, 1976). There are other 
conditions leading to herniation of brain tissue through a defect 
in the skull but they are much rarer and should be distinguished 
from anencephaly. They include cranial meningocele,
encephalocele and hydroencephalocele, in which there is a 
herniation of the meninges only, meninges and brain tissue, 
meninges and brain tissue and part of the ventricular system 
respectively.
Anencephaly is usually distinguished from exencephaly and 
iniencephaly.
Exencephaly is an overgrowth of the cerebral hemispheres 
accompanied by normally developing cranial nerves, midbrain and 
hindbrain. The over growing material expands from the cranial 
base, cranial vault being open in the midline and cerebral 
material is evented, the ventricular surface being exposed. 
Iniencephaly: failure of closure of the neural tube in the 
cervical and upper thgracic region.
Spina bifida: Failure of embryonic fusion caudally causes a
dorsal defect in the vertebral arches leading to spina bifida 
which shows considerable variation in severity.
Spina bifida occulta: This is the least serious form of spina
bifida. There is a localised defect in one or more vertebral 
arches due to the failure of fusion of the halves of the 
vertebral arches. The meninges and nervous tissue remain within 
the vertebral canal, with no associated disorders. The only 
external evidence of underlying bony maldevelopment is the 
presence of changes in overlying skin in the form of a dimple, 
patch of hair, pigmentation, a lipoma or a dermoid.
Spina bifida cystica: This occurs when vertebral arches are
deficient and there is external herniation of the meninges and 
nervous tissue. It includes meningocoele (herniation of the 
meninges out of the spinal canal while the cord remains in its 
position) and myelomeningocoele (in which there is a filled 
cystic swelling formed by meninges protruding through a defect in 
the vertebral arches under the skin, the spinal cord and nerve 
roots are carried out into the fundus of the sac). Myelocoeles, 
myelocytocoeles, hydromyelocoeles, syringomyelocoeles and 
localised rachischisis are all essentially the same lesion and 
best regarded as myelocoeles.
In all these lesions vertebral arches are deficient and neural 
plate material spreads out on the surface, sometimes in a shallow
depression, more commonly over a cystic swelling of the meninges 
with some degenerative changes at birth. The lesion is seen as a 
bluish semitransparent membranous sac due to the accumulation of 
cerebrospinal fluid which gives it its cystic nature.
Spina bifida cystica, in which there is skin cover, is called a 
closed defect. When there is no skin cover it is called open or 
aperta.
Hydrocephalus nearly always co-exists with a spina bifida defect, 
due to the Arnold-Chiari malformation (in which the medulla of 
the fourth ventricle and cerebellum are dragged caudally into the 
foramen magnum with consequent obstruction of the cerebro-spinal 
fluid pathway).
As with any other congenital defects there may be multiple 
developmental anomalies, talipes equinovarus, cleft lip or 
palate, cardiac lesions or supernumary digits.
In summary, failure of fusion of the neural tube at the cephalic 
end leads to anencephaly, and at the caudal end to spina bifida. 
Because of the multiplicity of anatomical variants and associated 
defects which can occur, a clear and unambiguous system of 
classification is necessary as a precondition of scientific 
research into these defects.
Classification: There is no universally agreed classification
but the International Classification of Diseases (ninth revision) 
(World Health Organisation, 1977) is widely used for 
classification of anencephaly and spina bifida. Anencephaly with 
spina bifida is most commonly included in the anencephaly group. 
Exencephaly, encephalocele and iniencephaly are separated from 
anencephaly.
Spina bifida includes open and closed cystica defects but does 
not include spina bifida occulta. Any abnormality secondary to 
or associated with spina bifida is classified under spina bifida 
(except for encephalocele).
In summary, 'anencephaly' includes anencephaly with or without 
spina bifida, and excludes exencephaly, iniencephaly and 
encepholocele. 'Spina bifida' includes open and closed cystica 
defects (along with secondary defects such as hydrocephalus) but 
excludes spina bifida occulta.
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1.3 AETIOLOGY AND NATURAL HISTORY 
Aetiology:
In spite of extensive studies of neural tube defects, there is no 
consensus about their causation. Epidemiological studies suggest 
that anencephaly and spina bifida may result either from genetic 
factors, environmental factors or by the combined action of 
genetic and environmental factors, so-called multifactorial 
aetiology. Each of these will be considered in turn.
Genetic Factors:
There is some evidence for the operation of genetic factors in 
the aetiology of neural tube defects. The preponderance in one 
or other sex is a pointer to a genetic cause. The number of 
affected females in the population of neural tube defects has 
been noted to be consistently greater than the number of affected 
males (Carter, 1974; Stone, 1981). The reason for this female 
predominance remains unclear. It could be due to selective 
prenatal loss but this has not been established.
There is a degree of stability of the prevalence rate in certain 
ethnic and racial groups. British and Sikh populations have high 
prevalence rates (up to eight per 1000) of neural tube defects 
(Carter, 1974). Although the rate decreases somewhat after 
migration of these groups to regions of low prevalence, a 
relatively high prevalence rate persists (Carter, 1974; Baird,
1983). Some African populations appear to have a low prevalence 
rate of neural tube defects (e.g one per-1000 in Lagos - Carter,
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1974). This low rate persists even after migration to an area of 
high prevalence such as Great Britain (Carter, 1974).
There is an excess rate of neural tube malformation if the 
parents are related (Carter, David and Laurance, 1968; Carter 
and Evans, 1973a; Leek, 1983). This indicates a polygenic 
determination of neural tube malformation, since consanguinous 
marriage implies a degree of assortive mating leading to a 
predisposition to the malformation (Carter, 1974).
There is a higher concordance rate among monozygotic than 
dizygotic twin pairs (James, 1972; Windham and Sever, 1982). 
This provides strong evidence for a genetic component. There is 
a higher risk (up to 6%) of neural tube defects to siblings of 
affected individuals (Carter and Evans, 1973) than that for the 
general population, although with the recent decline in 
prevalence it is now likely to be only 1-2% in the United States 
(Holmes, Driscoll and Atkins, 1976). The risk to an offspring of 
either affected mother or father is approximately 3% (Carter and 
Evans, 1973a).
It has been suggested that this genetic susceptibility may not be 
specific for neural tube defects but may be reflect a more 
general susceptibility to any defect involving the midline of the 
developing embryo. The planes of fusion of tissue or the midline 
of the embryo may be a developmental field under specific 
chromosomal control (Opitz and Gilbert, 1982). This theory is
supported by studies which have shown an increased risk of 
hydrocephalus (Robertson et al, 1981), tracheo-oesophagel 
dysraphism, cleft lip and palate (Fraser, Czeizel and Hanson, 
1982), diaphragmatic hernia and omphalocele (Czeizel, 1981) in 
families of individuals with neural tube defects. The presence 
of multiple anomalies such as congenital heart disease (Ferguson, 
Rouse and Lockhart, 1983), omphalocele, vertebral fusion defect 
(Jones, Jones and Chernoff, 1982) in individuals with neural tube 
defects is further evidence of a non specific mid-line 
involvement.
Environmental Factors:
While the following studies suggest that environmental factors 
increase the risk of neural tube defects they do not necessarily 
establish an environmental agent as the primary aetiology.
There has been a decline in the prevalence of neural tube defect 
over a time (Macmahon and Yen, 1971; Gwens et al, 1981). Most 
studies now show a fall in prevalence which cannot be attributed 
to prenatal screening (Khyoury, Erickson and James, 1982a; 
Windham and Edmonds, 1982; Stone et al, 1988).
Neural tube defects show a striking geographical variation both 
between and within countries. Neural tube defects are commoner 
in Europe than in Asia or Africa (Leek, 1974).
In the British Isles the prevalence rate is high in the north­
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west and low in the south-east (Carter, 1974). Similar 
variability has also been noted in the United States with high 
rates in the east and low rates in the west (Khoury, Erickson and 
James, 1982a).
In Great Britain infants conceived in March, April or May 
(Carter, 1974) appear to be at highest risk, while in Canada 
September and October conception appear to result in the highest 
rate of neural tube defect (Dallaire et al, 1984). The majority 
of affected children are born to mothers younger than 20 years or 
older than 35 years (Carter and Evans, 1973a; Stone, 1981). Most 
studies show an excess of first born children in the affected 
population (Carter, 1974). Some have shown a higher prevalence 
rate in lower socio economic classes as determined by the 
father's occupation (Carter, 1974; Stone, 1981).
Various dietary factors have been suspected of causing neural 
tube defects in man. Associations have been reported between 
neural tube defects in offspring and excessive tea drinking 
(Fedrick, 1974), and consumption of icecream, white bread loaves, 
canned meat, canned peas and corned beef (Knox, 1972) by the 
mothers during pregnancy. Knox suggested the nitrites and 
nitrates used for preserving canned food may be teratogens.
Penrose (1957) observed that areas in the United Kingdom where 
the prevalence of neural tube defects were the highest were also 
those areas where the drinking water was soft, rather than hard,
and suggested that the presence or absence of certain trace 
elements may be an important causation. Fedrick (1970) and 
Wilson (1971) found no relation between the type of water supply 
and the prevalence of neural tube defects.
Renwick (1972) suggested that the causal agent of neural tube 
defects was an unidentified substance occurring in blighted 
potatoes and that if women avoided ingesting such potatoes they 
would not have neural tube defects in their offspring. Nevin and 
Merret (1975) advised all parents of infants with anencephaly and 
spina bifida born at Belfast hospital from July 1972 onwards to 
avoid potatoes as soon as they decided on another pregnancy. 
They found there is no significant reduction in the incidence of 
neural tube defects in women who avoid potatoes.
Zinc deficiency appeared to be associated with anencephaly in 
Turkey (Cavdar et al, 1980) and in London (Buamah and Russel,
1984). Low plasma zinc may operate at the time of conception and 
during early embryogenesis (Soltan and Jenkins, 1982).
It has been noted that serum and RBC folate are low in mothers of 
children with neural tube defects compared to controls
(Smithells, Sheppard and Schorah, 1976). Trials of supplementing 
high risk mothers with folic acid (Laurence et al, 1981) or 
multivitamins (Smithells et al, 1981; Seller, 1985) have shown 
lower than expected frequency of neural tube defects in their 
offspring. These studies have been compromised, however, by poor
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compliance and unsatisfactory methodology. The role of folic 
acid in neural tube defects remains unsettled.
A study by Yates et al (1987) confirmed that red cell folate is 
depressed in women who have had offspring with neural tube 
defects; since this cannot be entirely attributed to lower 
dietary intake of folate, there, could be an unidentified 
inherited disorder of folate metabolism.
Maternal vitamin B12 levels were found to be low in fetuses with 
neural tube defects (Schorah, Smithells and Scott, 1980).
A significant increase in the risk of neural tube defect has been 
observed among the offspring of women who have had gastric by­
pass operations for morbid obesity (Haddow et al, 1986; Martin et 
al, 1988). These women are at risk of nutritional deficiencies, 
especially for iron, calcium, vitamin B12 and folate (Printer and 
Scott, 1982; Shilling, Gohdes and Hardie, 1984; Amaral et al, 
1985). This provides support for recent studies linking diet and 
neural tube defects (Smithells,. Sheppard and Schorah, 1976) and 
the association between folate and vitamin B12 deficiencies and 
neural tube defects found by Laurence et al (1981).
Parkinson and Tan (1982) found vitamin A concentration of 
amniotic fluid is significantly greater in the presence of a 
fetus with neural tube defect, but suggest that vitamin A should 
not be included in supplements until there is definite evidence
that it is harmless.
Maternal illness has been implicated as a factor in some neural 
tube defects. It was found that febrile illness during the first 
trimester of pregnancy was associated with congenital 
malformation (Miller, Smith and Sheppard, 1978; Lady, Edmonds and 
Erickson, 1980). During pregnancy a silent infection with an 
unknown teratogenic organism may take place, or involve exposure 
not during the affected pregnancy (Kalter and Warkany, 1983).
Diabetic mothers with poorly controlled diabetes mellitus before 
and during early pregnancy are at increased risk of having a 
malformed baby (Miller et al, 1981; Cousins, 1983). The 
mechanism of teratogenesis is unknown; however, altered metabolic 
control with associated hyperglycemia during organogenesis is 
considered causative (Pedersen, Tygstrups and Pedersen, 1964; 
Kalter and Warkany, 1983). -
Some drugs have a potential teratogenic effect. Accutane is used 
for treating severe acne and is isotretinoin, a vitamin A 
analogue. When mothers used this drug in early pregnancy some 
had babies with malformation of the central nervous system and 
other systems (Rosa, 1983; Braun et al, 1984; Lammer et al,
1985). The cause is thought to be a deleterious effect on 
cephalic neural-crest cell activity. Benditin, called Debendox 
in the United Kingdom, which contains anti - histamine was 
often given to pregnant women as an anti-emetic and may cause
neural tube defects (Harron, Griffith and Shank, 1980).
Anti-convulsant drugs such as phenytoin and phenobarbital lead to 
an increased frequency of congenital malformation in epileptic 
women taking such drugs during pregnancies (Montouris, Fenichol 
and McLain, 1979). Also exposure to valproic acid during first 
trimester of pregnancy is reported to be associated with spina 
bifida (Bjerkedal et al,. 1982; Staunton, 1989).
Other possible neural tube teratogens are aminopterin, a powerful 
folic antagonist which sometimes is taken by women to induce 
abortion (Emerson, 1962); antimitotic cancer chemotherapeutic 
agents, such as Methotroxate (Milunsky and Gaynor, 1968) and 
Busulfan (Abramovici, Shaklai and Pinkhas, 1978). Alcohol abuse 
in the first month of pregnancy has been reported in several 
mothers of infants with neural tube defects (Castro-Gago et al,
1984).
Multifactorial Aetiology
The vast majority of neural tube defects occur as isolated 
malformations and are believed to be multifactorial in origin. 
The teratogenic effect is attributed to the combination of 
several minor gene abnormalities and environmental factors. 
Their precise number and nature have not been determined (Carter 
and Evans, 1973; l.eck, 1974). Others suggest monogenic
inheritance with a large influence of environmental factors
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(Demenais et al, 1982). Kalter and Warkany (1983) suggest a 
multigenic inheritance with environmental influence.
The malformation is believed to occur during the first stage of 
development by environmental factors acting on the fetus when it 
is susceptible through inherited characteristics carried on 
several genes (Carter, David and Laurence, 1968; Carter, 1974).
A number of factors may be responsible; some of these factors may 
act as trigger mechanisms when certain threshold levels are 
reached, others may act only when deficient. Aminopetrin, a 
folic acid antagonist, now rarely used, has been shown to produce 
neural tube defects in man (Thiersch, 1952). This suggests that 
folic acid may act as a deficiency factor when the available 
concentration falls below certain thresholds.
Seller (1983) suggests that the cause of neural tube defects in 
man is due to a basic metabolic defect in the bio-synthesis 
bathway of DNA, folate, vitamin B12, zinc and other vitamins are 
intimately involved directly or indirectly in biosynthesis of 
DNA.
Holmes, Driscoll and Atkins (1976) suggest that there is 
aetiological heterogeneity within neural tube defects which 
expresses itself in the form of multiple anomalies. This might 
represent 6% (Martin, Fineman and Jonde, 1983) to 20% (Khoury, 
Erickson and James, 1982a) when associated with chromosomal
abnormality such as trisomies 13, 18 and 21 (Khoury, Erickson and 
James, 1982a). They have been reported as a disorder of major 
mutant genes with family patterns of x-linked recessive 
(Baraitsen and Burn, 1984), autosomal recessive (Robertson et al, 
1981) and autosomal dominant (Sever, 1983); it occurs in specific 
phenotype of unknown aetiology Meckels syndrome, cloaca1 extrophy 
(Holmes, Driscoll and Atkins, 1976).
The group with multiple anomalies varies from the group with 
isolated neural tube defect by showing equal involvement of male 
and female, lack of geographic variability, failure to decrease 
in prevalence over time and lack of predominance in white over 
black (Khoury, Erickson and James, 1982a). The potential
heterogeneity in the aetiology of neural tube defects must be 
carefully considered in counselling parents about the risk of 
subsequent children being affected (Holmes, Driscoll and Atkins, 
1976).
In summary, there appears to be a genetic component in up to 10% 
of births associated with NTD. but there is no consensus about 
the aetiology of the remainder which is the vast majority.
The most promising aetiological hypothesis relates to diet and 
particularly to the role of vitamin deficiency.
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Natural History:
Neural tube defect is one of the commonest abnormalities found at 
birth in the United Kingdom and is also one of the commonest 
abnormalities found in abortuses. The true rate of conception is 
difficult to estimate as some women are unaware that either a 
conception or an abortion has taken place.
Spontaneous abortion may be regarded as a natural screening 
method for the elimination of abnormal fetuses. Failure of this 
natural process leads to births of abnormal infants. It is 
possible, however, that the factor causing the malformation also 
causes the abortion (Sentrakul and Potter, 1966). The risk of 
spontaneous abortion is higher in women with previous spontaneous 
abortion and women who have given birth previously to a malformed 
baby (Warburton and Fraser, 1964). The incidence of neural tube 
defects in early pregnancy might be constant in different 
populations and the geographical variation in prevalence at birth 
might be due to differing rates of spontaneous abortion (Roberts 
and Lloyd, 1973).
Creasy and Alberman (1976) in London found that neural tube 
defects occurred in 3% of all spontaneous abortions and estimated 
that one quarter of conceptuses at eight weeks gestation with 
neural tube defects will be stillbirths, one quarter live births 
and half spontaneous abortions. They suggested that screening 
should be carried out on pregnancies subsequent to spontaneous 
abortion. Knowledge about the diagnosis of spontaneously aborted
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fetuses increases the accuracy of genetic counselling services. 
In Edinburgh a study by Bell and Gosden (1978) found an incidence 
rate (2.7%) of neural tube defects among conceptuses which are 
spontaneously aborted.
The great majority of fetures with anencephaly (88%) are 
stillborn while the remainder (10%) result in death within the 
first week of life and only 2% survive beyond the first week 
(Stone, 1981).
The proportions of anencephalic infants which are stillborn or 
live born appeared to vary from area to area. The live born 
proportions varied from about 19% in Belfast, 10% in Glasgow and 
1.5% in Aberdeen (Elwood and Mackenzie, 1971). Very occasionally 
a child with anencephaly may survive several months (Milunsky,
1979). For this reason parents of anencephalic infants should 
not be informed that the child will die immediately.
Roberts and Powell (1975) in Wales found that 9% of anencephalic 
fetuses had other congenital malformations outside the central 
nervous system. In Glasgow 14% of anencephaly fetuses had other 
congenital malformations (Stone, 1981).
Spina bifida is most commonly lumbosacral with associated 
paralysis of the legs and sphincters. About 15-20% have covering 
of intact skin and are known as "closed" spina bifida (Connor and 
Ferguson-Smith, 1987). About one third of infants with closed
spina bifida were severely disabled and a further third were 
moderately disabled (Wald and Cuckle, 1984).
Hydrocephalus occurs in about 80% of spina bifida cases (Conner 
and Ferguson-Smith, 1987); 20% of spina bifida fetuses are known 
to have other congenital malformations. The most frequent 
defects associated with spina bifida were deformities of the limb 
(Stone, 1981).
Wilson (1971) carried out a study in Glasgow and reported about 
19% stillborn and a survival rate after one year of 32.9%. Of 
those, 33.7% survived with minimal disability and 57.9% with 
severe disability. In a later Glasgow study Stone (1981) found 
that 17% of spina bifida were stillborn, 10% died within the 
first week of life and 73% survived beyond the first week. This 
proportion of stillbirths is slightly lower than in previous 
studies, while the survival rate is more favourable (Stone, 
1981).
Role of Treatment:
There has long been a controversy regarding the appropriate 
treatment of spina bifida cases. Before the late 1950's non- 
surgical treatment of infants with spina bifida was the rule as 
the risks of immediate operation were excessive. Closure of the 
defect was considered at 12-18 months of age to give time for 
hydrocephalus to be stabilised. Epithelisation of the sac had 
occurred by this time and the operative risk decreased.
The development of the mechanical valved shunt system for 
hydrocephalus (Nulsen and Spitz, 1951) provided a means of 
controlling hydrocephalus. Owing to the observation that spina 
bifida children survived in a state of paraplegia, hydrocephalus, 
mental retardation, incontinence and severe recurrent renal 
infection, changes in neonatal neurosurgery with early closure of 
open lesions became widespread and led to improved survival rate. 
Sharrard et al (1963) realised that muscle function tended to be 
preserved with early closure of the sac; but improved survival 
was associated with an increase in the proportions of severely 
disabled children among the survivors.
Studies from other centres demonstrate indirectly the effect of 
treatment. In Birmingham about 24% survived one year and 22% 
were stillborn (Knox, 1967). In Liverpool 36% survived one year 
and 23% were stillborn (Rickham and Mawdsley, 1966). In Belfast 
43% survived at one year and 16% were stillborn (Elwood and 
Nevin, 1973).
This period of active surgical treatment has been assessed by 
Lorber (1971; 1972) who established the major adverse neonatal
criteria for non-treatment. These included the presence of a 
thoracolumbar lesion, severe paralysis of the legs, advanced 
hydrocephalus, kyphosis or scoliosis, severe congenital defect or 
birth injury. A large number of children survived after non- 
selective early surgery with incapacitating mental and physical dis­
abilities, thus limiting the success of this therapeutic approach
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(Richards and McIntosh, 1973).
Various neonatal criteria have been used to select the more 
promising children for early treatment. Shurtleff et al (1974) 
proposed his own selection criteria which predicted poor 
prognosis and indicated non-treatment. These were similar to the 
Lorber criteria but additionally considered the social 
circumstances and the presence of the central nervous sytem, 
infection or haemorrhage.
An alternative approach has been proposed by Stein, Schut and 
Ames (1975). This takes into consideration the presence of an 
absence of Lacunar skull deformity which appears useful in 
predicting intelligence. These lesions which are present on the 
neonatal skull x-ray during the first month of life disappear 
from x-rays of older children. Early surgery is not recommended 
for children with lacunar skull deformity along with at least two 
of Lorber's major adverse neonatal criteria.
Opinions differ on where to strike the balance between active 
surgical intervention and simple nursing care. The most widely 
adopted approach is a selective one in which only those infants 
whose prognosis seems most promising are selected for surgery and 
active treatment. As a result of this the mortality rate for 
children with spina bifida appears to have increased with a 
decline in the proportion of survivors (Weatherall and White, 
1976).
Later the approach shifted toward early closure with appropriate 
shunting of hydrocephalus (Chervenak, 1984). Adopting such
treatment policy, one third of infants with open spina bifida 
lesions survived for five years, 84% of these being severely 
disabled, 10% moderately disabled and only 6% with no disability 
(Althouse and Wald, 1980).
McLaughlin et al (1985) found a significant improvement over time 
in the survival of newborn receiving early surgical care 
regardless of whether the initial prognosis was good or poor.
Others have suggested that early closure has no advantage over 
non-closure, in terms of the incidence of hydrocephalus mortality 
and ventriculitis. Non-closure is safe, spares the neonate a 
major operation and reduces the number of shunt operations needed 
in those babies who have limited life expectancy. It also gives 
time to the family to make their choice regarding the operation 
and allows time for the medical team to assess the baby fully 
(Deans and Boston, 1988).
Medical, social and educational services are needed for the
survivors; the majority (more than 80%) have some degree of 
disability whether physical, mental or both (Wilson, 1970).
In summary, different rates of spontaneous abaortions in
different geographical areas may be responsible for some of the
variation in birth prevalence of NTD.
In the case of anencephaly, those which are not spontaneously 
aborted are either stillborn or die early, usually during the 
first week of life. Some Spina bifida cases which are not 
spontaneously aborted are stillborn while some are born alive 
with consequent physical and mental disabilities of varying 
degrees. Several approaches to treatment of the survival of spina 
bifida cases have been reported, and these have changed over the 
years. Even with active treatment, spina bifida is associated 
with high rates of early infant mortality and a high degree of 
physical and mental disability in the survivors whether surgical 
treatment is carried out early or late.
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1.4 EPIDEMIOLOGY
Prevalence of Anencephaly and Spina Bifida:
There is a continuing controversy about whether to use the term 
prevalence or incidence in expressing the frequency of neural 
tube defect. Most authors now use the term prevalence rather 
than incidence. This is because the true incidence is unknown 
since it is probable that many severely malformed fetuses are 
aborted early in pregnancy (Biggar, Montimer and Haughie, 1976).
Prevalence rates are widely quoted in the literature and are 
expressed as the number of affected individuals divided by the 
total number of births (live and still). The proportions of 
newborns with the defect recognised at birth are referred to as 
prevalence rates at birth, and have the characteristics of point 
prevalence rates in being simultaneously influenced by both 
incidence and duration (Lowry and Thunem, 1988; Pharoah, 1990). 
They are observations of the frequency of defects at birth 
because the events that led to those defects may have occurred 
six months or more before birth. The proportion of new born 
(live and still birth) and fetuses (terminated as a result of 
prenatal diagnosis) with the defect recognised at any time during 
pregnancy are referred to as adjusted prevalence or pregnancy 
prevalence.
The prevalence of neural tube defects within the British Isles 
may be represented as a gradient of decreasing prevalence from 
the relatively high risk regions of Ireland, Scotland and Wales
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to the relatively low risk south-east of England (Stocks, 1970). 
The reason for this pattern is likely to be related to both 
genetic and environmental factors.
In Dublin in 1900 the prevalence of anencephaly was 1 per 1000 
livebirths. There was a peak in 1938-1941, and after 1950 there 
was a persistent increase, reaching a remarkable peak in 
prevalence of 8 per 1000 in 1960-1961, which continued at a high 
level to 1964-1965 (Windham and Edmond, 1982). Thereafter the 
prevalence of both anencephaly and spina bifida started to 
decline and the adjusted prevalence for 1980-1986 in Dublin fell 
to about 3.28 per 1000 total births (Eurocat, 1989).
In the United Kingdom the highest prevalence of neural tube 
defects has been reported from Belfast and is probably the 
highest in the world (Elwood, 1970). It is about three times 
greater than that in London (Carter and Evans, 1973) and 20% 
above the prevalence in south Wales (Laurence, Carter and David, 
1967). It has recently started to decline - the adjusted 
prevalence in 1980-1986 was 3.09 per 1000 total births (Eurocat, 
1989).
It seems that in Dublin as well as in Belfast and Scotland the 
prevalence has increased since 1950 with a 1960-1961 peak 
occurring in the three areas at the same time (Elwood and 
Warnock, 1969). The prevalence of anencephaly and spina bifida 
in Glasgow in 1972-1978 was estimated by Stone (1981); the
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prevalence of anencephaly was found to be 1.82 per 1000 total 
births and that for spina bifida 2.62 per 1000 total births.
Windham and Edmond (1982) studied the trends up to 1975 in the 
United Kingdom particularly Edinburgh and Glasgow and suggest 
that the prevalence for anencephaly has been declining steadily.
In Liverpool a study of the epidemiology of neural tube defects 
between 1961-1979 shows a decline in prevalence from 1974 
onwards. This was more marked for anencephaly than for spina 
bifida, but overall there was a significant decrease in the 
incidence of both anencephaly and spina bifida over the nineteen 
years (Owens et al, 1981). The adjusted prevalence in Liverpool 
declined to about 2.19 per 1000 total births during the period 
1980-1986 (Eurocat, 1989). In England and Wales the prevalence 
has been high since 1932 with a peak in 1942-1943, followed by a 
second peak in 1954-1955 (Rogers and Morris, 1971). This was 
followed by a steady decline in prevalence to about 0.39 per 1000 
for anencephaly and 1.1 per 1000 for spina bifida (Leek, 1983).
It seems that the birth prevalence of anencephaly and spina 
bifida during the period 1971-1982 in Northern Ireland exceeded 
that for Scotland, England and Wales. While the birth prevalence 
of both defects in Scotland initially exceeded that in England 
and Wales, after 1978 similar rates are reported from both 
countries. But there has been a marked decline in birth 
prevalence in Northern Ireland, Scotland, Glasgow, and England
and Wales (Carstairs and Cole, 1984).
Elsewhere in Europe no such clear-cut decline in prevalence is as 
evident as the one in the British Isles. Some European countries 
including Italy, Belgium, Netherlands and France, have actually 
experienced a rise in the prevalence rate (Eurocat, 1986).
In North America, the prevalence of neural tube defects is high 
in the east and decreases towards the west coast. In Canada the 
prevalence rate of anencephaly and spina bifida is about 4 per
1000 in the east and 1.5 per 1000 in the west (Elwood and Elwood,
1980). The prevalence rate began to rise in British Columbia to 
a peak in 1950-1954, followed by a subsequent decline and then 
started to peak again in the early 1960's (Elwood and Elwood,
1980). In the United States the prevalence of neural tube
defects is similar to that in Canada, generally decreasing from 
the east to the west, with a four-fold difference between the 
highest risk region of the south-east and the lowest risk regions 
in Nevada and Montana (Elwood and Elwood, 1980).
The prevalence of anencephaly and spina bifida in Boston, 
Massachusetts, and Providence rose reaching a peak in 1930 
followed by a marked decline between 1930-1945 until another peak 
occurred in 1950-1954, followed by a steady decline thereafter 
(Naggan, 1969; MacMahon and Yen, 1971).
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In New York the prevalence rate declined until about 1955. In the 
last two decades (1955 to 1974) the rate has remained in the 
range 1 to 1.5 per 1000. During that period the rates of 
anencephaly and spina bifida remained approximately equal and 
parallel (Janerich, 1973a). It seems that the epidemic ended in 
New York State sometime during the early to mid-1950's (Janerich 
and Piper, 1978).
In Brooklyn, during 1968-1979, there was a significant decline in 
the prevalence of myelomeningocele, which is relatively 
consistent with a linear decline over the past 50 years in the 
north-eastern region of the United States (Stein et al, 1982). 
In New England the rate of anencephaly and spina bifida was about 
3 per 1000 births in the early years of this century and peaked 
to almost 10 per 1000 births in the 1930's; the rate had reached 
a level of 2-3 per 1000 births by 1960 (MacMahon and Yen, 1971).
Reports of NTD epidemiology outside of Europe and North America 
have been . sporadic and have not demonstrated any consistent 
pattern. In 1981-1987 the prevalence rate (adjusted prevalence) 
of anencephaly and spina bifida in Australia was 1.2 per 1000 
total births (National Perinatal Statistics Unit, University of 
Sydney, 1989). In Bursa, Turkey, the prevalence of anencephaly 
and spina bifida was about 5.8 per 1000 total births in the years 
1983-1986. In the first six months of 1987 there was an apparent 
increase in the prevalence rate to 20 per 1000 total births 
(Akar, Cavdar and Ancasoy, 1988). This raised the possibility
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that the Chernobyl disaster of May 1986 might have resulted in an 
elevation of the rate in an already susceptible population, 
associated with poor nutrition and/or zinc deficiency. The 
impact of radiological contamination from the Chernobyl accident 
was evaluated in relation to central nervous system and eye 
defects in nine countries of Western Europe (Eurocat Working 
Group, 1988). The results do not suggest an increase in the 
frequency of these malformations in the countries of Western 
Europe.
In summary, the highest rates of NTD in the world have been 
reported for the British Isles, particularly Ireland. There has 
been a decline in prevalence of .NTD in the British Isles, but 
no such a decline has occurred in Europe, or large parts of the 
U.S.A. This provides strong evidence of environmental factors in 
the aetiology of NTD but does not establish any specific agent 
as the primary teratogen.
Pregnancies at Increased Risk of Neural Tube Defects:
Some women are at increased risk of having a child with neural 
tube defects, most frequently because of family history. This 
group constitutes up to 10% (Main and Mennuti, 1986) of all 
NTD pregnancies.
The recurrence risk for neural tube defects depends on a number 
of factors, in particular the population prevalence (Nevin,
1980). In the United Kingdom the frequency of N.T.D. shows a
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marked geographical variation which steadily increases from the 
south and east to the north and west (Carter, 1974).
In British surveys from Greater London during 1965-68 (Carter and 
Evans, 1973), Southampton (Williamson, 1965), South Wales during 
1956-67 (Carter, David and Laurence, 1968), Glasgow during 
1964-68 (Richards, McIntosh and Sweenie, 1972), Northern Ireland 
(Elwood and Nevin, 1973), the recurrence rates were reported as 
4.45%, 5.63%, 5.18%, 5.64% and 8.87% respectively. The risk of
recurrence varies according to the population prevalence of 
neural tube defects and is high in Northern Ireland and low in 
Greater London; the recurrence risk also varies according to 
social class with mothers in higher socio-economic groups (I and 
II) having a lower recurrence risk (5.5%) than those in groups 
III, IV and V (9.0%) (Nevin, 1980).
The recurrence risk (calculated retrospectively) in the United 
States, has been estimated as 1.7%-1.8% (Holmes, Driscoll and 
Atkins, 1976; Janerich and Piper, 1978), while in a prospective 
study of women undergoing prenatal diagnosis due to a previously 
affected fetus or infant the recurrence risk was 1.5%-3.0% 
(Milunsky, 1980; Crandall and Matsumoto, 1984).
If parents are affected with neural tube defects the recurrence 
risk is the same as for full sibling recurrence rate (Connor and 
Ferguson-Smith, 1987).
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When there are two affected siblings, the recurrence risk for 
neural tube defects rises to 10% in the United Kingdom (Connor 
and Ferguson-Smith, 1987) and 5.7% in the United States 
(Milunsky, 1980).
The recurrence risk for half siblings should be lower than full 
siblings (Janerich and Piper, 1978). There is a high recurrence 
rate observed among mother's sister's children (Williamson, 
1965). The recurrence risk for second degree relatives is 1.4% 
and for third degree relatives is 0.7% (Connor and Ferguson- 
Smith, 1987).
There is a tendency for concordance of the defects within 
families, but there is a possibility of discordance of the defect 
(Carter, 1974). The recurrence of these anomalies in sibships 
is as likely to be due to persistent or recurrent environmental 
factors as to a common genetic inheritance (Yen and Macmahon, 
1968). The birth prevalence of neural tube defects has been 
declining recently in many parts of the world (Elwood and Elwood, 
1980) and especially in the United Kingdom (Windham and Edmonds, 
1982; Stone, 1987); the recurrence rate is also expected to have 
fallen. Seller (1981) calculated the recurrence rate of neural 
tube defects within a genetics centre population in the south­
east of England during 1972-79 when the recurrence rate was 3.2% 
(1 in 32) and calculated the rate for 1980-mid 1984 and it fell 
to 2.8% (1 in 35), concluding that as the birth prevalence
declines the recurrence rate also declines (Seller and Hancock,
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1985).
Spina bifida occulta of single vertebra in parents does not seem 
to indicate an increased risk of neural tube defect in their
offspring (Main and Mennuti, 1986). Spina bifida occulta
affecting multiple vertebrae in the same individual has been 
observed in the parents of children with neural tube defects 
(Wynne-Davies, 1975). If an index patient has multiple vertebral
anomalies and spina bifida occulta, the proportion of siblings
affected with neural tube malformation is as high as if the index 
patient had had spina bifida cystica or anencephaly.
If the index patient had multiple vertebral anomalies alone, the 
proportion of siblings with spina bifida or anencephaly is rather 
less, but still five times higher than in the general population 
(Wynne-Davies, 1975).
Siblings of patients with sacrococcygeal tumours (Teratomas, 
hamartomas) appear to have an increased risk of neural tube 
defects (Lemire, 1983).
There are other reported pregnancy risks to the fetus for neural 
tube defects. Valproic acid taken during the first trimester of 
pregnancy is associated with a l%-2% risk (Main and Mennuti,
1986). An increased number of NTD were reported both in children 
whose mothers had been treated with clomiphene used to induce 
ovulation (Cornel et al, 1989), and among children born after in
vitro-fertilisation (Lancaster, 1987). Maternal diabetes mellitus 
is associated with a 2% risk of having a child with neural tube 
defect (Milunsky et al, 1982; Ylinen et al, 1984).
It was found that women with a bad obstetric history, such as 
spontaneous abortion, stillbirth or child death from causes other 
than NTD., appear to be at a higher risk and if these events 
occur more than once the risk is higher again (Elwood and Elwood, 
1980).
In summary, the risk of NTD depends on the prevalence in the 
general population. Other factors may contribute to the 
increased risk such as the social class of the mother, family 
history of NTD (up to 10%), the presence of parental vertebral 
defects, drugs during pregnancy and bad obstetric history.
However we do not have precise enough estimates of the risk to 
enable subgroups to be targeted with specific public health 
measures.
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1.5 PREVENTION
It is widely accepted that neural tube defects have a 
multifactorial aetiology involving genetic predisposition and 
environmental triggering factors (Carter, 1969; Leek, 1974). 
Since there is little hope of being able to modify the genetic 
component in most cases, the primary prevention of neural tube 
defects depends ultimately on identifying the environmental 
factors so they can either be removed from the environment or 
avoided (Laurence, James and Campbell, 1983).
Methods of prevention of neural tube defects are applied either 
before conception (primary prevention) or after conception.
BEFORE CONCEPTION:
1 - Genetic counselling:
This is the major approach. It involves communication of
information and advice about inherited conditions and associated 
risk of the disorder in the offspring of prospective parents. 
The West of Scotland has a population of about 3 million of whom 
at least 3000 families are in need of genetic counselling. Each 
year only about 1000 of these families are formally counselled 
although some of the remainder are adequately counselled by other 
health professionals (Connor and Ferguson-Smith, 1987).
About 10% of neural tube defects occur in families with a 
previous history of neural tube defects or a near relative who 
have also had a child with neural tube defect. These families 
need information and advice about the nature and prognosis of the
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disorder they are confronted with, and be informed about the 
recurrence risk and this should be understood properly by the
parents (Carter et al, 1971; Morris and Laurence, 1976). It is
also important to explain that every couple has, with each
pregnancy, a 1 in AO risk of having a child with serious
abnormality (Carter et al, 1971; Leonard, Chase and Childs,
1972). Provided that genetic counselling is given
sympathetically at an appropriate time most couples with high 
risk either postpone pregnancy or avoid it altogether.
With the increasing availability of antenatal diagnosis some 
families may now choose to have further unaffected children if 
they are prepared to undergo therapeutic abortion. By this means 
the number of children placing a burden on the family and society 
can be reduced (Carter, 1974). Up to 80% of families with neural 
tube defects that attended counselling reported that they were 
positively influenced in their decision to have more children by 
the information received during the counselling sessions (Swerts, 
1987).
2 - Prenatal precautions:
All women who have decided on pregnancy and those already 
pregnant should reduce the use of drugs or preferably avoid the 
use of drugs during this period. This is believed to reduce the 
risk of congenital malformations including neural tube defects.
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Greenberg et al (1977) found an association between the use of 
the hormonal pregnancy test during the first trimester of 
pregnancy and central nervous system defects. Winship et al 
(1984) performed a case control study on women prescribed drugs 
during the trimester before the last menstrual period and the 
first trimester of pregnancy. There was a statistically 
significant difference overall between the numbers of mothers who 
were prescribed drugs in the study and control groups during the 
trimester before the last menstrual period, But no such 
difference was found for the first pregnancy trimester, nor was 
there a significant difference for any specific group of drugs. 
The same was found for non-steroid anti-inflammatory drugs, 
salicylates and sulphasalazine. Pregnant women are advised to 
avoid contact with possible sources of infection like influenza 
during the first trimester of pregnancy due to the observed 
association between pyrexia during the first trimester of 
pregnancy and congenital malformations (Lady, Edmonds and 
Erickson, 1980).
3 - Vitamin supplementation:
Intensive epidemiological and clinical studies in man have only 
recently produced evidence of specific environmental factors 
which might be of aetiological importance. Vitamin deficiency 
has been considered as a possible factor in the occurrence of 
neural tube defects. The following studies are the basis for 
the notion that preconception vitamin supplement may decrease the 
incidence of neural tube defects.
In a prospective study of blood vitamin levels in the first 
trimester of pregnancy, vitamin A, red cell folate, red cell 
riboflavin, white cell vitamin C, were low in lower social 
classes and lower still in women who later gave birth to infants 
with neural tube defects than in the controls (Smithells, 
Sheppard and Schorah, 1976). There was a significant social 
class difference in nutrient intake in women in the first 
trimester of pregnancy (Smithells et al, 1977). Laurence et al 
(1980) used a questionnaire to assess first trimester dietary 
intake retrospectively in mothers of neural tube defect infants. 
A relation undoubtedly exists between social class and maternal 
diet; he concluded that improving the quality of diet during 
early pregnancy in women at risk of fetal neural tube defects 
reduces the recurrence risk.
The evidence from the above studies, though not yet clear cut, 
suggests that minor deficiences of one or more vitamins may be 
implicated in the causation of neural tube defects. These data 
justify intervention studies designed to reduce or eliminate the 
recurrence of neural tube defects by vitamin supplementation. A 
preliminary study carried out by Smithells et al (1980) suggested 
that neural tube defects might be prevented by maternal vitamin 
supplementation. Later a multicentre study was performed by 
Smithells et al (1981a); the supplement used was Pregnavite forte 
F (Bencard - the compound contains ten vitamins or cofactors, the 
dose 'of each ingredient1 being either identical with or slightly 
lower than the current United States recommended daily intake).
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The vitamins were given before and after conception to women with 
a history of fetal neural tube defects and a highly significant 
reduction in the recurrence rate (0.5%) was observed in the 
supplemented group when compared with the recurrence rate (4.3%) 
of unsupplemented. This study was neither randomised, double 
blind nor controlled by a placebo group, but the result suggests 
that this multivitamin preparation might reduce the risk of 
recurrence of neural tube defects although there is no way of 
knowing which particular ingredient has this beneficial effect.
Extending the original study Smithells et al (1981b; 1983) showed 
that 0.7% of women who took the supplement had fetuses with 
neural tube defects compared with 4.7% of women who did not get 
the supplement; the recurrence rate after two or more previous 
neural tube defect pregnancies were 2.3% in the supplemented 
group and 9.6% in the unsupplemented. They examined the factors 
which might influence recurrence rates such as maternal age, 
social class, previous reproductive history. None was a
contributory factor to the difference between supplemented and 
the unsupplemented groups.
Smithells' study is open to several criticisms (Stone, 1980; 
Wald, 1983; Wald and Polani, 1984) not only because of the 
numbers but also because of the choice of controls who consisted 
of those women who were already pregnant when it was ascertained 
who, for one reason or another, were not supplemented or did not 
want supplementation.
Laurence et al (1981) offered a supplementation on a random 
basis, folic acid or placebo, to women who had a child with 
neural tube defects. The results suggest that folic acid 
deficiency may be an important factor in the causation of these 
malformations. This study was criticised because of small 
numbers and because non-compliers with folic acid treatment were 
utilised (Seller, 1982; Wald and Polani, 1984).
Comparison of the effectiveness of preconceptional vitamin 
supplementation for prevention of neural tube defects in two 
areas - the south-east of England (low prevalence area) and 
Northern Ireland (high prevalence area) - showed beneficial 
effects of supplementation are apparent in both areas, but were 
more marked in the high prevalence area (Seller and Nevin, 1984).
Wild et al (1986) assessed the influence of various factors such 
as area of residence, number of previous pregnancies with neural 
tube defects, prior miscarriages and inter-pregnancy interval on 
the recurrence risk in supplemented and unsupplemented mothers. 
They found a highly significant difference in the recurrence rate 
between supplemented and unsupplemented mothers. Mulinare et al 
(1988) found differences in neural tube risk between
preconceptional vitamin users and non-users and suggested that it 
is not possible to say whether this difference is due to 
multivitamin use or the result of other characteristics of women 
who use multivitamins. Although there were no reported adverse
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effects reported in these studies, it is not safe to assume that 
there would be no harmful effects if large numbers were involved. 
Since most vitamins have been reported to cause adverse effects 
when ingested in excessive doses this should be considered before 
embarking upon the use of high dose vitamin therapy for which 
scientific evidence of efficacy has not been provided (Oversen, 
1984). All vitamin preparations, except those containing folic 
acid, are freely available and can be bought without doctor's 
prescription. Before considering the possible advantage of 
supplementing the diet of the whole population with vitamins or 
folic acid further evidence is needed that neural tube defects 
would be prevented by these means.
Since there are unidentified factors influencing the risk of 
neural tube defects only a randomised clinical trial can provide 
the assurance that these do not bias the assessment of vitamin 
supplementation (Wald and Polani, 1984). In an attempt to 
resolve the issue the Medical Research Council ran a multicentre, 
controlled randomised and double blind trial designed to 
establish whether multivitamin supplementation (including folic 
acid) in high risk women can help to reduce the number of 
recurrences of neural tube defects (Wald and Polani, 1984). The 
supplement was one of four kinds - minerals and folic acid (4 
mg); minerals, folic acid and multivitamins; minerals and 
multivitamins but no folic acid; minerals only (calcium and 
iron). There is also a placebo group. The design of the trial 
enabled an analysis of whether folic acid alone is sufficient to
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prevent neural tube defects or whether multivitamins without 
folic acid are effective in preventing recurrence. The result of 
the study confirms that a supplementation of folic acid before 
conception is effective in reducing the number of neural tube 
defects in those women who have had previous NTD pregnancies and 
are therefore considered to be at high risk. (MRC Vitamin Study 
Research Group 1991.)
The other current trial is a study which has been started in 
Dublin where antenatal diagnosis and induction of abortion are 
largely unacceptable. In this trial women receive either 
multivitamins and folate, folate alone or multivitamins alone.
In summary, primary prevention of congenital defect is the most 
desirable objective. Genetic counselling may be offered to 
parents who have had an affected child, since they appear to be 
exposed to a recurrent risk. Prenatal precautions, such as 
reduction in use drugs once decided on pregnancy and avoidance of 
contact with possible sources of infection, should be taken.
Another form of primary prevention is the use of preconceptional 
folic acid supplementation.
AFTER CONCEPTION:
The only method of prevention of neural tube defects is prenatal 
diagnosis. A prenatal test is offered as a screening procedure
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for those with a previous history of neural tube defects or 
because of clinical suspicion of fetal abnormality. The parent 
should be informed about the limitations of the test, since no 
single test can exclude all known fetal abnormalities.
If the test is positive, selective termination of pregnancy is 
offered. (Selective termination became a reality in the United 
Kingdom with the Abortion Act 1967, which stated that termination 
of pregnancy is permitted when there is a 'substantial risk that 
if the child were born it would suffer from such physical or 
mental abnormality as to be seriously handicapped1.) The product 
of the conception is sent to pathology for diagnostic 
confirmation.
Prenatal screening of all pregnancies for NTD has been in 
operation in many areas since the discovery of serum marker for 
affected pregnancies (Brock, Bolton and Monaghan, 1973).
Because of its unique ethical implications the implementation of 
screening on a mass scale requires careful evaluation both a 
priori and as a means of assessing its impact. Over the past few 
decades various criteria for evaluating screening have been 
proposed.
Screening:
The success of any screening depends on many well recognised 
criteria such as characteristics of the disease, test and
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screening system that combine to make screening desirable.
A number of criteria for screening are required to be satisfied 
prior to the introduction of any screening programme (Wilson and 
Jungner, 1968; Cochrane and Holland, 1971; Holtzman, 1981).
Criteria for Screening (Holtzman, 1981)
Disease
Characteristics
- Occurs frequently
- Causes severe 
functional 
impairment
- Untreatable or 
treatment effective 
only when begun 
before the age when 
clinical diagnosis is 
usually made
- Associated with a 
quantitative or 
qualitative 
alteration of a 
substance that 
permits affected 
individuals to be 
distinguished
Test
Characteristics
- Reliable
- Valid
- Adapted to 
mass
screening
Screening System
Characteristics
- Mechanism for 
determining 
effectiveness 
under field
- conditions
- Specimens 
analyzed 
reliably 
and promptly
- Results reported 
promptly
- Adequate follow-up 
and management
- Physician and 
parent knowledge 
of screening
- positive 
benefit-cost ratio
Screening techniques should be introduced not only because they 
are available but because they solve a serious medical problem.
Characteristics of the disease:
Neural tube defects including anencephaly and spina bifida are 
among the most common congenital anomalies.
Open lesions associated with a poorer prognosis for survival and 
with much greater incidence of severe disability include mental 
retardation, paralysis and orthopedic and urological
complications. As treatment of spina bifida is ineffective in
restoring normality, and there is no evidence at the present time 
to suggest that fetal malformation such as anencephaly and spina 
bifida can be prevented, selective abortion of affected fetuses 
can allow families the option of trying again for a healthy 
child.
Maternal serum Alphafetoprotein (Ms AFP) is known to be of fetal
origin and it is an indirect marker of neural tube defect. In
the case of neural tube defects, AFP provides a non-specific 
quantitative difference so absolute separation of the affected 
from the non-affected is not possible. The aim of antenatal 
screening for neural tube defects by Ms AFP is to identify women 
with a high risk of having an affected infant to justify carrying 
out special diagnostic procedures such as detailed ultrasound, 
amniocentesis for amniotic fluid Alphafetoprotein (Am AFP) and 
Acetylcholinesterase (AchE) determination.
Women who have previously had an infant with neural tube defect 
have a high risk of having another - they are undergoing 
amniocentesis on account of their history alone.
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Characteristics of the screening test:
The screening test must he reliable, easily performed 
reproducible and precise.
Ms AFP as a screening tool is most often measured by
Immunoradiometric assay. The techniques are identical to those 
used in many other routine laboratory studies. Although the test 
is available through a number of clinical laboratories there is 
as yet no uniform standard and results from one laboratory cannot 
be compared directly with those from another. Laboratories must 
establish their own normative data at each gestational age.
The reliability of Ms AFP measurement as an effective screening 
tool and the suitable gestational age at which it should be
performed was investigated by the ninteen-centre collaborative 
study (Report of UK Collaborative Study, 1977).
In the west of Scotland a centralised laboratory in the Duncan 
Guthrie Institute of Medical Genetics for maternal serum 
screening programme can most reliably screen large populations. 
In order to improve precision, reliability and accuracy of
maternal serum screening programmes and to allow the study of the
clinical significance of low levels of Ms AFP and small changes 
of levels, immunoradiometric assay has been introduced. A large 
number of specimens can be processed so any deviations from the 
expected distribution of results can rapidly be identified.
The validity of a test depends on its sensitivity and 
specificity, predictive value and ease of performance.
Determination of the sensitivity and specificity of a test 
requires that a diagnosis of disease be established or ruled out 
for every person tested. Sensitivity and specificity of Ms AFP 
for the detection of anencephaly and spina bifida have been 
calculated by the United Kingdom Collaborative Study (Report of 
the United Kingdom Collaborative Study, 1977). The use of 
multiples of the normal median (MOM) allows pooling of data from 
different centres. At 2.5 MOM 88% of anencephaly and 79% of 
spina bifida cases will be detected (Report of the UK 
Collaborative Study 1977). The probability that a pregnancy with 
a positive result involves an affected fetus is dependent on the 
prevalence of the condition, the detection rate and the false 
positive rate.
The AFP test is stable both for short-term shipment at room 
temperature and after several cycles of freezing and thawing. 
The assay allows many specimens to be processed and the test 
itself is not expensive. Because of these characteristics the 
test can be adapted for mass screening. A more detailed 
discussion of AFP and its use in screening is presented later 
(Alpha-fetoprotein, pp77)
Characteristics of screening system:
The use of a screening test during pregnancy places strict time 
limits on the entire sequence if the information is to be acted
on within legal constraints on pregnancy termination. In the 
West of Scotland screening programme specimens obtained by the 
obstetrician or the general practitioner are processed reliably 
and promptly by their laboratory and results are reported 
promptly; follow-up testing counselling and management are 
carried out if needed.
The prospective >parents should be given adequate information 
about screening for neural tube defects, the procedure before 
prenatal diagnosis and the meaning of inaccurate diagnosis (false 
positive and false negative), the mechanism of diagnostic 
intervention and the risk involved, what type of information the 
procedures can and cannot provide, and the need to consider the 
possibility of terminating the pregnancy.
Support after the birth of a child or termination of the 
pregnancy is required - families will also need recurrence risk 
counselling at an appropriate time.
Economic aspects;
The financial cost of population screening depends on the 
prevalence of neural tube defects in the area, the lower the 
prevalence the greater the cost. Ms AFP screening for neural 
tube defect should be cost-effective, and should have sufficient 
resources to ensure adequate diagnostic and follow-up facilities. 
The cost-effectiveness of antenatal screening for NTD. decreases 
as the birth prevalence declines (Pharoah and Alberman, 1987).
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In summary, successful Ms AFP screening programmes need a 
high-quality laboratory analysis, rapid and skilled communication 
between laboratory and physician, adequate resources for follow- 
up testing,adequate counselling and epidemiological surveillance.
Antenatal screening for Neural Tube Defects:
Antenatal screening provides early information concerning the 
clinical state of the fetus and recognition of congenital 
malformations in utero. Over 95% of all children with neural
tube defects are born to couples with no previous family history. 
It is only by screening the pregnant population that most 
pregnancies at risk can be identified. Antenatal screening may 
be the basis for many important decisions regarding the future of 
the mother and child and enables the physician to consider 
selective termination.
Alpha-fetoprotein (AFP):
AFP was first identified in the serum of early human fetuses 
(Bergstrand and Czar, 1956). Embryonic and fetal blood contain a 
high concentration of AFP. It is a glycoprotein with a molecular 
weight of 69000 daltons.
During fetal development, AFP is synthesised by the yolk-sac at 
the end of the first trimester; the yolk-sac atrophies so 
synthesis shifts to the liver (Gitlin, 1975). It is believed 
that the two sources produce different molecular forms of AFP, 
though whether these have any significance for antenatal
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diagnosis is unknown. The biological function of AFP is unknown 
although it has been suggested that it may have an 
immunoregulatory role protecting the fetus against maternal 
immunologic attack (Burton, 1988). It is present in fetal serum 
from about six weeks of gestation; it peaks at the end of the 
first trimester (10-13 weeks) (Conner and Ferguson-Smith, 1987) 
but falls rapidly in the second trimester. At birth the AFP 
level falls but basal levels of up to 25 micrograms per litre 
persist into adult life (Conner and Ferguson-Smith, 1987).
That Am AFP is elevated when a fetus has an open neural tube 
defect was first reported by Brock (Brock and Scrimgeour, 1972; 
Brock and Sutcliff, 1972). Leakage of AFP into amniotic fluid 
occurs by transudation when the fetus has an open neural tube 
defect. Later an association between maternal serum AFP and open 
neural tube defects was also found (Brock, Bolton and Monaghan,
1973).
Fetal serum AFP levels are not increased in the case of open 
neural tube defects (Seller, Creasy and Alberman, 1974) but the 
concentration in the amniotic fluid is raised on account of 
leakage of fetal AFP through the open lesion. This leads to an 
increased transfer across amniotic fluid membranes producing the 
raised maternal serum level of AFP which forms the basis of the 
antenatal screening test. Consequently closed lesions would not 
be expected to be associated with raised maternal serum or 
amniotic fluid AFP levels (Laurence et al, 1973). There is some
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degree of overlap in AFP concentration between normal pregnancies
and those with neural tube defects. Ms AFP measurement is
therefore more useful as a screening tool rather than as a 
diagnostic test.
To improve the precision and accuracy of AFP assay and to produce 
one method suitable for maternal serum and amniotic fluid 
testing, Immuno Radio Metric assay (IRMA) has been developed.
Normally Am AFP concentration is largely maintained by fetal 
urination peaks in early pregnancy and decreases steadily 
thereafter by about 13% a week (Wald and Cuckle, 1980). MsAFP is 
normally detected in increased quantities in the serum of 
pregnant women from approximately 12-14 weeks of gestation 
(Brock, Bolton and Monaghan, 1973) and increases steadily 
throughout pregnancy (by about 19% a week) during the second
trimester (Wald and Cuckle, 1980), peaks around 32 weeks of
gestation before falling towards term (Connor and Ferguson-Smith,
1987). Because there is a concentration gradient from fetal 
serum to amniotic fluid to maternal serum, contamination of 
either amniotic fluid or maternal serum with even a small 
quantity of fetal blood can produce AFP levels above normal.
To take account of the methodological differences found between 
laboratories the AFP result is expressed in multiples of each
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laboratory's own median level in unaffected pregnancies for 
relevant gestational age. (Report of the UK Collaborative Study, 
1971)
Maternal Serum AFP
There is an overlap in distribution between affected and 
unaffected pregnancies. In screening routine pregnancies, a 
cut-off defining norma.l results must be selected so that an 
acceptable rate of detection can be achieved while limiting the 
percentage of normal pregnancies subjected to further testing.
The best time for screening was found to be between 16-18 
completed weeks of gestation (Report of UK Collaborative Study, 
1977) at which the detection rate for anencephaly and spina 
bifida is high and adequate time is available to allow for 
follow-up testing and the eventual possibility of pregnancy 
termination.
Ferguson-Smith (1983) suggested offering screening only to women 
between 16-20 weeks of gestation since prenatal diagnosis beyond 
20 weeks of gestation increased the distress for the mother.
The efficiency of Ms AFP screening in selecting pregnant women 
who are at increased risk for neural tube defects, for whom more 
definitive procedures of ultrasound and amniocentesis are needed, 
is documented in the Report of United Kingdom Collaborative Study 
(1977). The number of unaffected pregnancies with AFP levels 
above 2.5 (MOM) at 16-18 weeks of gestation can be reduced by
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about a third if women with border-line AFP levels are retested 
(Report of UK Collaborative Study, 1977) although this would not 
greatly change the detection rate of affected pregnancies. 
Retesting only women with results just above the cut-off value 
and using a lower cut-off value for the second test is probably 
the most efficient way of reducing the false positive rate and 
necessitates the retesting of only about 2% of screened women 
(Fourth Report of the UK Collaborative Study on AFP, 1982). 
Maternal serum AFP screening is a powerful and effective 
screening tool and can be successfully integrated in routine 
obstetric practice (Macri and Weiss, 1982; Haddow et al, 1983).
Maternal weight needs to be taken into consideration when 
interpreting Ms AFP results. Lighter women have on average high 
Ms AFP levels presumably as a result of greater concentration of 
AFP in their relatively smaller blood volume (Haddow et al, 1981; 
Wald et al, 1981). Adjusting Ms AFP values according to maternal 
weight among those with border-line positive results might 
therefore reduce the number of women having a diagnostic 
amniocentesis.
The most common benign explanation for Ms AFP elevation is 
underestimated gestation. In about 15%-20% of pregnant women 
found to have elevated Ms AFP by routine screening at 18-20 weeks 
of gestation, the cause is underestimated gestation (Ferguson- 
Smith, 1983).
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The other common cause of Ms AFP elevation is multiple pregnancy. 
Twins, on average, produce twice as much AFP as a single fetus 
both in the first and second half of pregnancy (Wald et al, 1975) 
but this does not exclude the possibility of neural tube defects 
in one or both.
In some instances the barrier between fetal and maternal 
circulations is altered by abnormalities in the placenta which 
permits direct transport from the fetal to the maternal 
circulation and leads to an elevation of Ms AFP. If this is
associated with vaginal bleeding the diagnosis is threatened 
abortion. Ms AFP returns to normal a week later (Ferguson-Smith, 
1983). Sometimes there are no overt symptoms of threatened 
abortion other than feto maternal haemorrhage which leads to high 
Ms AFP. This may be the only evidence of concealed threatened 
abortion (Ferguson-Smith, 1983). Other causes of high Ms AFP are 
haemangioma of the placenta or the cord, tumour attached to the 
placenta or the cord, cardiac monsters (consisting of amorphous 
mass of fetal tissue resulting from previous intrauterine death 
of monozygous twin whose development has been partially 
maintained by the circulation of its living co-twin) (Ferguson- 
Smith, 1983).
High Ms AFP value is found to be more commonly associated with 
male fetuses but there is no explanation for this (Wald and 
Cuckle, 1984).
Hereditary persistence of AFP may be the explanation in pregnant 
women who have high levels of Ms AFP throughout pregnancy with 
normal Am AFP (Ferguson-Smith, 1983). Amniocentesis can also 
cause feto-maternal haemorrhage and elevate Ms AFP levels. For 
this reason post-amniocentesis determinations are avoided (Chard 
et al, 1976). The use of Ms AFP as an indicator of fetal well­
being was suggested by Seppala and Ruoslahti (1973). Though 
pregnant women with high Ms AFP but normal Am AFP can be 
reassured that there is no evidence of neural tube defects, they 
constitute a high risk group for sub-optimal outcome of pregnancy 
such as spontaneous abortion, stillbirth, low birth weight (about 
15% identified in this way) and neonatal death (Wald et al, 1977; 
Macri and Weiss, 1982; Brock et al, 1977).
Amniotic Fluid AFP
There is an overlap in values of amniotic fluid AFP between 
affected and unaffected pregnancies (Second Report of UK 
Collaborative Study, 1979). The values for anencephaly 
pregnancies are well separated from the distribution of 
unaffected pregnancies, while those for spina bifida show a small 
degree of overlap which was least at 16-18 weeks of gestation. 
This is consequently the best time to do Am AFP testing (Second 
Report of UK Collaborative Study, 1979).
As with Ms AFP, multiples of the median (MOM) are used to reduce 
the systematic differences in Am AFP measurement observed between 
laboratories but to obtain the same false positive rate at each 
gestational period it was necessary to increase the cut-off
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levels with alvancir.g gestational age as follows: 2.5 (MOM) at
13-15 weeks of gestation; 3.0 (MOM) at 16-18 weeks of gestation;
3.5 (MOM) at 19-21 weeks of gestation and 4.0 (MOM) at 22-24 
weeks of gestation (Second Report of UK Collaborative Study, 
1979). Using these cut-off levels the detection rate for 
anencephaly was 98.2% and for spina bifida 97.6%. The practical 
false positive rate (the number of viable pregnancies without 
abnormality terminated) in all samples was 0.48% and 2.7% in
clear (non-blood stained) samples (Second Report of UK
Collaborative Study, 1979). Fetal blood contamination of
amniotic fluid AFP is a recognised cause of false positives 
(Doran et al, 1977). To exclude this possibility most
laboratories routinely perform either a kleihaver test or 
haemoglobin electrophoresis on blood stained amniotic fluid 
samples to distinguish fetal from maternal blood contamination. 
It is preferable not to delay Am AFP determination beyond 18 
weeks, of gestation (Second Report of UK Collaborative Study, 
1979).
If the Am AFP result is borderline or a blood stained specimen, 
it is worth obtaining a fresh amniotic fluid sample and 
performing a repeat AFP test. This will only have a marginal
effect on the detection rate but will reduce the practical false 
positive rate by more than a half (Second Report of UK 
Collaborative Study, 1979).
The risk of having a fetus with neural tube defects in test
positives is important information for planning a screening 
programme and can be estimated accurately from the UK 
Collaborative Study data (1977; fourth report 1982) (Appendix 1).
A nomogram has been produced for estimating the individual risk 
of having a fetus with open spina bifida by using information 
from both maternal serum and amniotic fluid AFP levels when the 
amniotic fluid level is borderline (Wald and Cuckle, 1984) 
(Appendix 2).
High Ms AFP and Am AFP levels are associated with the presence of 
fetal open neural tube defects, but this is not specific. Other 
malformations of ventral wall defects such as exomphalos 
(abdominal viscera herniate into the umbilical cord) in the 
absence of neural tube defects have been associated with raised 
Ms AFP and Am AFP (Seppala et al, 1976; Wald et al, 1980).
Both gastroschisis (a defect in the abdominal wall lateral to the 
umbilicus) and body stalk abnormality (in which umbilical vessels 
are short so that the fetus is closely attached to the chorionic 
plate) are associated with high Ms AFP and Am AFP (Ferguson- 
Smith, 1983).
Meckels syndrome (a combination of encephalocele, polydactyly and 
polycystic kidneys) is an autosomal recessive disorder associated 
with high Ms AFP and Am AFP. Congenital nephrosis inherited as 
an autosomal recessive disorder in which the fetal kidneys may
excrete large quantities of AFP into the amniotic fluid. 
Confirmation of the diagnosis requires electron microscopy of the 
fetal kidney (Seppala et al, 1976; Kjessler et al, 1975).
Other abnormalities associated with high Am AFP are: polycystic 
kidney (Chemke et al, 1977); renal agenesis (Balfour and 
Laurence, 1980) which causes a failure of urinary and AFP 
excretion into amniotic fluid but this condition is associated 
with oligohydraminos in which there is high concentration of AFP 
in amniotic fluid (Stirrat et al, 1981).
Bladder neck obstruction (Vinson et al, 1977) and congenital 
absence of the urethra (Nevin et al, 1978) are both associated 
with high AFP in amniotic fluid due to oligohydraminos. Fetal 
teratomata are usually non-malignant and are associated with 
elevated Ms AFP and Am AFP. Some are amenable to surgery, for 
example when the tumour is large and pedunculated and visible oh 
ultrasound screening (Ferguson-Smith, 1983). Intra-uterine death 
leads to raised Ms AFP and Am AFP due to fetal autolysis (Seppala 
and Rouslahti, 1972). About 12% of miscarriages are associated 
with a positive Am AFP result (Second Report of UK Collaborative 
Study, 1979). Esophageal atresia is associated with raised Am 
AFP in the third trimester of pregnancy (Seppala, 1973). In 
duodenal atresia Am AFP is high in the second trimester of 
pregnancy (Weinberg et al, 1975) due to reduced AFP digestion in 
the gut consequent on fetal swallowing. Fetuses with skin 
defects such as in nuchal bleb and pilonidal sinus (Bieber and
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Petres, 1978; Jandial, Tham and Gibson, 1976) have raised Am AFP 
levels, probably due to leakage of AFP through the skin defect.
Turner's syndrome is associated with high Am AFP, the cause is 
thought to be leakage through the wall of cystic hygroma, or 
sampling of cystic fluid (Hunter et al, 1976).
Both normal Am AFP (Ishiguro and Nishimura, 1973) and abnormal 
levels (Seppala and Unnerus, 1974) have been reported in the 
presence of hydrocephaly in either the second or third trimester 
of pregnancy. In normal twin pregnancy Am AFP is not elevated 
(Second Report of UK Collaborative Study, 1979). If both of the 
fetuses are affected a high Am AFP is found. If one is affected, 
the Am AFP is high in one of the sacs. But problems arise if AFP 
from the affected sac diffuses through the membrane to the 
unaffected one leading to a high Am AFP in both sacs (Wald and 
Cuckle, 1984).
In order to avoid performing amniocentesis on a large number of 
unaffected pregnancies with elevated Ms AFP levels, a repeat 
maternal serum sample and ultrasound examination should be 
performed.
In an attempt to evaluate the performance of the screening 
programme, a large prospective study based in Glasgow has been 
reported (Ferguson-Smith, et al, 1978). It comprised two phases 
and in the first the 99th percentile (3.5 MOM) was used as a cut-
off point. The sensitivity for anencephaly was 88% and for spina
bifida 71%. In the second phase the 97th percentile (2.8 MOM)
was used as a cut-off point. The sensitivity for anencephaly was 
100% and for spina bifida 81%. About 0.63% of pregnancies 
proceeded to amniocentesis, 46.4% of amniocentesis showed raised 
Am AFP, due to fetal abnormality. Fetal loss by abortion or 
perinatal death after amniocentesis occurred in 0.03% of 
pregnancies screened.
Wald et al (1979) measured the acceptability of the screening 
programme among patients who knew that they had a positive 
screening test. It was found that about 93% expressed a wish to 
be tested again in any future pregnancy.
Dangers of Amniocentesis
Mid-trimester amniocentesis has become common procedure in 
prenatal care and several studies have been conducted to assess 
the risks involved. In the United Kingdom (Report of the MRC,
1978), Canadian Medical Research Council, (1977) and the NICHD
study by the United States Department of Health Education and 
Welfare (Lowe et al', 1978). It is difficult to compare these 
studies because of the different categories used by each but all 
showed a high risk of spontaneous abortion following
amniocentesis. In the United Kingdom (Report of MRC 1978) a 
1-1.5% spontaneous abortion risk after amniocentesis was found, 
while in South Carolina the abortion rate was about 1% (Young et 
al, 1983). A study in Canada (Simpson et al, 1976) observed a 
reduction in the number of spontaneous abortions in the
amniocentesis group. The abortion rate after amniocentesis in 
San Francisco was 1.5% (Golbus et al, 1979). In Belfast, at the 
regional referral clinic for genetic amniocentesis, spontaneous 
abortion rate was 2.2% (Ritchie and Thompson, 1982). This was 
reduced to 0.7% by excluding those that occurred more than two 
weeks after the amniocentesis and which were thought not to be 
due to the procedure. In the Queen Mother's hospital in Glasgow 
spontaneous abortion rates after amniocentesis were 1.4% reducing 
to 0.2% if those that occurred more than two weeks after 
amniocentesis were excluded (McNay and Whitfield, 1984). In an 
uncontrolled study of women undergoing amniocentesis for 
chromosomal abnormalities, spontaneous abortion resulting from 
the procedure was increased by 0.3%-0.7% (Philip and Bang, 1978).
The risk of fetal death or abortion is about 0.5% within three 
weeks after mid-trimester amniocentesis if only experienced 
obstetricians using modern techniques are involved (Leschort, 
Verjaal and Treffers, 1985). This is similar to the finding of 
Porreco et al (1982) who estimate the risk of procedure related 
fetal deaths in the range of 0.6%-0.9%.
Patients who have amniocentesis may have a higher than average 
risk of miscarriage and other abnormal outcomes not only from 
amniocentesis but also because of the factors which dictated the 
need for amniocentesis. Amniocentesis performed for elevated Ms 
AFP appears associated with greater fetal loss than when 
performed for other indications (Bennett, 1978).
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Increased perinatal mortality rates have been reported in women 
who have had amniocentesis for elevated Ms AFP (Wald et al, 1977; 
Brock et al, 1979). Increased perinatal mortality rates have 
also been observed when Ms AFP has been elevated but amnioentesis 
has not been carried out (Read et al, 1980).
Sant-Cassia, Macpherson and Tyack (1984), in a controlled 
prospective study, found no significant increase in fetal loss, 
perinatal mortality or vaginal bleeding among women undergoing 
amniocentesis.
Bleeding from the fetal circulation as a result of placental
puncture is now nearly always avoidable with ultrasound guidance 
(McNay and Whitfield, 1984), although some reported no
significant difference in the frequency of complication whether 
an ultrasound scan is performed or not either before or at the 
time of amniocentesis (Sant-Cassia, Macpherson and Tyack, 1984).
In the West of Scotland during 1978-80 in 14 centres pregnancies 
in which high Ms AFP was not the indication for amniocentesis had 
an excess rate from abortions and perinatal deaths of 0.7% 
compared with a control group. While pregnancies in which
amniocentesis was performed because of high maternal serum AFP
had a wastage rate of 7.2% (comprising an abortion rate of 4.4% 
and a perinatal mortality rate of 2.8%) (Ferguson-Smith, 1983).
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In the United Kingdom (Report of MRC study, 1978) premature 
labour did not occur more often in women who had undergone mid­
trimester amniocentesis than in their controls. However there 
was an increase in deaths from respiratory distress syndrome in 
infants whose mothers had had amniocentesis compared with the 
controls. This could be due to altered amniotic fluid volume 
after amniocentesis or subsequent to chronic amniotic fluid 
leakage interfering wrth normal lung development (Hislop and 
Fairweather, 1982). There also appears to be increased frequency 
of antepartum haemorrhage due to placental abruption in the 
United Kingdom (Report of MRC 1978) following amniocentesis.
An increased number of orthopaedic postural malformations, such 
as talipes, dislocated hip (Report of MRC, 1978) have been 
reported. This is similar to the finding of Sant-Cassia, 
Macpherson and Tyack, (1984). This could be due to compression 
of the fetus in utero due to loss of amniotic fluid. Others have 
found no significant association between mid-trimester 
amniocentesis and congenital talipes or hip malformation (Wald et 
al, 1983). In a controlled study on women aged 35-40 years who 
were at risk of fetal chromosomal abnormality, amniocentesis was 
found not to influence infant mental and motor development, 
temperament, physical growth or risk of orthopaedic abnormalities 
(Finegan et al, 1985).
Fetal trauma is thought to be caused on occasions by mid­
trimester amniocentesis. Minor skin trauma such as skin scars or
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dimpling have been identified (Finegan et al, 1985). Major
trauma include neonatal small bowel obstruction in association 
with an epigastric abdominal wall defect with no satisfactory 
embryological explanation (Swift, Driscoll and Vowles, 1979);
ilial atresia, ileo cutaneous fistula (Rickwood, 1977) and
gangrene of a fetal limb (Lamb, 1975) have also been described. 
But the use of ultrasound greatly reduces the risk of needle 
injury during amniocentesis (Jeanty et al, 1983).
Amniocentesis may also have a psychological effect on parents. 
It was found that more maternal stress was engendered when the 
indication was elevated Ms AFP than when amniocentesis was 
carried out for other reasons (Farrant, 1980). This stress can 
be alleviated by supportive counselling given prior to
venepuncture and sustained until after the result of amniotic 
fluid analysis is known (Earle, 1981).
In the west of Scotland by repeating any high Ms AFP estimation 
and using 2.8 MOM (97th percentile) in both samples as the cut 
off point, the amniocentesis rate was kept below 0.7% of screened 
pregnancies (Ferguson-Smith et al, 1978).
Acetylcholine esterase
The most reliable test for the prenatal diagnosis of neural tube 
defects is amniotic fluid AFP assay. Its false positive rate 
remains low (Report of UK Collaborative Study, 1979), the mixture 
of fetal blood with amniotic fluid and other less well defined 
causes not infrequently prevents the accurate interpretation of
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elevated amniotic fluid AFP concentration. This problem, as well 
as the non-specificity of the assay (Milunsky and Alpert, 1974), 
have spurred the search for more specific indicators of neural 
tissue exposure in utero. Acetylcholine esterase (AchE) for 
example has been proposed as a promising complementary test to 
AFP (Smith et al, 1979). AchE is released from the tissue of
the brain and spinal, cord and has an important role in
neurotransmission; the source may become diminished as the 
nervous system matures, since the immature nerve terminals are 
expected to release more AchE than adult tissue (Chubb et al,
1979). It is likely that a fetal lesion in which cerebrospinal 
fluid is exposed to amniotic fluid will be associated with high 
amniotic fluid AchE (Smith et al, 1979). Red blood cells and 
muscle are enriched in AchE (Brock, 1983). AchE gains access to 
the fetal serum in the absence of a blood brain barrier (Silver, 
1974) and also gains access to amniotic fluid from exposed nerve 
plexuses in the case of aomphalocele or transudation of fetal
plasma through the skin following fetal death (Buamah, Evans and
Milford-Ward, 1980).
Raised amniotic fluid AchE levels are closely associated with 
anencephaly and open spina bifida. It is a useful marker in the 
diagnosis of neural tube defects in pregnancies with high 
amniotic fluid AFP results (Smith et al, 1979). Positive AchE 
results are observed in pregnancies associated with Turner’s 
syndrome (Chubb et al, 1979) and Gastroschisis (Milunsky and 
Sapirstein, 1982); positive results are also observed in fetuses
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with Trisomy 21, hyperplasia of the heart and lungs and fetal 
teratoma (Report of the Collaborative Acetylcholinesterase Study, 
1981).
Amniotic fluid samples in the second trimester contain 
appreciable amounts of non-specific pseudo cholinesterase and 
those fetuses with neural tube defects usually have AchE together 
with an increased amount of non-specific pseudocholinesterase 
activity (Smith et al, 1979).
AchE can be distinguished from non-specific pseudocholinesterase 
by the qualitative method using polyacrylamide.gel electrophoresis 
(Smith et al, 1979). In those with neural tube defects AchE 
appears as a fast-migrating band which can be suppressed by 
inhibitors.
Polyacrylamide gel electrophoresis appears 100% sensitive and 
specific as a test to discriminate between pregnancies with and 
without neural tube defects. Only 2/3 of abdominal wall defects 
were correctly predicted (Toftagen-Lansen, Wandrup and Norgaard- 
Pedersen, 1984).
False positive AchE results arise when amniotic fluid samples are 
contaminated with fetal blood (Report of Collaborative Study on 
Acetylcholinesterase, 1981) giving rise to a misleading band of 
AchE. The degree of blood contamination has to be greater than 
that giving rise to a spurious AFP result (Barlow et al, 1982).
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Mishandling of amniotic fluid in which AchE has been stripped 
from red cells may lead to false positive results (Brock, 1983).
By using the AchE test when a high amniotic fluid AFP is found 
the amniotic fluid false positive can be reduced by 94% (Report 
of Collaborative Study on Acetylcholinesterase 1981). AchE is 
characterised by a low number of false positives. Its high 
specificity is explicable by its derivation from the nervous 
system while AFP originates from other fetal tissue (Elejalde, 
Peak and Elejalde, 1986).
--a
Thus AchE is more sensitive and more specific for neural tube 
defects than is Am AFP (Smith et al, 1979). The great accuracy 
and reliability of the AchE result has reduced anxiety 
significantly and probably helped avert abortion (Milunsky and 
Sapirstein, 1982). Although AchE cannot distinguish fetal 
anterior abdominal wall defects from neural tube defects (Wald et 
al, 1980), AchE/total cholinesterase activity ratio is low in 
abdominal wall defects and high in open neural tube defects 
(Dale, 1980).
It was found that AchE polyacrylamide gel electrophoresis is more 
sensitive than ultrasound scanning in the detection of open 
neural tube defects (Toftager-Larsen and Norgaan-Pedersen, 1988). 
Although the AchE test is found to be a reliable and accurate 
test, it is no substitute for the AFP test (Read et al, 1982).
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In summary, the development of antenatal screening (secondary 
prevention) for NTD by measurement of maternal serum AFP at 16- 
20 weeks gestation represents a major scientific advance which 
will help to reduce the birth prevalence of NTD as a major public 
health problem. Maternal serum AFP is not specific for NTD there 
are other conditions also associated with high Ms AFP but the use 
of amniocentesis for amniotic fluid AFP and AchE as diagnostic 
tests solve this problem.
The objective of antenatal screening is termination of the 
affected fetuses which may help to relieve some of the burden on 
family and society. These screening tests have usally been found 
to be valid, reliable and acceptable by the pregnant population.
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Ultrasound in Antenatal Screening for Neural Tube Defects 
Ultrasound is a non-invasive technique which allows visual­
isation of the fetus in utero. Improvements in ultrasound 
technology have resulted in high resolution pictures.
Two main types of ultrasound are in common use. Continuous 
ultrasound using the Doppler principle which is used to detect 
moving structures such as the fetal heart and blood flow. And 
pulsed ultrasound which is used to outline structures within the 
uterus. The high resolution pictures which can now be obtained 
with both static and real time pulsed ultrasound, enables the 
ultrasonographer to identify intrafetal structures in the second 
trimester of pregnancy.
Ultrasound is regarded as an integral part of antenatal care and 
is used to screen all pregnancies, not only those at risk 
(Campbell and Little, 1980).
The real time scanners give a promising future - they are easy to 
operate, inexpensive, portable, clinically reliable and should be 
preferred as an initial test because it is without risk and 
produces no side effects (Kurjak et al, 1980). It was found 
that the real time is the method of choice for detection of 
anomalies (Campbell and Pearce, 1983). High operator expertise 
is required to avoid errors with ultrasound (Smith, Chudleigh and 
Campbell, 1984).
96
All users consider ultrasound safe when used at the intensities 
currently employed (below 20 mw/cm2) (Gough, 1984; Stark et al, 
1984). There is no evidence that ultrasound has adverse effects 
on the human fetus; there has been no evidence that children 
exposed to ultrasound during pregnancy have an increased 
incidence of cancer (Kinner-Wilson and Waterhouse, 1984; 
Cartwright et al, 1984). The risk and efficacy of imaging 
ultrasound cannot be assessed until a large adequately designed 
randomised controlled trial is carried out (Mole, 1986).
The average time taken per real time scanning is six minutes 
(Anderson, Phillips and Midwinter, 1982). The shorter time taken 
by the scan allows a greater number of patients to be scanned.
The diagnosis of NTD has been enhanced by recent ultrasonic 
improvement which enables detailed evaluation of intracranial 
structure.
Diagnosis of anencephaly must be made through the long axis of 
the fetus when the normally ovoid and regular outline of the 
fetal head is replaced by an irregular mass of the fetal skull 
and facial bones. Sometimes there is a knot of echoes at the 
cephalic pole representing the base of the skull and orbits. The 
visualisation can be made as early as 12 weeks gestation, but to 
avoid mistake a definitive judgement should be delayed to 14-20 
weeks gestation; the diagnosis should be confirmed by one or two 
scans or an elevated Am AFP (Campbell, 1977) but, due to the flexion,
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the fetal head is often in a different linear plane to that of 
the body and early engagement of the fetal head can sometimes 
give a false impression of anencephally (Campbell, 1977). 
Experienced investigators, however, rarely have trouble in making 
the diagnosis (Kurjak et al, 1980). The diagnosis facilitated by 
real time examination should not be missed with good equipment
and experienced technicians. The fetal head occasionally is too 
deep within the maternal pelvis, in which case allowing the 
maternal bladder to fill will improve the view and ultrasound is 
the ideal method for detecting this condition (Campbell and 
Pearce, 1983).
The first anencephaly terminated on the basis of an ultrasound
diagnosis was in 1972 (Campbell et al, 1972). Anencephaly is
associated with spina bifida in approximately 50% of cases 
(Campbell and Pearce, 1983). Sonography has been shown to be 
100% sensitive in identifying cases of anencephaly (Hashimoto et 
al, 1985; Roberts et al, 1983; Campbell, 1977).
Fetal spine visualisation has been improved by the introduction 
of real time techniques (Kurjak et al, 1980). The ability to
demonstrate spina bifida on ultrasound examination is directly 
proportional to the resolution of the equipment used and the size 
of the defect (Petres and Redwine, 1982).
Scans performed in longitudinal axis of the fetal body (figure 
1), the double or (tramline) outline of the fetal spine will be
Figure 1. Longitudinal section of fetal spine showing 
discontinuity at the "tramline", with "Lumbar Spina bifida".
QUEEN MOTHERS HPL 
CLASCOM 14-M^y-SO 
11 34 03 
SPA/ 3 5/30 
-8 <18
120 M X  1.00 
75 <fg 10 fp» 
S CURVE
FF TP 24*
Figure 2. Transverse section of the fetal spine showing 
"Lumbar Spina bifida".
Source: Dr. McNay; Queen Mothers Hospital
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identified and shown to be caused by echoes from the wall of the 
spinal canal, is best detected between 16-20 weeks gestation 
(Campbell, 1977; Kurjak et al, 1980) because the spinal curvature 
is not marked and the full length of the spine can usually be 
displayed on a single longitudinal scan at this stage (Campbell, 
1977).
The transverse scanning of the fetal spinal canal is needed from 
the cervical spine to the sacrum, the normal spine with intact 
neural arch appears as a closed circle while in the case of an 
incomplete neural arch it appears as a saucer or V-shaped or U- 
shaped deformity (Campbell, 1977; Campbell and Pearce, 1983). In 
practice, both the longitudinal and transverse scan is used; the 
real time scanner allows the site and the extent of the lesion to 
be predicted with a high degree of accuracy (Campbell and Pearce, 
1983). Defects involving more than three vertebral segments can
easily be diagnosed; if only one or two segments are involved the
diagnosis is more difficult (Harrison, Golbus and Filly, 1984). 
These abnormal bone features should be used to make the diagnosis 
when the sac cannot be visualised. If a sac can be demonstrated 
(Figure 2), and the anomaly easily recognised as cystic 
extension of the dorsal aspect of the spine, even the neural 
element into the sac can be demonstrated by ultrasonography 
(Vintzileos et al, 1987). This will allow for differentiation 
between a meningocele and meningomyelocele (Campbell and Pearce, 
1983). Open spina bifida may be easily diagnosed if the fetal
position is appropriate; excessive fetal movement and kyphosis
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may make precise transverse examination of the spine difficult 
(Lindfors et al, 1987).
Associated sonographic findings may also facilitate discovery of 
open spina bifida. The cranial and cerebellar signs were seen 
retrospectively in 70 fetuses with open spina bifida diagnosed by 
ultrasound at 16-23 weeks gestation (Nicolaides et al, 1986), 
such as microcephaly, ventriculomegaly scalloping of the frontal 
bones (Lemon sign) and anterior curvature of the cerebellar 
hemispheres (Banana sign) or apparently absent cerebellum (Figure 
3).
Campbell et al (1987) carried out a prospective study in 
pregnancies at high risk of fetal open spina bifida; they 
recognised the same markers as Nicolaides et al (1986) had found. 
In both studies the B.P.D. and head circumference were reduced, 
while Wald et al (1980) also observed that and suggested that 
this was due to intrauterine growth retardation.
These ultrasound markers should alert the sonographer to the 
possibility of spina bifida and encourage a detailed examination 
of the fetal spine (Nicolaides et al, 1986; CAmpbell et al, 
1987); they are helpful in identifying fetuses with spina 
bifida.
The sensitivity and specificity of these markers was measured by 
Campbell et al (1987). The presence of a Banana sign or absent
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Figure 3. Suboccipital bregmatic view of fetal head 
showing the "Lemon sign".
Source: Dr. McNay; Queen Mothers Hospital
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cerebellum gave a sensitivity of 96%; the specificity, predictive 
value of a positive and negative test, were all 100%. While the 
Lemon sign gave a sensitivity of 100%, specificity of 99%, the 
predictive value of a positive and negative test were 84% and 
100% respectively.
In addition, observation of purposeful movement of the lower 
extremities may be helpful in counselling the patient regarding 
prognosis (Roberts et al, 1983). About 15% of spinal lesions
that are skin covered are not amenable to diagnosis by AFP
(Laurence, 1974). Ultrasound is the only examination suitable
for their detection (Kurjak et al, 1980).
Second trimester ultrasonography can be extremely useful in 
determining the cause of an elevated maternal serum AFP. While 
AFP cannot define or indeed describe the particular abnormality, 
ultrasound has the ability to do so and may give qualitative
information to the doctor or patient which will enable them to
decide whether to continue with the pregnancy or opt for 
termination (Campbell et al, 1975).
Ultrasound can complement AFP estimation in accurate assessment
of fetal maturity and determine gestational age which is 
calculated by measurement of the BPD . in women attending
antenatal care. Women who were sure of the dates of their last
menstrual period (81%) were found to have appropriate ;BPP_,. 
measurement; in 3% the pregnancy was more than two weeks further
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advanced and in 14% was more than two weeks less than calculated 
(Bennett et al, 1982). Gough (1984) found about 20.2% of 
pregnancies appear to be below the cut-off after gestational age 
is readjusted. Women tend to over-estimate the duration of 
pregnancy while ultrasound dating will tend to reduce the number 
of abnormal AFP predictions in the amniotic fluid and increase 
the number in the maternal serum (Campbell et al, 1975). Other 
causes of high Ms AFP which can be readily diagnosed by 
sonography were multiple pregnancy and fetal demise (Campbell et 
al, 1975; Gough, 1984).
There are other potentially correctible defects which have high 
Ms AFP and can be imaged sonographically - anterior abdominal 
wall defects and urinary tract obstruction. Often amniocentesis 
can be avoided if a satisfactory explanation for elevated Ms AFP 
can be determined by ultrasound (Lindfors et al, 1987). If a 
satisfactory explanation for elevated Ms AFP level cannot be 
determined by ultrasound, amniocentesis for amniotic fluid AFP 
and AchE determination should always be carried out (Lindfors et 
al, 1987). No false negative result for open spina bifida with 
elevated Am AFP level and positive AchE was found (Maslak, 1985).
False positives have been reported in the presence of fetal blood 
but these are usually distinguishable from the true positive 
results by examination of the fluid for blood and by the 
distinctiveness of the AchE band on electrophoresis (Crandall and 
Matsumalo, 1986) although the diagnosis requires confirmation by
high resolution diagnostic ultrasound before termination of 
pregnancy could be recommended. Fetuses with normal AchE but 
raised Am AFP are likely to have anterior abdominal wall defects 
or kidney defects, some of which are surgically correctible 
(Buamah, Evans and Milfordward, 1980). The termination of 
fetuses with correctible defects should not be dismissed as an 
unimportant side effect of maternal serum AFP (Harris and Read, 
1981).
Experienced ultrasound operators should be able to confirm 
normality with a high degree of confidence (Campbell and Pearce, 
1983). Failure to identify a lesion related to its size and 
location with the majority of failures occurring with small 
defects in either the higher cervical or low sacral regions 
(Chamberlain, 1985). It was found that the false negative 
diagnosis rate by ultrasound was about 0.1% (Sabbagha, Tamura and 
Dalcompo, 1981) but Harris and Read (1981) found about 5%-10% of 
spina bifida are missed by ultrasound. They suggest that 
maternal obesity may be one reason for poor scans.
The accuracy of ultrasound depends greatly on operator experience 
together with the improvement in instrumentation (Campbell et al, 
1975; Smith, Chudleigh and Campbell, 1984). The use of real 
time ultrasound for the identification of spinal defects appears 
to be very good (Campbell and Pearce, 1983). In some 
institutions this modality has now totally replaced the role of 
Am AFP assay (Chamberlain, 1985).
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Ultrasound screening of all pregnant women can be a reliable and 
acceptable technique in the diagnosis of anencephaly and spina 
bifida and with experienced operators is probably superior to any 
other method (Christie, 1984). Detection rates of 73% were 
achieved in a small population in a period of eight years 
(1975-1983). In the same population during 1982 the detection 
rate was 100% due to improvements in equipment and technique 
(Christie, 1984).
Hobines et al (1979) concluded that in contrast to anencephaly, 
spina bifida is difficult to diagnose with ultrasound and 
requires significant operator experience.
The detection rate for open spina bifida was found to be 79%, 
suggesting that the fetal position made spinal visualisation more 
difficult (Robinson et al, 1980). A two-stage study was carried 
out in 1977-83 in high risk mothers; it was found that the 
sensitivity for anencephaly was 100% during both stages, while 
for open spina bifida sensitivity improved from 33% to 80%, 
specificity improved from 96% to 99%, the false positive rate 
fell from 57% to 9% and the false negative rate fell from 1% to
0.3%. It was concluded that improvements in operator experience 
led to improvement in the detection rate from stage one to stage 
two (Roberts et al, 1983).
The use of ultrasound as a screening technique during pregnancies
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was increased gradually. In France in 1976 only 11% of pregnant 
women received screening by ultrasound; by 1981 it had increased 
dramatically to 82% (Poisson-Salomon et al, 1987).
When antenatal diagnosis of certain fetal abnormalities is made 
the parent should receive appropriate genetic and perinatal
counselling based on antenatal findings and the management should 
take their wishes into consideration; the parents should be
offered the option of termination (Vintzileos et al, 1987).
In summary, ultrasound is a non-invasive method of visualising
the fetus in utero. It may become routine for all pregnancies. 
Ultrasound acts as an adjunct to AFP screening, though it may be 
used independently in the future as an alternative to AFP 
estimation in maternal serum and amniotic fluid for the detection 
of Anencephaly and Spina bifida. This would require the 
development of considerable skills and experience for their
accurate interpretation.
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Criteria for Evaluation:
In order to evaluate a screening programme various interdepenent 
factors which can effect its success require exploration: (Wilson 
and Junger 1968; Hotlzman 1981). These may be summarised as 
follows:
A. Definition of the problem:
1. What abnormality of medical significance is to be 
detected?
2. What prevention or therapy is to be offered?
3. Which group is to be screened?
B. Review of position before screening:
1. Evidence concerning the epidemiology. The Natural 
history and medical significance of the abnormality.
C. Review of evidence concerning the screening procedure:
1. Effectiveness of proposed treatment and its 
acceptability.
2. Effectiveness of proposed diagnostic methods (Validity).
3. Acceptability of screening test.
4. Available resources.
The present study has been designed to address these issues which 
have been already discussed in some detail in the introduction, 
section one.
SECTION II - OVERVIEW OF LITERATURE
AND RATIONALE OF THE STUDY
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SECTION II: OVERVIEW OF LITERATURE AND RATIONALE OF THE STUDY
Open neural tube defects (Anencephaly and Spina bifida) are the 
commonest malformations in the European Community. The 
population of the West of Scotland suffer one of the highest 
prevalance rates of congenital neural defects in the world.
The chief consequence of Anencephaly is either stillbirth or 
neonatal death, while Spina bifida is often associated with a 
high early infant mortality rate and physical and mental 
disability in the survivors.
Genetic factos appear to play a minor role in the aetiology of 
the defects: about 95% of all children with NTD are born to 
couples with no relevant family history. To reduce birth 
prevalence is by secondary prevention, whereby diagnosis of these 
malformations is made in early pregnancy while therapeutic 
abortion is still possible. These methods should be both cost- 
effective and acceptable to pregnant women.
Screening for NTD became a practical proposition when it was 
discovered that an increase in alpha-fetoprotein in the blood and 
amniotic fluid of the affected fetus was accompanied by increased 
maternal serum alphafeto-protein. This phenomenon, along with 
the use of ultrasound, has been exploited to enable neural tube 
defects to be either detected or suspected at a relatively early 
gestational age (16-20 weeks). The detection and termination of
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affected pregnancies by antenatal screening may therefore be 
offered to the entire pregnant population and has been done so in 
the West of Scotland for several years.
In order to clarify the issue, an epidemiological approach is 
necessary. The essence of any epidemiological investigation lies 
in its population-based methodology, in contrast to most clinical 
studies which often 'define subjects in terms of groups of 
patients or comparisons with other patient categories. Antenatal 
screening is a good example of this conceptual divide: a
clinically orientated judgement of performance will tend to 
evaluate success in terms of the sensitivity and specificity of 
the test, while a public health view requires an extension of 
these data to embrace the impact of the screening procedure on 
the frequency of affected births in the population at risk rather 
than merely amongst those screened. These are not mutually
exclusive approaches, but they do represent different research 
philosophies and hence methodologies. An epidemiological 
evaluation of screening should incorporate several elements into 
its frame of reference:
The epidemiological characteristics (including any secular 
changes in prevalence) of the conditions being screened, or 
understanding of the natural history of the condition (and 
consequently of the outcome of non-intervention).
An assessment of the effectiveness of the screening in 
changing the outcome (both for the individuals and
especially for the population as a whole).
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An assessment of the efficiency of screening (since this 
will influence its ultimate effectiveness), including the 
proportions screened, detected and terminated, and an 
appraisal of the practical implications of the findings for 
service providers.
The present study was designed to evaluate antenatal screening 
for NTD in epidemiological public health terms, along the lines 
of the conceptual framework described above.
Glasgow is ideal for an epidemiological evaluation of antenatal 
screening programmes because it is a high risk geographical area 
with a population bassed register of congenital malformations and 
it has been served by an antenatal screening programme for NTD 
since 1975.
SECTION III - OVERALL AIM AND OBJECTIVES
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SECTION III: OVERALL AIM AND OBJECTIVES
OVERALL AIM
To evaluate the programme of antenatal screening for Neural tube 
defects (Anencephaly and Spina bifida) in Greater Glasgow for the 
years 1976-1986.
OBJECTIVES OF THE STUDY
In order to evaluate antenatal screening for the detection of NTD 
(Anencephaly and spina bifida), the following questions required 
to be answered:
1 - What is the epidemiology and the natural history of the
condition?
What is the prevalence of Anencephaly and spina bifida in 
the study population?
Are there any significant secular trends, and what are their 
implications for screening?
- What is the natural history of Anencephaly and spina bifida
and how is it affected by screening?
2 - What is the effectiveness of screening?
- What is the impact of screening on the birth prevalence of 
NTD?
- Has birth and pregnancy prevalence diverged over time?
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3 - What is the efficiency of screening?
- How successfully is screening delivered to the target 
population?
- What are the technical and organisational obstacles to 
efficiency?
- What is the sensitivity and specificity of the screening
test?
4 - What are the conclusions of the study?
- How effective and efficient is screeing for NTD as a public 
health measure?
- What are the key factors influencing the impact of 
screening?
5 - What are the policy implications?
- What do the findings mean for screening policy in the West 
of Scotland, and generally?
- How can screening be improved in terms of its effectiveness
and efficiency?
- What is the future of antenatal screening for NTDs?
- What future research is required?
SECTION IV: MATERIAL AND METHODS
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SECTION IV: MATERIAL AND METHODS
4.1 Study Population:-
The Greater Glasgow Health Board area was created after the 
reorganisation of the NHS in 1974. Five main maternal hospitals 
serve pregnant women (Figure 4). Its total population is
currently less than one million and is about one fifth of that
for Scotland. There has been a continuous decline in the 
estimated size of the GGHB population from 1976-1986 (Table 1) . 
The annual number of total births has fluctuated around 13,000 
while the annual outward migration has decreased from about 2% 
of the total population in the 1970's to 1% or less in the 
1980's.
The social class distribution in the GGHB area compared with that 
of Scotland and England (Table 2) indicates that social classes I 
and II are under-represented in Glasgow compared to Scotland and 
England, while the population of social classes IV and V are 
higher in Glasgow than in Scotland and England. .
There has been a consistent marked decline in stillbirth, 
perinatal, neonatal and infant mortality rates (Table 3). In 1986 
the stillbirth rate for GGHB was the same as that for Scotland,
while the neonatal and infant mortality rates were less than that
for Scotland. Neonatal mortality in Scotland was similar to that 
in England, 5.2 per 1000 live births during 1986; while infant 
mortality in Scotland was lower than that in England during the
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Maternity Hospitals in Glasgow:
Stobhill Hospital 
Queen Mothers Hospital 
Royal Maternity Hospital 
Southern General Hospital 
Rutherglen Maternity Hospital
Hospitals closed:
Eastern District Hospital (Duke Street)
Robroyston Hospital 
Redlands Hospital
Other Glasgow Hospitals:
Royal Samaritan Hospital (associated with Rutherglen - terminations) 
St. Frances Maternity Hospital (Catholic hospital)
Hospitals not in the GGHB area but with maternal address in Glasgow: 
Paisley Maternity Hospital 
Vale of Levan Maternity Hospital 
Bellshill Maternity Hospital
Figure 4. Hospitals contributing data to the study.
same year, 8.8 and 9.5 per 1000 live births respectively (Pharoah 
and Alberman 1988). In the 1970’s Glasgow had higher stillbirth, 
perinatal, neonatal and infant mortality rates than Scotland 
(Registrar General Scotland 1970). This may be partly due to 
advances in neonatal and obstetric care and to the higher 
proportion of mothers attending early for antenatal care and 
screening.
119
4.2 Glasgow Register of Congenital Malformations
The Glasgow Register of Congenital Malformations was established
in 1972 by the Corporation of Glasgow health department. After 
the reorganisation of the NHS in 1974 the responsibility for the 
Register was assumed by the Greater Glasgow Health Board. It is 
population-based in that it relates to the population resident 
within the boundaries of the Greater Glasgow Health Board area.
Glasgow was selected as one of the centres to participate in the 
multi-national EUROCAT (European Registration of Congenital 
Anomalies and Twins) project of the European Community in 1979
(Weatherall, De Wals and Lechat, 1984).
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A.3 Sources of Ascertainment
Multiple sources of information were employed in order to achieve 
maximum levels of ascertainment and to ensure that as few cases 
as possible were missed. No formal time limit exists for 
registration of newly diagnosed cases. Whatever the source of 
ascertainment, all diagnostic information was validated by direct 
scrutiny of clinical or pathological records.
The ascertainment was both active and passive (Figure 5). Active 
ascertainment involves the careful scrutiny of data which are 
held centrally or in clinical departments. Passive ascertainment 
is a process of communication of details of malformations from 
the notifying agency directly to the Register.
Different sources of information have been used over the years; 
the number and nature of these sources changed either because one 
or more of the sources ceased or because more rewarding sources 
became available (Hamilton et al, 1985).
The principal active sources of data were:
Hospital Records:-
Maternal and paediatric case notes at the various maternity 
hospitals located throughout the Greater Glasgow Health Board 
area are scrutinised by the clerical staff of the Information 
Services Unit. The main areas of interest in these case 
notes are the routine hospital discharge forms. A summary
document is completed for every woman discharged from the
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Active Sources Passive Sources
Hospital records 
Scanning of routine hospital 
discharge forms (SMR1, SMR2, 
SMR11)
Post-mortem reports 
Perinatal meetings 
Department of medical genetics
Paediatric discharge letters 
Health visitor notification 
Stillbirth and death registers
Figure 5. Sources of ascertainment, Glasgow Register of Congenital Malformations 
Source: Stone and Hamilton (1987)
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hospital after childbirth and for every child discharged after 
delivery.
Form SMR2 - Maternal Discharge Record:
This covers details recorded concerning the mother and can be 
used as a check on data already in the reports, e.g. post code, 
gestation, mother's date of birth, date of l.m.p., previous 
pregnancies, occupation of the mother (not always available), 
occupation of the father (not always available). (Appendix 3)
Form SMR11 - Neonatal Discharge Record:
This contains details concerning the baby and lists malformations 
if any. One of three copies is retained by the maternity units 
which permitted Register staff to examine batches of the forms 
periodically. The main shortcoming of this source was its 
incomplete coverage. (Appendix A)
Form SMR1 - Hospital Discharge Record:-
A child hospitalised after the neonatal period has a hospital 
summary form (SMR1) completed on discharge. These forms have 
diagnostic information including the presence of any congenital 
anomaly. It comes in a computer printout of all hospital 
discharges in Scotland from the Information Statistics Division, 
Common Services Agency, Edinburgh. (Appendix 5)
Post Mortem Reports
A report of all post mortems performed on fetuses terminated with
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congenital malformations is sent to the Department of Medical 
Genetics from the pathology department in Yorkhill. The clerical 
staff at the Registry examine them during their visits to the 
Medical Genetics Department.
Department of Medical Genetics
A computer printout of all terminations known to have been 
performed subsequent to prenatal diagnosis of a congenital 
anomaly, is examined regularly by Registry staff. (This is 
discussed in more detail later, 4.4.)
Perinatal Meetings:-
The Registry staff attend many of these meetings which are held 
in maternity units in order to obtain further information about 
known cases. Occasionally a new case of congenital anomaly is 
identified in this way.
The principal passive sources of data were:- 
Paediatric discharge letters
When a child with congenital abnormality is discharged from the 
hospital a copy of the letter from the paediatrician to the 
family doctor is sent to the Registry. If the information 
contained in the letter is not complete the hospital case record 
is examined.
Health Visitor notification:-
Every child resident within the Greater Glasgow Health Board area
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has a health visitor and child health record. This record is 
structured for developmental screening and immunisation consent. 
There are four tear-out pages in the record (Appendix 6), the 
immunisation consent form and three developmental screening 
returns for use at 8-10, 16-20 and 42-48 months of age. On each 
of the four returns a question is specifically asked about the 
presence of any congenital malformation. The health visitor 
notifies the child health department about the congenital 
malformations and the Registry staff have direct access to this 
information.
Stillbirth and Death Registers;-
The Registrar General for Scotland in Edinburgh provides a 
computer printout for these events and they are used to identify 
cases of congenital malformation in which the appropriate 
causes of death are coded (Appendix 7).
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4.4 Department of Medical Genetics
In the West of Scotland Ms AFP has been used as a screening test
for neural tube defects since 1974. The test is voluntary and
its purpose is to identify a group of women in which AFP levels
were above the normal range since the option of termination may 
arise from abnormal test results.
Blood samples were drawn by the general practitioner or the 
obstetrician at 16-20 weeks of gestation during the antenatal 
care. All the samples are sent to the Duncan Guthrie Institute 
of Medical Genetics laboratory for testing. The screening
programme not only depends on assay precision but also on the 
precision with which the period of gestation is determined in 
every pregnancy tested.
Once the patient's Ms AFP level is determined it is compared with 
normal values established within the laboratory for each week of 
gestation. An intervention point has to be chosen which is a 
reasonable compromise between affected and unaffected 
pregnancies. At the start of the West of Scotland programme a 
high cut-off level was used - the 99th centile (3.0 MOM) - to 
keep the number of false positives to a minimum. In 1979 the 
cut-off level was reduced to the 97th centile (2.5 MOM). In 1983 
only the design of the form was changed; from 1985 to the present 
the 95th centile (2.0 MOM) has been used as an intervention level 
(Appendix 8). It takes about 4-7 days (from the date the sample 
is taken) for the result to be ready. The reports are typed with
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the aid of a mini-computer which simplifies filing and helps in 
the maintenance of adequate quality control.
Those with normal Ms AFP levels have no further action taken 
(Figure 6) and a written report is sent to the referring 
obstetrician. Those with Ms AFP above the intervention point are 
reported by telephone to the referring obstetrician, antenatal 
clinic sister or the unit secretary for immediate examination of 
the antenatal clinic notes with recall of the patient for 
ultrasonography.
Ultrasound examination is an integral part of the screening 
programme; in some clinics ultrasound was used at the booking 
visit to check the patient's dates. This is called a routine 
scanning.
One of the following causes for elevation of Ms AFP may be found, 
such as wrong date, twin pregnancy, fetal demise, abortion or an 
abnormality.
If no cause is found a second blood sample is taken and sent to 
the laboratory. It usually takes about 2-3 days for the result 
to be ready from the date the sample is taken from the patient. 
If the result is normal, a written report is sent to the 
referring obstetrician and if the ultrasound is normal no further 
action is taken.
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Routine Antenatal Care
yesroutine scan?
no no yes
blood sample for MS AFP at 16-20 weeks 
of gestation
no elevated MSAFP?
yes
second blood sample and/or 
ultra sound
yes
normal result?
no
yes
explained?
anencephaly 
spina bifida 
other
wrong gestation 
fetal death 
multiple pregnancy 
threatened abortion
no
Amnio centesis - AFP, AchE 
and detailed scan
no certain
yes
yes (  high risk 
\  group
normal result?
no
parental decision making 
terminate pregnancy?
no
yes
Appropriate 
measures takenNo further action Induced abortion
Figure 6. Flow chart for follow up of antenatal screening programme 
in Greater Glasgow Health Board Area
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If the result is high (above the intervention point), this is 
reported by telephone. The obstetrician is informed and asked to 
consider a detailed ultrasound (diagnostic) and amniocentesis. 
It takes about 2-3 days from the time the sample is taken to get 
Am AFP and polyacrylamide gel for AchE electrophoresis (usage 
started in 1981) to ensure that false negative Am AFP results 
will become even rarer.
Those with normal Am AFP and AchE are considered to be high risk 
obstetric patients and they need a good follow-up. Those with a 
result of Am AFP above the intervention point and a second AchE 
band are offered termination of pregnancy by the obstetricians 
after counselling.
Mothers who have an increasing risk due to an affected previous 
birth and maternal age more than 35 and who have requested 
prenatal diagnosis are offered amniocentesis and detailed
ultrasound.
An increasing number of anencephalic cases have been detected by 
routine ultrasound examination without requiring an Ms AFP test.
All amniotic fluid samples are examined for fetal blood 
contamination.
Information is obtained by the Medical Genetic Department about
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the result of those with levels above the intervention point from 
several sources.
Postcards
The Medical Genetic Department keep postcards in each hospital in 
the labour room so that those terminated or born with an 
abnormality are reported on these cards and sent back to them.
Pathology Department:-
The product of termination is usually sent to pathology. After 
examination a copy of the result is sent to the Medical Genetics 
Department.
Labour Room:-
Staff from the Medical Genetics Department regularly check the 
labour room record to see if any congenital abnormality is 
recorded.
Surgical Ward:-
Some of the staff from the Medical Genetics Department check the 
surgical ward record in the Royal Hospital for Sick Children. In 
this way most of the missed cases and those not tested are 
identified.
In recent years a cross-check of known cases has been conducted 
with the Register of Congenital Malformation. All the cases with 
neural tube defects in the whole of the west of Scotland known to
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the Department of Medical Genetics are recorded on cards 
structured alphabetically by surname of person, address, date of 
birth, report about the result of the test including detection 
and diagnosis, missed or not tested, abnormality present, result 
of pathology if termination carried out.
Those who are tested by AFP and missed are reported in a separate 
book called 'the missed book' with the reason of missing them.
A detailed analysis of each step in the screening process Fig.26 
was confined to a single year (1986) because it was only for 
this year that comprehensive data were available.
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4. 5 Numerator and Denominator Data:
The study was carried out in Glasgow for the period 1976-1986. 
The Glasgow Register of Congenital Malformations and the Duncan 
Institute of Medical Genetics, Yorkhill, are the key points for 
collection of data on anencephaly and spina bifida births (live 
and still), both multiple and singleton births are included, 
therapeutic termination and antenatal screening. Spina bifida 
occulta is not included.
The Register, involved in EUROCAT, has adopted the five-digit 
British Paediatric Association code, based on the latest revision 
of the International Classification of Diseases which was used 
for diagnostic coding (World Health Organisation, 1977).
If a combination of defects was present, like anencephaly and 
spina bifida, anencephaly was always regarded as the principal 
malformation.
Although the study is a retrospective one, all the data and 
information were collected prospectively (on the expected date of 
delivery for those terminated).
Because Glasgow is one of the members of EUROCAT a special form 
called the EUROCAT Report on Congenital Malformations (Appendix 
9) started to be used in 1980. One form is filed for each 
registered defect, such as anencephaly and spina bifida births 
(live and still) and therapeutic termination with relevant
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material in date of birth order. Therapeutic terminations were 
filed separately on date of termination. For each defect, 
whether birth or termination, information is recorded about the 
child, the mother and, to a limited extent, the father.
For NTD births (live and still) for the years 1976-1979 there was 
information missing, usually on maternal age, previous 
pregnancies, occupation of the father and antenatal screening. 
Some were sought from hospital case records with the assistance 
of the Medical Records Office (but some of them were not recorded 
on the case notes).
For therapeutic terminations for the years 1976-1979 the only 
information available was on maternal age, address and the cause 
for therapeutic termination. All the rest of the information 
required was sought from the hospital case record with the 
assistance of Medical Records Office. All the detailed 
information about the antenatal screening for neural tube defects
was sought from the Department of Medical Genetics, Yorkhill, on
both alpha-feto protein and ultrasound screening.
If a patient had high Ms AFP then an ultrasound scan and 
amniocentesis was carried out. If the fetus turns out to have a 
NTD then the case was referred to be detected by Ms AFP and 
diagnosed by ultrasound or Am AFP and AchE. If the patient had a 
chance to have a routine scan at booking and before the test of
Ms AFP and an abnormality was observed, it will be said that it
was detected by ultrasound.
Because the total number of pregnant women 1976-1986 in GGHB 
area was unknown, the number of pregnant women in GGHB area 
screened was also unknown. (In the west of Scotland programme
the number of patients referred from General Practitioners or 
from the hospital to get AFP screening tests were recorded but 
not by area of resident.) Those screened by GGHB hospital and 
General Practitioner were used as an estimate number of those 
screened for the GGHB area for those expected to be born in 
1982-1986 were available.
Information on maternal age, parity and social class to enable a 
comparison of the screened and not screened pregnancies was not 
available.
Information about the date of birth and date of death for those 
who died were sought from the GGHB Register of Congenital 
Malformations. For those surviving there was no information 
about the degree of disability they have.
For calculating the pregnancy prevalence for Anencephaly and 
Spina bifida the denominator consisted of the number of total 
births (live and still) during the period but did not include 
abortions (spontaneous or induced). This does not undermine the 
value of the prevalence later as the number of induced abortions 
for fetal malformations is very low compared with the total
numbers of births. Data on spontaneous abortions are not 
available from any source.
Methodological Note
Although the complete study period is 1976-1986 the results and 
tables occasionally deviate from this period for the following 
reasons:
1. In order to demonstrate the secular trend in the prevalence, 
it is necessary to look at an earlier period, so the years 
1964-1986 are presented.
2. In order to estimate the proportion of all pregnant women 
who were screened in the years 1982-86 were employed because 
data for earlier years were not available; even for 1982-86 
information on the maternal age parity and social class for 
screened and not screened was not available.
3. Data on age parity and social class were available for 
affected pregnancies for the years 1979-86. They were not 
available for the period 1976-78.
4. The number of normal fetuses aborted during 1976-1981 was 
not known and so assessment of the specificity of screening 
was confined to the period 1982-86.
5. In order to describe each step in the screening process, the 
single year 1986 was employed for detailed study because it 
was only for this year that all data necessary for this 
analysis were available.
SECTION V: METHODS OF ANALYSIS
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SECTION V METHODS OF ANALYSIS
5.1 - Data processing
The Register collected information on both affected births and 
therapeutic termination. Figures 7 and 8 illustrate the many 
steps involved in the transmission of data along the pathways 
from sources to analysis.
Following the birth of an affected child, an initial diagnosis 
was made which was either suspected or definitive, followed by a 
prolonged clerical process involved in identifying defects from 
sources which had to be scrutinised by Registry staff. Because 
some data were incomplete or unsatisfactory, verification was 
required. This was followed by completion of a registration form 
(Eurocat) related to diagnostic classification. If more than one 
defect was listed in order of severity, then the form was filed 
in date of birth order.
Updating of the file is carried out in the event of death, which 
is ascertained from the death register, by recording the date, 
place and cause of death.
Missing data on maternal age, parity and social class were sought 
from hospital case records with the assistance of the medical 
records officer.
Data from the registration forms were transferred to coding forms
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Ana lysis
Filing (manual)
Intermittent updating
Filing (computerised)
Search for missing data
Birth of affected child
Verification (if necessary)
Transfer of data to coding form
Diagnosis (suspected or definitive)
Completion of registration form (EUROCAT)
Ascertainment by Register of Congenital Malformation
Figure 7. Flow chart of data on Anencephaly and Spina bifida births.
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Analysis
Filing (computerised)
Search for missing data
Transfer of data to coding form
Pathology conformation of diagnosis
Completion of registration form (EUROCAT)
Termination of pregnancy for suspected Anencephaly or Spina bifida
Entry of data into "Termination Book" of Department of Medical Genetics
Ascertainment by termination file of Register of Congenital Malformations
Figure 8. Flow chart of data on Anencephaly and Spina bifida terminations.
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The coded data was then entered on a computer file and a series 
of computer print-outs generated for analysis.
After termination of pregnancy for suspected anencephaly or spina 
bifida all aborted specimens were examined pathologically and the 
Department of Medical Genetics received written details about the 
aborted fetuses which were entered into their termination book. 
Access to this book was granted to Registry staff who entered the 
case details into a termination file of the Glasgow Register of 
Congenital Malformations. The registration forms (Eurocat forms) 
were completed, then a search for missing data such as maternal 
age, parity and social class was carried out by the Registry 
staff with the assistance of hospital medical record officers. 
Thereafter analyses were carried out.
The data concerning this study were transferred to a 
microcomputer ar. !> standard statistical packages SPSSX were used 
on the Glasgow University mainframe.
The graphics were produced by Harvard Graphics on IBM PS/2.
The numbers are presented in percentages or rates per 1000. To 
obtain an estimate of the prevalence the numerators and the 
denominators were transformed into annual rates per 1000 total 
births (live and still).
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The data are presented in tables, diagrams, and graphs. A 
variety of statistical tests were used to assess trends and 
associations between variables. These included standard chi- 
squares, Z-test-scores, poisson and logistic regression analyses.
The data were analysed in order to generate tabulation as 
follows:
Epidemiology and natural history (see 5.2)
Effectiveness of antenatal screening (see 5.3)
Efficiency of delivery screening service (see 5.4)
Efficiency of screening procedure (see 5.5)
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5.2 Epidemiology and the natural history
Prevalence rate of NTD. (Anencephaly, Spina Bifida and both 
together) per 1000 total births in Glasgow population for 
the years 1976-1986.
Glasgow, the period 1976-1986 being disaggregated into two 
periods, 1976-1981*and 1982-1986, the rates being calculated 
and examined for evidence of secular trends
Glasgow, the period 1979-1986 being treated as a single unit
for comparison with an earlier period
The outcome of anencephalic pregnancies from conception to 
birth, birth to survival (all died), the percentages
compared between the two time periods (1976-1981 and
1982-1986)
The outcome of spina bifida pregnancies from conception to 
birth and following the survival to more than one year. 
From birth and following the survival to more than one year. 
Comparison between the two time periods (1976-1981 and 
1982-1986).
Perinatal, neonatal and infant mortality for anencephaly, 
spina bifida and compare the two time periods (1976-1981 and 
1982-1986).
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5.3 Effectiveness of Antenatal Screening
Anencephaly and spina bifida. Pregnancy prevalence and 
birth prevalence per 1000 total births and percentages of 
pregnancies terminated in Glasgow 1976-1986 for evidence of 
the effectiveness of antenatal screening for neural tube 
defects
The period 1976-1986 being disaggregated into two periods 
(1976-1981 and 1982-1986) and the percentages of termination 
and birth for anencephaly and spina bifida were compared
The proportions screened, detected and those terminated when 
detected for anencephaly and spina bifida, which give an 
insight into the effectiveness of antenatal screening, 
Glasgow 1976-1986, were examined for evidence of a trend.
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5.4 Efficiency of delivery of screening service
Pregnancies screened as a proportion of total births Glasgow 
1982-1986 and pregnancies screened as a proportion of total 
pregnancies Glasgow 1982-1986. To show the difference when 
total birth is used and total pregnancy. They also can be 
used as an estimate of the acceptability of antenatal 
screening for NTD. '
A comparison of the proportions of NTD pregnancies, screened 
and not screened, in terms of maternal age, parity and 
social class for the screened and not screened and the 
outcome of pregnancy.
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5.5 Efficiency of the technique
The method which is used for the identification of those at
a high risk of neural tube defects and the method of
diagnosis were analysed for anencephaly, spina bifida and 
neural tube defects. For those terminated to identify which 
method was more frequently used.
The sensitivity for anencephaly, spina bifida and ASB to
identify the detection rate for NTD in Glasgow using the 
combined approach during the periods 1976-1982 and 
1982-1986.
The proportion of those detected and terminated as a 
consequence of antental screening for anencephaly, spina 
bifida and NTD. Glasgow (1976-1981 and 1982-1986) for 
measurement of the efficacy of the techniques.
The specificity for Anencephaly and Spina bifida antenatal 
screening in Glasgow for the years 1982-1986 only.
A detailed description of the process of screening during 
the single year 1986 to elucidate the proportion with high 
MsAFP in the first blood sample, second blood sample, and 
the proportion offered amniocentesis.
SECTION VI: RESULTS
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SECTION VI: RESULTS
6.1 THE EPIDEMIOLOGY AND NATURAL HISTORY
During the study period 1976-1986 there were 142,565 total births 
to Glasgow residents. The following are the numbers (and 
prevalence rates) of anencephaly and spina bifida births both 
live and still, (i.e. fetuses born at 28 weeks or more 
gestation):
Anencephaly 61 (0.43 per 1000 total birth)
Spina bifida 180 (1.26 " " " " )
Anencephaly and spina bifida 241 (1.69 11 " " " )
The time trend in prevalence of ASB were* "examined in terms of 
both annual and secular trends.
The annual changes in prevalence within the study period 
(1976-1986) are shown in Tables 4, 5, 6. There was a marked
decline in birth prevalence of anencephaly, particularly in 1982 
and 1985. There was a decline in birth prevalence of spina 
bifida, with the lowest during 1983. Trends in birth prevalence 
were modelled using poisson regression models (Figures 9, 10).
Lines for the trend were fitted to the rates for anencephaly and 
spina bifida birth prevalence over the study period 1976-1986. 
There was a significant decline in birth prevalence for both 
anencephaly (X2 = 44.42 (ldF) p<0.0005) and spina bifida (X2 =
20.9 (ldF) p<0.0005).
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Figure 9. Birth prevalence of anencephaly : 
Glasgow 1976-86.
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Figure 10. Birth prevalence of spina bifida: 
Glasgow 1976-86.
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The rates of birth prevalence of anencephaly and spina bifida 
were divided into two periods 1976-1981 and 1982-1986 (Table 7). 
There was a marked and significant decline in birth prevalence 
for anencephaly (X2 = 30.8 (ldF) p<0.05) and spina bifida (X2 =
12.2 (ldF) p<0.05) during 1982-1986 compared to 1976-1981 time 
period
There was also a significant decline in pregnancy prevalence for 
anencephaly, spina bifida and ASB (Table 8).
Evidence of secular trend (Table 9, 10; Figure 11, 12) was sought 
by comparing the prevalence found in the present study period 
(1979-1986) with that reported in an earlier Glasgow study by 
Wilson (1970) and Stone (1981); these too drew upon multiple 
sources of ascertainment.
There was a significant decline in . anencephaly birth prevalence 
in 1972-1978 compared to 1964-1968 (X2 = 21.2 (ldF) p<0.001) and 
in 1979-1986 compared to 1972-1978 (X2 = 129.7 (ldF) p<0.001).
For spina bifida birth prevalence during 1972-1978 compared to 
1964-1968 (X2 = 0.06 (ldF) p>0.05) did not decline significantly. 
When 1979-1986 was compared to 1972-1978 there was a significant 
decline (X2 = 71.0 (ldF) <0.001).
In the case of pregnancy prevalence (birth and termination) the 
picture was different. There was a non-significant decline in 
both anencephaly and spina bifida pregnancy prevalence during 
1972-1978 compared to 1964-1968 (X2 = 2.56 (ldF) p>0.05 and X2 = 
0.03 (ldF) p>0.05) respectively, while 1979-1986 compared to 
1972-1978 for both anencephaly and spina bifida shows a
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Figure 11. Trend in anencephaly and spina bifida 
pregnancies : Glasgow 1964-68; 1972-78; 1979-86.
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Figure 12. Trend in anencephaly and spina bifida births : 
Glasgow 1964-68; 1972-78; 1979-86.
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significant decline for anencephaly (X2 = 18.3 (ldF) p<0.05) and 
spina bifida (X2 = 18.7 (ldF) p<0.05).
Figure 13 shows anencephaly and spina bifida pregnancies from 
1964-1986; for the years 1969-1971 data were not available.
Of 91 anencephaly pregnancies during 1982-1986 - 93% were induced 
abortions (Figure 14,' Table 11). This was a statistically 
significant difference from the 65% in 1976-1981 (X2 =24.6 (ldF) 
p<0.001). Still-births comprised about 1.10% which is a 
significantly lower proportion (X2 = 28.5 (ldF) p<0.001) than
that (28%) during 1976-1981. But there were no significant
differences in the number of live births during the two time
periods (X2 = 0.06 (ldF) p>0.05). All died during the first week
of life. Frequency of death during 1982-1986 was not 
significantly different from 1976-1981 (X2 = 0.06 (ldF) p>0.05).
In the case of spina bifida pregnancies (Figure 14, Table 12) 
there were 107 total spina bifida births during 1982-1986 of 
which induced abortions accounted for about 44% (X2 = 8.4 (ldF) 
p<0.01) and stillbirths about 6% (X2 = 3 . 9  (ldF) p<0.05). From 
1976-1981 induced abortions accounted for 27%, stillbirths 13%. 
(These differences are statistically significant.
If we follow the survival of spina bifida fetuses starting from 
pregnancy (Table 13) 32.7% survived more than one year during
1982-1986 compared to 34% during 1976-1981, but this difference
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Figure 13. Anencephaly and spina bifida pregnancies : 
Glasgow 1964-86.
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Figure 14. Outcomes for anencephaly and spina bifida 
pregnancies in Glasgow : 1976-81 and 1982-86.
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is not statistically significant (X2 = 0.06 (ldF) p>0.05).
But if we follow the survival from birth (Table 14) to those 
surviving more than one year, about 60.4% survived more than one 
year among 1982-1986 births in comparison with 47.5% during 
1976-1981. This is a non-significant difference (X2 = 2.6 (ldF) 
p>0.05).
Table 15, 16, show the perinatal, neonatal and infant mortality
for anencephaly and spina bifida respectively. All anencephaly 
babies died during the perinatal period.
For spina bifida the perinatal, neonatal and infant mortality was 
lower during 1982-1986 in comparison with 1976-1981, but the 
differences are not significant (X2 = 3.5 (ldF) p>0.05) (X2 =
0.84 (ldF) p>0.05) and (X2 = 1.25 (ldF) p>0.05) respectively.
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6.2 THE EFFECTIVENESS OF ANTENATAL SCREENING
The differences between pregnancy prevalence and birth prevalence 
is one means of estimating the effectiveness of antenatal 
screening.
The effectiveness of antenatal screening is affected by three 
factors: the proportions of affected pregnancies screened, the
proportion of affected pregnancies detected (sensitivty) and the 
proportion of affected pregnancies terminated when detected.
The annual trends in pregnancy prevalence, birth prevalence and 
percentage terminated for anencephaly and spina bifida are shown
in Table 17 and 18. The total number of anencephaly pregnancies
was 250 during 1976-1986 and the pregnancy prevalence (birth + 
termination) was 1.75 per 1000 total births; 75.6% of these 
pregnancies were terminated during the same period. The total 
number of spina bifida pregnancies was 277 giving a pregnancy
prevalence of 1.94 per 1000 total births; only 35.02% of
pregnancies terminated during this period.
The trend in birth and pregnancy prevalence were analysed using 
poisson regression models. In the case of anencephaly (Figure 
15) the regression slopes for both birth and pregnancy prevalence 
were found to be significant over the period 1976-1986 (X = 44.42 
(ldF) p<0.0005), (X2 = 8.68 (ldF) p<0.005) respectively (Appendix 
10 (i)).
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Figure 15. Pregnancy and birth prevalence of anencephaly 
with fitted trends : Glasgow 1976-86
In the case of spina bifida pregnancy prevalence (Figure 16) 
there was no significant trend in the regression slope during 
1976-1986 (X2 = 3.78 (ldF) p>0.05) while in the case of birth 
prevalence there was a significant trend during 1976-1986 (X2 =
20.9 (ldF) p<0.0005) (Appendix 10 (i)).
There was a significantly lower births for anencephaly during 
1982-1986 compared to ' 1976-1981 (Table 19) (X2 = 24.6 (ldF)
p<0.005) with a high percentage terminated. In the case of spina 
bifida (Table 20) there was also a significantly lower birth with 
a higher percentage terminated during 1982-1986 compared with 
1976-1981 (X2 = 8.9 (ldF) p<0.005). A high proportion (97.8%) of
anencephaly pregnancies were screened during 1982-1986. This was 
significantly different from 1976-1981 (X2 = 25.0 (ldF)
p<0.0005). (Table 21).
The proportion of spina bifida pregnancies screened during 
1982-1986 was 75.7% compared with 61.8% during 1976-1981. This 
is also a significant difference (X2 = 5.8 (ldF) p<0.025).
(Table 22).
The proportion of anencephaly and spina bifida pregnancies 
terminated is an outcome of the proportion screened, the 
proportion detected when screened (sensitivity) and the 
proportion terminated when screened and detected. Changes in 
proportion terminated, (an estimate of the effectiveness of 
screening), could be due to changes in one or any combination of
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Figure 16. Pregnancy and birth prevalence of spina bifida 
with fitted trends : Glasgow 1976-86.
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these three factors. Trends over time were modelled individually 
for these three factors using logistic regression. The details 
of the significance and fit of the regression curves are given in 
Appendix 10 (ii).
Factors Contributing to the Effectiveness of Antenatal Screening 
for Anencephaly:
The proportion of anencephaly pregnancies screened was below 50% 
in 1976, increased rapidly to 100% in 1982 until 1985, and in 
1986 dropped to 92.3% (Table 23, Figure 17, 18). There was a
significant trend in the proportion of affected pregnancies 
screened (Z score = 8.5 p<0.0001).
The proportion of anencephaly pregnancies detected when screened 
(sensitivity) was 91.6 in 1976 and increased to 100% in 1986 (Table 
23, Figure 17, 19). There was a significant upward trend in the 
proportion detected when screened (X2 = 6.6 (ldF) p<0.025).
The proportion terminated when screened and detected fluctuated 
between 90% and 100% during 1976-1986 (Table 23, Figure 17, 20).
Factors Contributing to the Effectiveness of Antenatal Screening 
for Spina Bifida
The proportion of spina bifida screened in 1976 was also below 
50% and then started to increase gradually to more than 84% in 
1985 and declined in 1986 to 71.4% (Table 24, Figure 21, 22).
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Figure 17. Screening and outcomes of screening for 
anencephaly: Glasgow 1976-86.
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Figure 18. Anencephaly screening : proportion (%) 
screened in each year 1976-86.
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Figure 19. Anencephaly detected : sensitivity of 
screening (%) for each year 1976-86.
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Figure 20. Anencephaly terminated : terminated 
when detected (%) for each year 1976-86.
There was a significant trend in the proportion screened (Z score 
= 6.45 p<0.05).
The proportion of spina bifida pregnancies detected when screened 
also increased gradually over the period 1976-1986 (Table 24,
Figure 21, 23). There was a significant upward trend in the
proportion detected when screened (Z score = 4.16 p<0.05).
The proportion terminated when screened and detected (Table 24, 
Figure 21, 24) also shows a significant upward trend over the
period (Z score = 6.03 p<0.05).
The trends in proportion screened, proportion detected, 
proportion terminated when detected, enable the trend in 
termination to be modelled. The expected proportions for these 
variables are multiplied together to produce the expected
proportion terminated (Figure 17, 21). The fit of the expected
number terminated is assessed by Pearson's goodness of fit Chi-
Square statistic (Appendix 10 (ii)).
The results may be summarised as indicating a more consistent 
improvement over time in the effectiveness of screening for
anencephaly than for spina bifida.
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Figure 21. Screening and outcomes of screening for 
spina bifida : Glasgow 1976-86.
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Figure 22. Spina bifida screening : proportion (%) 
screened in each year 1976-86.
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Figure 23. Spina bifida detected : sensitivity of 
screening (%) for each year 1976-86.
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Figure 24. Spina bifida terminated : terminated 
when detected {%)  for each year 1976-86.
6.3 EFFICIENCY OF SCREENING SERVICE
The acceptability of antenatal screening for neural tube defect 
was assesseded indirectly by examining the proportions of 
pregnancies screened in the GGHB area, whether in hospitals or by 
general practitioners. 84.5% of total pregnancies were screened 
during 1982-1986.
There were 117,193 pregnancies in Glasgow during 1979-1986 with 
359 ASB pregnancies; of these 297 ASB pregnancies were screened 
and 227 detected and terminated; 21 were detected and born and 
about 49 missed (Figure 25).
Only 62 ASB pregnancies (17%) were not screened; 24 declined 
screening; 28 booked too late and 10 were put under other 
reasons, which included those with no antenatal care or only 
minimal antenatal care, no record of antenatal screening on their 
case note, or concealed pregnancy.
Figure 25,a summarises the outcome of anencephaly pregnancies 
1979-1986. 91.6% were screened, and of them 86.23% were detected
and terminated. 2.39% were detected and born and only 2.99% 
missed by the screening technique. Only 8.38% were not screened, 
while 4.19% declined and 2.39% booked too late.
Figure 25,b summarises the outcome of spina bifida pregnancies 
during 1979-1986. 75% were screened but only 43.23% were
detected and terminated, 23% were not detected. 25% were not
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ASB in Glasgow population 1979-1986
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Figure 25. Outcomes of screened and not screened pregnancies with ASB.
Glasgow 1979-1986.
no antenatal screening or minimal antenatal care 
no record of antenatal screening on the case note 
concealed pregnancy
numbers in brackets represent a percentage
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screened. Of these 8.85% declined and 2.5% booked too late.
This contrasting pattern confirms the view that the screening 
process tends to favour the detection of anencephaly rather than 
spina bifida.
The frequencies of the variables of maternal age, parity and 
social class were compared jin the screened and not screened ASB 
pregnancies 1979-1986. There were significant differences in the 
proportions of affected pregnancies screened and not screened in 
different age groups. The age-group least screened were those 
aged under 20, 34.2% were not screened (X2 = 16.22 (4dF) p<0.01) 
(Table 27).
There was a variation in different parity groups in the 
proportions of affected pregnancies screened and not screened, 
but this is not statistically significant (X2 = 9.5 (4dF) p>0.05) 
(Table 28).
There was a high proportion of these NTD pregnancies not screened 
in lower social classes: about 23.2% in social class IV and
25.78% in social class V (Table 29) compared with 6.3% and 13.6% 
in social classes I and II respectively. There is a trend in 
social class (not screened) with a significant increase in 
proportions not screened in lower social classes.
Anencephaly in Glasgow population 1979-1986 
167(100%)
Screened 
153 (91.61)
Detected Detected Not Detected
Terminated Bom (Missed)
144 (86.23) 4 (2.39) 5 (2.99)
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14 (8.38)
Declined Booked Other
7(4 .19) too late reasons*
4(2 .39) 3 (1.79)
Figure 25a. Outcomes of screened and not screened pregnancies with Anencephaly. 
Glasgow 1979-1986.
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Figure 25b. Outcomes of screened and not screened pregnancies with Spina bifida. 
Glasgow 1979-1986.
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concealed pregnancy
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6.4 EFFICIENCY OF THE SCREENING PROCEDURE
Table 30 shows the proportions of those terminated upon detection 
and then diagnosed by specific methods. (Ms AFP/ultra - means 
detected by maternal serum AFP and diagnosed by ultrasound.) 
67.06% of anencephaly cases were detected and diagnosed by 
ultrasound during 1982-1986; this is highly significant (X2 = 
42.6 (ldF) p<0.001) when .compared with 1981-1982, while in the 
case of spina bifida the use of ultrasound for detection and 
diagnosis of spina bifida accounted for only 8.2% which is not 
significant (X2 = 2.2 (ldF) p>0.1).
A high proportion, 48.98%, of spina bifida pregnancies were 
detected by Ms AFP and diagnosed by AmAFP compared with only 
3.53% of anencephaly during the same period 1982-1986. Those 
spina bifida pregnancies detected by MsAFP and diagnosed by 
ultrasound and AmAFP was 26.53% during 1982-1986 compared with 
26.09% during 1976-1981; despite a growing use of ultrasound as a 
diagnostic procedure, AFP remained an important case finding 
method.
In the case of anencephaly, 4.71% detected be MsAFP and diagnosed 
by Uls and AmAFP during 1982-1986 compared with 45.19% during 
1976-1986.
The sensitivity for anencephaly in Glasgow during 1982-1986 was 
96.7% (Table 31) compared to 93.9% during 1976-1986.
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The sensitivity for spina bifida was 67.9% during 1982-1986 
compared to 58.1% during 1976-1981.
For ASB the sensitivity was 83.14% (Table 31).
(Table 32) The proportion of anencephalic pregnancies detected 
and terminated as a consequence of antenatal screening techniques 
during 1982-1986 for anencephaly was 93.4%. This was
significantly higher than the 65.4% in that category in 1976-1981 
(X2 = 24.18 (ldF) p<0.001). For spina bifida the proportions
were 45.8% which is also significant in comparison with only 27% 
during 1976-1981 (X2 = 9.8 (ldF) p<0.005). For both together it 
was 67.68% which is highly significant (X2 = 23.7 (ldF) p<0.001).
The specificity of the screening process for anencephaly (Table 
33) and spina bifida (Table 34) was 100% during 1982-1986. There 
were no false-positive terminations for either anencephaly and 
spina bifida.
The specificity refers to the pereformance of the screening 
programme in the total pregnant population, in contrast with teh 
performance of the laboratory assay or other individual elements 
within the screening process.
However the detailed analysis of screening process shown in 
Figures 26,27 enable the reader to examine the sensitivity and 
specificity of the individual screening steps.
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Analysis of the various steps involved in MsAFP and ultrasound 
screening in Glasgow is presented for 1986 in Figure 26. The 
salient points are as follow:
The proportion of women offered antenatal screening for ASB 
represented 77.4% of all pregnancies.
709 (6.2% of women initially tested my MsAFP fel above the 
intervention level which is 95th centil 2.0 (MOM).
In 251 (35.4%) of those (with high first blood sample) the result 
was explained by the use of ultrasound. 152 pregnant women with 
high first blood sample had normal results on repeat testing.
Four pregnancies with Spina bifida were missed by the initial 
MsAFP testing despite screening.
281 pregnant women had two elevated MsAFP results follow-up 
procedures involved first detailed ultrasound scanning in which 
one Anencephalic and five Spina bifida were diagnosed resulting 
in a total of 24 cases of ASB diagnosed by ultrasound.
Four pregnancies with sequential MsAFP above the intervention 
point refused amniocentesis and did not accept abortion, two of 
them led to anencephaly births and two to Spina bifida.
195 of 202 women offered amniocentesis had normal results. Seven 
Spina bifida pregnancies were diagnosed, resulting in a total of
174
)* expressed as a percentage of the immediately preceding total 
]** expressed as a percentage of all pregnancies
(14798)
yes
(11456, 77.4%)’ 
Proudne scan? I—— —
no
(3342, 22.6%)
yes
(9790, 85.5%) (18, 0.2%)
no
(1666, 14.5%)
no
(9772, 99.8%)
yes
(10729, 93.8%;
amniocentesis 
(25, 3.5%)
[14071, 95.1%] yes (251, 36.7%)
no
(433, 63.3%)
no
(152, 35.2%)
yes
(281, 64.9%)
yes (104, 37.0%)
no
[14223, 96.1%] (177, 63.0%)
|  normal resuhT|  ^  ------[highrisk group"}
no
(7, 3.5%) [544, 3.7%]
no (0)
yes
(31, 100%)
1986 pregnancies
abnormality
detected?
no further 
action
elevated MSAFP? 
[433, 2.9%]
appropriate measures 
taken
induced abortion
anencephaly (16, 88.9%) 
spina bifida (2, 11.1%)
anencephaly (1, 0.4%) 
spina bifida (5, 1.8%)
previous NTD (5,20.0%) 
maternal age>35 (20, 80.0%)
amniocentesis - AFP, AchE 
[202,1.4%]
detailed scan recommended 
[281,1.9%]
blood sample for MSAFP at 
16-20 weeks gestation 
[11438, 773%]**
parental decision making- 
terminate pregnancy? 
[31, 0.2%]
second blood sample and/or 
ultra sound scan recommended 
or go to amniocentesis 
[709, 4.8%]
wrong gestation (172, 68.5%) 
multiple pregnancy (61, 24.3%) 
threatend abortion (15, 6.0%) 
refused 2nd sample (2, 0.8%) 
fetal death (1, 0.4%)
non attenders (31, 29.8%) 
threatend abortion (27, 26.0%) 
refuse amnio (15, 14.4%) 
multiple pregnancy (12, 11.5%) 
intra uterine death (7, 6.7%) 
other cong. abnormality (6, 5.89i
Figure 26. Flowchart of the screening process 1986
175
affected
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programme 31
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Figure 27. Extent of benefit of screening for ASB and physical harm 
from screening to unaffected pregnancies. 1986.
Adapted from Chamberlain, J. 1978.
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SUMMARY OF THE RESULTS
1 - What is the epidemiology and the natural history of the 
conditions?
- What is the prevalence of anencephaly and spina bifida in 
the study of the population?
The birth prevalence during 1976-1986 for anencephaly was 0.43 
per 1000 total births. The birth prevalence for spina bifida was
I.26 per 1000 total births during the same period.
There was a marked decline in birth prevalence for anencephaly 
and spina bifida which was statistically significant (Table 4,5; 
Figure 9,10).
- Are there any significant secular trends, and what are their 
implications for screening?
There was a downward secular trend in both birth and pregnancy 
prelavence of anencephaly and spina bifida (Table 9,10; Figure
I I , 12 ) .
- What is the natural history of anencephaly and spina bifida 
and how is it affected by screening?
For anencephaly a high proportion (93%) of fetuses were 
terminated during 1982-1986, while a low proportion (1.1%) were
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stillbirths over the same period (Table 11). The perinatal and 
neonatal mortality was 100% (Tablel5).
For spina bifida during 1982-1986 was under 50% affected fetuses 
terminated, while a low proportion (5.6%) were still births in 
comparison with 12.9% for 1976-1981 (Table 12).
The proportion of affected pregnancies surviving more than one 
year after birth was higher during 1976-1981 than 1982-1986 but 
this is not significant (Table 13).
If we follow the survival from birth, a higher proportion survive 
more than one year in 1982-1986 compared to 1976-1981. This is 
not a significant difference either (Table 14).
Perinatal, neonatal and infant mortality during 1976-1981 was 
lower than during 1981-1986, but this ' is not significant (Table 
16).
2 - What is the effectiveness of screening?
- What is the impact of screening on the birth prevalence?
Have birth and pregnancy prevalence diverged over time?
The difference between the pregnancy prevalence and birth
prevalence (which is equal to the proportion terminated)
represents the impact of antenatal screening.
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75.6% of anencephaly were terminated during 1976-1986, but only 
35.02% of spina bifida terminated during the same period. There 
was a significant downward trend in both birth and pregnancy 
prevalence during 1976-1986 in anencephaly, . but a significant 
trend found for spina bifida birth only. (Table 17,18; Figure 
15,16).
There were significant increasing trends in affected pregnancies 
with regard to the proportion screened, proportion detected and 
proportion terminated when detected during 1976-1986 for both 
anencephaly and spina bifida (Table 23, 24; Figure 17,21).
3 - What is the efficiency of screening?
- How succesfully was screening delivered to the target 
population?
84.5% of all pregnancies were screened during 1982-1986 when 
total birth was used as the denominator, a figure which 
dropped to 75% when total pregnancies (live + still + 
termination) are used as the denominator during the same 
period (1982-1986)
- What are the technical and organisational obstacles to 
efficiency?
For the period 1979-1986, 82.75% of ASB pregnancies were
screened. Of these, 63% were detected and terminated, 5.85% 
detected and born and 13.65% were missed by the technique. 
17.27% of ASB were not screened (Figure 25).
91% of anencephaly were screened and only 8.38% were not 
screened.
In the case of spina bifida, 75% were screened and 25% were 
not screened (Figure 25 a, b).
A high proportion (76.1%) of anencephaly was detected and 
diagnosed by ultrasound during 1982-1986 in comparison with only 
8.2% of spina bifida during the same period (Table 30).
- What is the sensitivity and specificity of screening?
The sensitivity for anencephaly was 97.6% while the 
specificity was 100% during 1982-1986 (Table 31,33).
For spina bifida the sensitivity was 67.9% with a 
specificity of 100% during 1982-1986 (Table 31, 34).
While the sensitivity and specificity of the assay can be 
calculated from figure 27.
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Table 1. Annual C hanges in B irths, D eath s, and M igration (1971-1986) 
G reater G lasgow H ealth  Board
Year
Estim ated
Home
Population
Changes Affecting Population
Population
Change
Births Deaths Natural
Increase
Net
M igration
Other
Changes
1976 1,082.0 -23.2 12.3 14.1 -1.8 -21.8 + 0 .4
1977 1,058.7 -20.7 12.4 14.6 -2.2 -18.7 + 0 .2
1978 1,038.0 -14.9 12.8 14.8 -1.9 -13.2 + 0 .2
1979 1,022.1 -11.0 13.3 14.0 -0.7 -10.2 -0.1
1980 1,012.0 -10.2 13.4 13.7 -0.3 -13.9 + 4 .0
1981 1,007.3 -11.0 12.9 14.2 -1.2 -9.8 0.0
1982 996.3 -11.2 12.8 13.5 -0.7 -10.5 0.0
1983 985.1 -6.1 12.4 13.4 -0.9 -5.1 0.0
1984 979.1 -10.3 12.9 13.1 -0.2 -10.1 0.0
1985 968.8 -9.0 13.1 13.4 -0.3 -8.6 0.0
1986 959.8 -8.6 12.9 12.7 0.2 -8.8 0.0
Source: Annual Reports o f the Registrar General for Scotland. (1981, 1987)
Edinburgh.
Table 2. Percentage Distribution of the Populations of Greater
Glasgow Health Board,
Scotland and England by the Registrar General’s Social Classes (1981)
Social Class G .G .H .B . Scotland England
I 5.8 5.6 6.0
II 20.0 22.4 25.9
III N ' 13.7 12.9 14.1
III M 34.2 34.4 32.5
IV 17.5 18.1 16.3
V
coCO 6.7 5.2
Sources:
Census 1981 Scotland Report for Strathclyde Region  
vol. 2 table 49.
Census 1981 N ational Report for Great Britain  
vol. 2 table 49.
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Table 3. Infant, N eonatal, Perinatal M ortality  and Still B irths  
G reater G lasgow H ealth  Board A rea and Scotland  (1981-1986)
Scotland G .G .H .B .
Years Infant*
M ortality
Neonatal*
M ortality
Perinatal**
M ortality
Still**
Births
Infant*
M ortality
Neonatal*
M ortality
Perinatal
M ortality
Still**
Births
1976 15 10 18 10 17 11 20 10
1977 16 11' 18 9 18 12 20 9
1978 13 9 15 18 14 8 16 10
1979 13 9 14 7 13 9 13 6
1980 12 8 13 7 13 9 14 7
1981 11 7 12 6 12 7 12 7
1982 11 7 12 6 11 6 11 6
1983 10 6 11 6 9 5 9 5
1984 10 6 11 6 9 5 10 6
1985 9 5 10 5 9 5 10 7
1986 9 5 10 6 8 4 9 6
Source: A nnual Report o f the General Registrar for Scotland (1981-1986).
* Per 1000 live births.
** Per 1000 total births.
Table 4. Birth Prevalence of Anencephaly in Glasgow 1976-1986
Year Total Births 
(Live +  still)
Anencephaly
Births
Anencephaly  
Birth Prevalence*
95% C.I.**
1976 12889 17 1.32 0.77 - 2.11
1977 12487 11 0.88 0.44 - 1.58
1978 12491 10 0.80 0.38 - 1.47
1979 13339 9 0.67 0.31 - 1.28
1980 13438 5 0.37 0.12 - 0.87
1981 13491 3 0.22 0.05 - 0.65
1982 12884 0 0.00 0.00 - 0.29
1983 12661 1 0.08 0.00 - 0.44
1984 12783 1 0.08 0.00 - 0.44
1985 13089 0 0.00 0.00 - 0.28
1986 13013 4 0.31 0.08 - 0.79
Total 142565 61 0.43 0.33 - 0.55
* Prevalence is expressed as rate per 1000 total births.
** Confidence interval.
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Table 5. B irth  P revalence o f  Spina B ifida in  G lasgow  1976-1986
Year Total Births 
(Live -f still)
Spina Bifida  
Births
Spina Bifida  
Birth Prevalence*
95% C.I.**
1976 12889 19 1.47 0.82 - 2.30
1977 12487 30 2.40 1.62 - 3.43
1978 12491 24 1.92 1.23 - 2.86
1979 13339 24 1.80 1.15 -2 .6 8
1980 13438 17 1.27 0.74 - 2.03
1981 13491 8 0.59 0.26 - 1.17
1982 12884 20 1.55 0.95 - 2.40
1983 12661 7 0.55 0.22 - 1.14
1984 12783 8 0.63 0.27 - 1.23
1985 13089 11 0.84 0.45 - 1.63
1986 13013 12 0.92 0.48 - 1.61
T otal 142565 180 1.26 1.09 - 1.46
* Prevalence is expressed as rate per 1000 total births.
** Confidence interval.
Table 6. Birth Prevalence of Anencephaly and Spina Bifida Combined
in Glasgow 1976-1986
Year Total Births 
(Live +  still)
A .S .B .
Births
A .S .B .
Birth Prevalence*
95% C.I.**
1976 12889 36 2.79 2.03 - 3.85
1977 12487 41 3.28 2.43 - 4.44
1978 12491 * 34 2.72 1.96 - 3.79
1979 13339 33 2.47 1.77 - 3.46
1980 13438 22 1.64 1.03 - 2.48
1981 13491 11 0.81 0.41 - 1.46
1982 12884 20 1.55 . 0.95 - 2.40
1983 12661 8 0.63 0.27 - 1.24
1984 12783 9 0.71 0.32 - 1.34
1985 13089 11 0.84 0.42 - 1.50
1986 13013 16 1.23 0.70 - 2.00
Total 142565 241 1.69 1.49 - 1.92
* Prevalence is expressed as rate per 1000 total births.
** Confidence interval.
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Table 7. Prevalence of Anencephaly and Spina Bifida Births:
Glasgow, 1976-1981 and 1982-1986
Year
Grouping
Total Births 
(Live +  Still)
Anencephaly
Births
Spina Bifida 
Births
A .S .B .
Births
No. R ate No. R ate No. R ate
1976-1981 78135 55 0.70 122 1.56 177 2.26
1982-1986 64430 6 0.09 58 0.90 64 0.99
1976-1986 142565 61 0.43 180 1.26 241 1.69
x l  =  30.8 ( ld f ) X2 =  12.2 ( ld f ) x 2 =  33.9 ( ld f )
P  <  0.05 P <  0.05 P <  0.05
Table 8. P revalence o f  A nencephaly  and Spina B ifida Pregnancies: 
G lasgow, 1976-1981 and 1982-1986
Year
Grouping
Total Births 
(Live +  Still)
Anencephaly
Pregnancies
Spina Bifida  
Pregnancies
A .S .B .
Pregnancies
No. Rate No. R ate No. R ate
1976-1981 78135 159 2.03 170 2.18 329 4.21
1982-1986 64430 91 1.41 107 1.66 198 3.07
1976-1986 142565 250 1.75 277 1.94 527 3.69
x 2 = 7.82 ( ld f ) X2 =  4.83 ( ld f ) X2 =  12.4 ( ld f )
P <  0.05 P <  0.05 P  <  0.001
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Table 9. Secular Change in B irth  Prevalence o f A nencephaly and Spina
Bifida:
G lasgow, 1964-1968; 1972-1978; 1979-1986
Year
Grouping
Total Births 
(Live +  Still)
Anencephaly
Births
Spina Bifida  
Births
A .S .B .
Births
No. R ate No. Rate No. R ate
1964-1968*
1972-1978**
1979-1986***
103,123
92,325
104,698
292 2.83 
168 1.82 
23 0.22
289 2.80  
242 2.62 
107 1.02
581 5.63 
410 4.44  
130 1.24
Anencephaly Births 
Spina Bifida Births
A nencephaly and  
Spina Bifida Births
1972-1978)/(1964-1968) x 2 =  21.2 ( ld f )  P <  0.001
1979-1986)/(1972-1978) x 2 =  129.7 ( ld f )  P <  0.001
1972-1978)/(1964-1968) x 2 =  0.6 ( ld f )  P >  0.05 (N .S .)
1979-1986)/(1972-1978) x 2 =  71.0 ( ld f )  P <  0.001
1972-1978)/(1964-1968) x 2 =  13.7 ( ld f )  P  <  0.001
1979-1986)/(1972-1978) x 2 =  183.7 ( ld f )  P <  0.001
* W ilson, T .S . (1970).
** Stone, D .H . (1981).
*** Present study. (1979-1986) chosen so as not to overlap w ith Stone (1981).
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Table 10. Secular Change in Pregnancy Prevalence o f  A nencephaly  and
Spina Bifida:
G lasgow, 1964-1968; 1972-1978; 1979-1986
Year
Grouping
Total Births 
(Live +  Still)
Anencephaly
pregnancies
Spina Bifida 
Pregnancies
A .S .B .
Pregnancies
No. Rate No. R ate No. R ate
1964-1968* 103,123 292 2.83 289 2.80 581 5.63
1972-1978** 92,325 227 2.46 255 2.76 482 5.22
1979-1986*** 104,698 167 1.59 192 1.83 359 3.43
Anencephaly Pregn. (1972-1978)/ 
(1979-1986)/
Spina Bifida Pregn. (1972-1978)/ 
(1979-1986)/
Anencephaly and 
Spina Bifida Pregn.
(1972-1978)/
(1979-1986)/
1964-1968) x 2 =  2.56 ( ld f )  P  >  0.05 (N .S .)
1972-1978) x 2 =  18.3 ( ld f )  P  <  0.05
1964-1968) x 2 =  0-03 ( ld f )  P  >  0.05 (N .S .)
1972-1978) x2 =  18.7 ( ld f )  P <  0.05
1964-1968) x 2 =  1-54 ( ld f )  P <  0.05 (N .S.)
1972-1978) x2 =  37.1 ( ld f )  P  <  0.05
W ilson, T .S . (1970).
Stone, D .H . (1981).
Present study. (1979-1986) chosen s o  as not to  overlap w ith  Stone (1981).
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Table 11. O utcom e o f A nencephaly Pregnancies  
Glasgow: 1976-1981 and 1982-1986
Years
Grouping
1976-1981 1982-1986
No. % No. %
Induced
Abortions
104 65.41 
X2 =  24.6 (1
85 93.41  
df) P <  0.001
Still'
Births
45 28.30 
X2 =  28.5 (1
1 1.10 
df) P <  0.001
1st Week 
D eath
10 6.29 
X2 =  0.06 (:
5 5.49 
df) P >  0.05
Total 159 91
There were no spontaneous abortions or death after 7 days in either periods.
Table 12. Outcome of Spina Bifida Pregnancies
Glasgow: 1976-1981; 1982-1986
Years
Grouping
1976-1981 1982-1986
No. % No. %
Spontaneous
Abortions
2 1.18 2 1.87
Induced
A bortions
46 27.06 
X2 =  8.4 (lc
47 43.92 
f )  P <  0.01
Still
Births
22 12.94 
X2 =  3.9 ( lc
6 5.61 
!f) P  <  0.05
Live
Births
100 58.82 
X2 =  2.8 ( lc
52 48.60  
if) P >  0.05
Total
Pregnancies
170 100 107 100
* Proportions surviving to live birth (%)
Table 13. Outcome of Spina Bifida Pregnancies
Glasgow: 1976-1981; 1982-1986
Years
Grouping
1976-1981 1982-1986
No. % No. %
Spontaneous
Abortions
2 1.18 2 1.87
Induced
Abortions
46 27.06 
X2 =  8.4 (1<
47 43.92  
If) P <  0.01
Still - 
Births
22 12.94 
X2 =  3.9 (lc
6 5.61 
f)  P  <  0.05
1st Week 
Death
15 8.82 
X 2 =  2.7 (lc
4 3.74  
f)  P >  0.05
1st Month 
Death
13 7.65 7 6.54
1st Year 
Death
14 8.23 6 5.61
Survival 
>  One Year
58 34.12  
X2 =  0.05 (1
35 32.71  
df) P >  0.06
Total
Pregnancies
170 100 107 100
* Proportions surviving to one year {%)
Table 14. Outcome of Spina Bifida B irths
Glasgow: 1976-1981; 1982-1986
Years
Grouping
1976-1981 1982-1986
No. % No. %
Still
Births
22 18.03 
X2 =  1-7 (lc
6 10.34 
[fj P  >  0.05
1st Week 
Death '
15 12.29 4 6.90
1st Month 
Death
13 10.66 7 12.07
1st Year 
Death
14 11.48 6 10.34
Survival 
>  One Year
58 47.54  
X2 =  2.6 (lc
35 60.35  
If) P  >  0.05
Total births 122 ■»- 58 i ® c .
Percentage distribution of deaths 
and survival
Table 15. Births, Perinatal, Neonatal and Infant Mortality
associated with Anencephaly: Glasgow, 1976-1981 and 1982-1986
Years
Grouping
1976-1981 1982-1986
No. % No. %
Live
Births
10 5
Still 
Births -
45 1
Perinatal Mortality* 
Still Births -f  
1st Week D eath
55 100.0 6 100.0
N eonatal Mortality** 
Death 1-28 
Days Old
10 100.0 5 100.0
Infant Mortality** 
D eath <
One Year Old
0 0 0 0
* Proportions out o f Live Births and Still Births.
** Proportions out o f Live Births.
Table 16. Births, Perinatal, Neonatal and Infant Mortality
associated with Spina Bifida: Glasgow, 1976-1981 and 1982-1986
Years
Grouping
1976-1981 1982-1986
No. % No. %
Live Births 100 52
Still Births 22 6
Perinatal Mortality* 
Still Births +
1st Week Death
37 30.33  
x 2 =  3.5 (1<
10 19.23 
If) P  >  0.05
N eonatal Mortality** 
D eath 1-28
Days Old
28 28.00  
x 2 =  0.84 (1
11 21.15 
df) P >  0.05
Infant Mortality** 
D eath <  1 yr
42 42.00 | 17 32.69  
X2 =  1.25 ( ld f )  P  >  0.05
T he d ata  in th e  above tab le can also b e  presented  as
Years 1976-1981 1982-1986
Grouping No. % No. %
Live Births 100 52
Still Births 22 6
Perinatal Mortality* 37 30.33 10 19.23
Early Neonatal Mortality** 15 15.00 4 7.69
Late Neonatal Mortality** 13 13.00 7 13.46
Post N eonatal Mortality** 14 14.00 6 11.54
* Proportions out o f Live Births and S till Births.
** Proportions out o f Live Births.
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Table 17. Anencephaly: Annual Rates of Pregnancy and Birth
Prevalence
and percentage of affected pregnancies terminated: Glasgow 1976-1986
Year
T otal Births 
(Live +  still)
Total
Anencephaly
Anencephaly
Births
Anencephaly
Pregnancy
Prevalence
A nencephaly
Birth
Prevalence
%
Anencephaly
Term ination
1976 12889 27 17 2.09 1.32 37.04
1977 12487 '2 6 11 2.08 0.88 57.69
1978 12491 30 10 2.40 0.80 66.67
1979 13339 34 9 2.55 0.67 73.53
1980 13438 20 5 1.49 0.37 75.00
1981 13491 22 3 1.63 0.22 86.36
1982 12884 22 0 1.71 0.00 100.00
1983 12661 18 1 1.42 0.08 94.44
1984 12783 14 1 1.10 0.08 92.86
1985 13089 11 0 0.84 0.00 100.00
1986 13013 26 4 2.00 0.31 84.62
T otal 142565 250 61 1.75 0.43 75.60
(Prevalence is expressed as rate per 1000 total births.)
Trend in Pregnancy Prevalence x 2 =  8.68 ( ld f )  P <  0.005  
Trend in Birth Prevalence x 2 =  44.42 ( ld f )  P <  0.0005
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Table 18. Spina B ifida A nnual R ates o f  P regnancy and B irth
P revalence
and p ercentage o f  affected  pregnancies term inated: G lasgow  1976-1986
Year
T otal Births 
(Live +  still)
Total 
Spina Bifida
Spina Bifida 
Births
Spina Bifida 
Pregnancy  
Prevalence
Spina Bifida  
Birth  
Prevalence
%
Spina Bifida  
Term ination
1976 12889 21 19 1.63 1.47 9.52
1977 12487 *36 30 2.88 2.40 16.67
1978 12491 28 24 2.24 1.92 14.29
1979 13339 30 24 2.25 1.80 20.00
1980 13438 28 17 2.08 1.27 39.29
1981 13491 27 8 2.00 0.59 70.37
1982 12884 25 20 1.94 1.55 20.00
1983 12661 16 7 1.26 0.55 56.25
1984 12783 19 8 1.49 0.63 57.89
1985 13089 26 11 1.99 0.84 57.69
1986 13013 21 12 1.61 0.92 42.86
Total 142565 277 180 1.94 1.26 35.02
(Prevalence is expressed as rate per 1000 tota l b irths.)
Trend in Pregnancy Prevalence y 2 =  3.78 ( ld f )  P  >  0.05  
Trend in Birth Prevalence y 2 =  20.9 ( ld f )  P  <  0.0005
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Table 19. Anencephaly: Terminations, Births and Pregnancies:
Glasgow, 1976-1981; 1982-1986
Years
Grouping
Anencephaly
Term inations
Anencephaly
Births
Anencephaly
Pregnancies
No. % No. % No. %
1976-1981
1982-1986
104 65.4  
85 93.4
55 34.6  
6 6.6
159 100 
91 100
1976-1986 189 75.6 61 24.4 250 100
X2 =  24.6 ( ld f )  P  <  0.0005
T able 20. Spina Bifida: T erm inations, B irth s and Pregnancies: 
G lasgow, 1976-1981; 1982-1986
Years
Grouping
Spina Bifida 
Term inations
Spina Bifida  
Births
Spina Bifida  
Pregnancies
No. % No. % No. %
1976-1981 48 28.2 122 71.8 170 100
1982-1986 49 45.8 58 54.2 107 100
1976-1986 97 35.02 18 64.98 277 100
X2 =  8.9 ( ld f )  P <  0.005
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Table 21. A nencephaly: D istr ib u tion  o f P regnancies Screened and not
Screened:
G lasgow, 1976-1981; 1982-1986
Years
Grouping
Anencephaly
TotalScreened Not Screened
No. % No. %
1976-1981
1982-1986
115 72.33 
89 97.80
44 27.67  
2 2.20
159
91
X2 =  25.0 (ld f] P <  0.0005
Table 22. Spina Bifida.'D istribution o f  Pregnancies Screened and n o t
Screened:
G lasgow, 1976-1981; 1982-1986
Years Spina Bifida
Grouping Screened Not Screened Total
No. % No. %
1976-1981 105 61.76 65 38.24 170
1982-1986 81 75.70 26 24.30 107
X2 =  5.8 (ld f] P <  0.025
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Table 23. A nencephaly: affected  pregnancies screened; 
d etected  and d etected  and term inated: 
G lasgow , 1976-1986
Year
Affected Pregnancies* 
Screened
Affected Pregnancies** 
D etected (Sensitivity)
Affected Pregnancies*** 
D etected and Term inated
No % No % No %
1976 12 44.4 11 91.6 10 90.9
1977 18 69.2 15 83.3 15 100.0
1978 21 70.0 21 100.0 20 95.2
1979 30 88.2 26 86.6 25 96.2
1980 15 75.0 15 100.0 15 100.0
1981 19 86.4 19 100.0 19 100.0
1982 22 100.0 22 100,0' 22 100.0
1983 18 100.0 18 100.0 17 100.0
1984 14 100.0 13 92.9 13 100.0
1985 11 100.0 11 100.0 11 100.0
1986 24 92.3 24 100.0 22 91.6
Total 204 81.6 195 95.6 189 96.9
Z-score =  8.5 P <  0.0001 X2 =  6.61 ( ld f )  P  <  0.025 X2 =  0.042 ( ld f )  P  >  0.8
* Proportion out o f total Anencephaly pregnancies.
** Proportion out o f the total screened.
*** Proportion out o f Anencephaly pregnancies screened and detected (sen sitiv ity).
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Table 24. Spina Bifida: affected pregnancies screened; 
d etected  and d etected  and term inated: 
G lasgow, 1976-1986
Year
Affected Pregnancies* 
Screened
Affected Pregnancies** 
D etected (Sensitivity)
Affected Pregnancies*** 
D etected and Term inated
No % No % No %
1976 9 42.8 . 3 33.3 2 66.7
1977 16 44.4 7 43.8 6 85.7
1978 17 60.7 5 29.4 4 80.0
1979 18 60.0 11 61.1 6 54.6
1980 23 82.1 16 69.5 11 68.8
1981 22 81.5 18 81.8 17 94.4
1982 15 60.0 7 46.6 5 71.4
1983 13 81.3 9 69.2 9 100.0
1984 16 84.2 11 68.8 11 100.0
1985 22 84.6 17 77.3 15 88.2
1986 15 71.4 11 73.3 9 81.8
Total 186 67.1 115 61.8 95 82.6
Z-score =  6.45 P  <  0.05 Z-score = 4.16 P <  0.05 Z-score == 6.03 P  <  0.05
* Proportion out o f to ta l -S p in a , b i f i d a  p r e g n a n c i e s
** Proportion out o f the to ta l screened.
*** Proportion out o f Anencephaly pregnancies screened and detected (sensitiv ity).
Table 25. Pregnancies Screened as Proportion of Total Pregnancies
Glasgow (1982-1986)
Expected Year 
of Confinement
Total Pregnancies* 
Live -f still -f Term.
Pregnancies Screened**
No. %
1982 14521 10751 74.0
1983 14117 10633 75.3
1984 14418 10435 72.4
1985 14766 11171 75.7
1986 14798 11456 77.4
1982-1986 72620 54446 75.0
* Total births (live +  still) +  total term inations for all causes.
** Pregnancies screened in G .G .H .B . hospitals and G.P.
Table 26. Pregnancies Screened as P rop ortion  o f  T otal B irth s  
G lasgow (1982-1986)
Expected Year 
o f Confinement
Total Births 
(Live +  still)
Pregnancies Screened**
No. %
1982 12884 10751 83.4
1983 12661 10633 84.0
1984 12783 10435 81.6
1985 13089 11171 85.3
1986 13013 11456 88.0
1982-1986 64430 54446 84.5
** Pregnancies screened in G .G .H .B . hospitals and G.P.
Table 27. A .S .B . Pregnancies: A ge D istr ib u tio n  (%) o f  
Screened and not Screened G roups 
G lasgow (1979-1986)
Age
Group
Screened Not Screened
No. % No. %
< 20 25 65.8 13 34.2
20-24 _ 99 82.5 21 17.5
25-29 105 91.3 10 8.7
30-34 42 75.0 14 25.0
35-39 20 87.0 3 13.0
4 0 + 6 85.7 1 14.3
Ages over 35 com bined, x 2 — 16.22 (4dF) P <  0.01
Table 28. A .S .B . Pregnancies: P arity  D istr ib u tio n  (%) o f  
Screened and not Screened G roups 
G lasgow (1979-1986)
Parity
Group
Screened N ot Screened
No. % No. %
0 132 82.5 28 17.5
1 99 88.4 13 11.6
2 40 76.9 12 23.1
3 9 81.8 2 18.2
4 7 70.0 3 30.0
5 + 4 50.0 4 50.0
Not Known 6 100
para 4 and 5 com bined, and excluding “not known” , 
X2 =  9.5 (4dF) P >  0.05 (N .S .)
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T a b le  2 9 . A .S .B .  P r e g n a n c ie s :  S o c ia l C la ss  D is t r ib u t io n  o f  
S c r e e n e d  a n d  n o t  S c r e e n e d  G r o u p s:
G la sg o w , 1 9 7 9 -1 9 8 6
Social Screened Not Screened
Class No. % No. %
I 15 93.8 1 6.3
II 38 86.4 6 13.6
III 141 84.9 25 15.1
IV 43 76.8 13 23.2
V 49 74.2 17 25.8
N ot Known 11 100.0
X2 =  6.07 ( ld f )  P <  0.025
(Social class I and II combined, not known excluded)
Table 30. Methods of detection or diagnosis of Anencephaly and Spina
Bifida terminations:
Glasgow, 1976-1981; 1982-1986
M ethods o f  
D et/D ia g
Anencephaly Spina Bifida
1976-1981 1982-1986 1976-1981 1982-1986
No % No % No % No %
M S .A F P /U ltra 10 9.62 21 24.70 2 4.35 5 10.20
M S .A F P /A m nio 17 16.35 3 3.53 27 58.69 24 48.98
U ltra /U ltra 21 20.19 57 67.06* 0 0.00 4 8.16
U ltra /A m nio 2 1.92 0 0.00 0 0.00 0 0.00
A m n io/A m nio 7 6.73 0 0.00 5 10.87 3 6.13
MS. A F P /U ltr a / A m nio 47 45.19 4 4.71 12 26.09 13 26.53
Total 104 100.00 85 100.00 46 100.00 49 100.0
* Anencephaly U ltra /U ltra  x 2 — 42.4 ( ld f )  P  <  0.001
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Table 31. S en sitiv ity  o f  A ntenatal Screening for A nencephaly
and Spina Bifida:
G lasgow, 1976-1981; 1982-1986
Years Anencephaly Spina Bifida A .S .B .
Grouping 1976-1981 1982-1986 1976-1981 1982-1986 1976-1981 1982-1986
No of True Positives 108 88 61 55 169 143
No o f False Negatives 7 3 44 26 51 29
Sensitivity (%) 93.9 96.70 58.09 67.90 76.82 83.14
Table 32. Efficacy o f  A ntenatal Screening for A nencephaly  
and Spina Bifida:
G lasgow, 1976-1981; 1982-1986
Years Anencephaly Spina Bifida A .S .B .
Grouping 1976-1981 1982-1986 1976-1981 1982-1986 1976-1981 1982-1986
T otal No o f  
Pregnancies Affected
159 91 170 107 329 198
No o f detected  
and Term inated
104 85 46 49 150 134
Efficacy o f  
the Screening %
65.41 93.41 27.06 45.79 45.59 67.68
Anencephaly Efficacy o f the Screening x 2 =  24.18 ( ld f )  P  <  001
Spina Bifida Efficacy o f the Screening x 2 =  9-8 ( ld f )  P  <  005
A .S .B . Efficacy o f the Screening x 2 — 23.7 ( ld f )  P  <  001
Table 33. Specificity of Antenatal Screening for Anencephaly:
Glasgow, 1982-1986
Anencephaly 1982 1983 1984 1985 1986
No o f TVue Negative 
No o f False Positive 
Specificity %
10729
0
100.0
10615
0
100.0
10421
0
100.0
11160
0
100.0
11430
0
100.0
Table 34. Specificity  o f  A ntenatal Screening for Spina Bifida: 
G lasgow , 1982-1986
Spina Bifida 1982 1983 1984 1985 1986
No o f True Negative  
No o f False Positive 
Specificity %
10736
0
100.0
10620
0
100.0
10419
0
100.0
11149
0
100.0
11441
0
100.0
SECTION VII: DISCUSSION
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SECTION VII: DISCUSSION
7.1 Epidemiology and Natural History
It is generally agreed that a decline in the prevalence of 
neural tube defects has occurred in the British Isles as well as 
in some other parts of the world. In Northern Ireland, which is 
considered as one of the highest risk areas for neural tube 
defects, there was a decline in both birth prevalence and 
pregnancy prevalence over the period 1964-1979. Antenatal 
screening by the use of AFP is not routinely offered but 
mothers at risk have access to prenatal diagnosis. The decline 
is therefore unlikely to be due to prenatal diagnosis (Nevin, 
1981).
In south-east Wales, which is also a high risk area, primary 
prevention has been attempted by genetic counselling and 
supplementation with folic acid since 1969. Antenatal screening 
using AFP has been carried out since 1973 and lately ultrasound 
scanning. During 1964-1987 both birth prevalence and pregnancy 
prevalence fell (Laurence, 1989).
In the Liverpool and Bootle area during 1961-1979 a progressive 
decline in both birth and pregnancy prevalence was noted by Owens 
et al (1981). Antenatal screening by AFP started in 1975 in that 
region.
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A clear decline appeared to take place in continental Europe, 
including Italy, Belgium and France (Eurocat, 1986).
In the Netherlands during 1950-1980 there was a decline in 
anencephaly prevalence apart from some minor fluctuations. 
Antenatal screening was introduced in 1974 and more reliable 
ultrasound techniques have been available only in recent years 
(Romijn and Treffers, 1983).
The United States and Canada appear to have experienced a long­
term epidemic of ASB. Prevalence apparently began to rise in 
Boston and Providence towards the end of the last century, 
reaching a peak in 1930-1934 and thereafter decreasing until the 
occurrence of another peak in 1950-1954, followed by a steady 
decline thereafter (Elwood and Elwood, 1980; MacMahon and Yen, 
1971; Naggan, 1969). Naggan analysed the decline from 1930 to
1965 in Boston and found that it affected all ethnic groups 
(except Jews, whose rate was always low) and all occupational and 
parity groups (Naggan, 1969).
In British Columbia data indicate that 1950-1954 was an epidemic 
period, although the subsequent decline seems to have been less 
clear-cut as was the slight peak in the early 1960's (Elwood and 
Elwood, 1980).
In New York the prevalence of myelomeningocele decreased at a 
linear rate since 1930 so the decline started well before
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screening was available (Stein et al, 1982).
Glasgow shares with Ireland, Wales and other Celtic areas of 
Britain a relatively high prevalence of neural tube defects. The 
programme of antenatal screening, based both on the measurement 
of Ms AFP and ultrasound for the whole of the west of Scotland 
(including Glasgow) has been operating since 1974. In Glasgow 
the annual birth prevalence of anencephaly (Table 4, Figure 9) 
declined from 1.32/1000 in 1976 to 0.31/1000 in 1986; there were 
no affected births during 1982 and 1985. There was a 
statistically significant decline in both anencephaly birth and 
pregnancy prevalence rates. There were two peaks in pregnancy 
prevalence, one in 1979 and the other in 1986 (Figure 15).
Although spina bifida birth prevalence declined from 1.47/1000 in 
1976 to 0.92/1000 in 1986 (Table 5, Figure 10), which is a 
significant decline, there was a steady non-significant decline 
in spina bifida pregnancy prevalence during the study period 
(Figure 16).
The decline in anencephaly prevalence (birth and pregnancy) was 
more obvious than that for spina bifida. The same observation 
has been made in Dublin, Belfast, and Liverpool (Eurocat Working 
Group, 1987).
There was a significant decline in both birth and pregnancy 
prevalence for both anencephaly and spina bifida during 1982-1986
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compared to 1976-1981 (Table 7, 8) which might indicate that
antenatal screening programme was more effective during 1982-1986 
for both anencephaly and spina bifida.
There were a number of peaks and troughs in pregnancy prevalence 
in Glasgow for both anencephaly and spina bifida; during 
1964-1986 they are not consistent and diverging (Figure 13) 
which is different from, what is found in Northern Ireland (Nevin,
1981) and Liverpool (Owens et al, 1981) where the peaks and 
troughs are more parallel. It is possible that in Glasgow the 
mechanism which caused the decline for one defect was not 
responsible for the same effect on the other defect.
By comparing the previous studies by Wilson (1970) and Stone 
(1981) with the present study (1979-1986, Table 9, 10)a
statistically significant secular trend in both birth and 
pregnancy prevalence in Glasgow was evident.
It seems that the secular trend in prevalence was independent of 
intervention during pregnancy (Figure 11, 12). This presumably 
reflects a true decline. Similar observations have been made in 
Dublin, Belfast and Liverpool (Eurocat Working Group, 1987).
Prenatal diagnosis and termination of affected fetuses have 
played an increasingly large part in reducing the birth 
prevalence. Prenatal diagnosis is not, however, the sole 
explanation for the decline which began in most places before
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prenatal diagnosis was available (Nevin, 1981; Owens et al, 1981; 
Laurence, 1989).
Other possible explanations for the decline include an increased 
public health awareness of neural tube defects resulting in 
better prenatal care; improved maternal life style; a changing 
maternal environment; and alteration in maternal diet and 
nutrition.
An increase in requests for genetic counselling, especially by 
families who had a child with ASB, may be causing a decline in 
familial recurrence of cases by avoidance of further pregnancies; 
this would have had little effect, however, on the overall 
prevalence of NTD, at least 90% of which are not familial 
recurrences.
Another factor which might be expected to lower the prevalence of 
ASB is the drop in the overall birth rate particularly in 
younger and older women. In Greater Glasgow the annual number of 
births in the early 1970's was more than 19000 and dropped to 
about 13000 in the 1980's (Annual Report of the Registrar General 
for Scotland, 1970-1986).
The total number of births to mothers in younger and older age 
groups fell proportionately more than did births to mothers in 
all age groups. Changes also occurred in social class ratio 
favouring social class one and two (Bradshaw, Weale, Weatherall,
1980). The lower social classes may be in a state of transition 
from relatively ineffective family planning to more effective 
contraception causing the rate of unplanned pregnancies to 
decline (Westaff, 1976), particularly at the extremes of maternal 
age. In contrast to NTD, however, the prevalence of other 
congenital anomalies including chromosomal defects has not 
decreased (Stone, 1989).
Several dietary factors have been implicated as a cause of neural 
tube defect including tea (Fedrick, 1974), blighted potatoes 
(Renwick, 1972) zinc and other minerals (Coffey, 1970). Evidence 
from two studies by Smithells et al (1980) and Laurence et al 
(1981) show reductions in neural tube defect prevalence in those 
given preconceptional vitamin treatment, particularly folic acid.
While the secular decline in ASB prevalence antedates the 
vitamin supplementation debate, the continuing decline in the 
early 1980's presumably coincides with the increased use of 
vitamins in pregnancy and could therefore represent a preventive 
effect. (However, the slight upward trend in prevalence in the 
mid-1980's in Glasgow tends to undermine this explanation.) But 
the recent results of the Medical Research Council on vitamin 
study (1991) suggest that preconceptional supplementation with 
folic acid may indeed prevent neural tube defects. There is also 
a view that the mother's diet during childhood may be as 
important as her preconceptional diet and the subsequent 
conception of an affected fetus (Emanuel and Sever, 1973; Baird, 
1974). The steep decline in the 1970's and early 1980's (Figure
13) occurred about a generation after the prosperous 1950s and
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early 1960's when most of these mothers were born and reared. 
Unemployment and poverty, which have been implicated as a risk 
factor in some studies, declined throughout the 1960's and 1970's 
in the United Kingdom but this trend may have been reversed in 
the 1980's (Morris, 1990).
The rise in ASB prevalence observed in the mid-1980's could be a 
manifestation of the increasing poverty and unemployment levels 
occurring at that time. This interpretation assumes the 
existence of an unspecified teratogen mediated through a 
component of social deprivation. Despite its lack of
specificity, the socio-economic hypothesis is plausible given the 
repeated observation of a high risk of ASB in social classes IV 
and V (Elwood and Elwood, 1980).
Identification of the reasons for the secular decline would be 
valuable for etiological and preventive purposes. Recognising 
the scale of the decline even without knowing the reason is 
important for health services planning. But the decline should 
not lead to complacency given our ignorance about its causes. 
The rate which has been labile historically could presumably 
increase at any time (Elwood and Elwood, 1980).
Before screening started most anencephalic babies were 
stillborn, while those born alive died a few days after birth. 
Spina bifida is a more variable malformation, ranging widely in 
severity, leading either to stillbirth or livebirth. Larger
lesions are associated with a poorer survival, and these 
infants are often severely handicapped and require frequent 
surgical procedures and institutional care.
After screening started (Table 11, Figure 14) there was a 
statistically significant increase in the proportion of induced 
abortion during 1982-1986 for anencephaly, while the proportion 
of stillbirths significantly decreased during 1982-1986; the 
proportion of live births also declined but the reduction is not 
significant. It seems therefore that most of the anencephalic 
stillbirths became abortions. Those that were live births, all 
died during the first week.
For spina bifida two approaches to the natural history were 
employed - the first approach started from conception (Table 12, 
Figure 14); there was a significant increase in the proportion of 
induced abortion, with a significant decrease in the proportion 
of stillbirths during 1982-1986. The proportion of live births 
decreased by about 10% compared to 1976-1981. Following the 
infants beyond one year of age (Table 13), fewer survived during 
1982-1986 than in the earlier period, but the difference is not 
significant.
The second approach adopts birth as the starting point (Table
14). The proportion of those surviving more than one year was 
higher during 1982-1986 than in the earlier period. Although 
this is not statistically significant, it lends some support to
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the hypothesis that screening selects out the most lethal lesions 
(Bradshaw, Weal and Weatherall, 1980). This interpretation is 
reinforced by the observation that perinatal, neonatal and infant 
mortality all decreased during 1982-1986, in comparison with 
1976-1981 (Table 16).
Anencephaly showed little variation since all such babies died 
during the first week of life; the perinatal, mortality and 
neonatal mortality rates were 100% (Table 15) for this defect.
7.2 Effectiveness of Antenatal Screening
The effectiveness of any programme is ideally measured by 
assessing its achievements in relation to its objectives. The 
epidemiological effectiveness of antenatal screening programme is 
judged by its ability to reduce the birth prevalence of neural 
tube defects in the population.
Arguably the most rigorously scientific way of obtaining evidence 
about the effectiveness of antenatal screening for neural tube 
defects is by assessing the alteration in the natural history 
through a randomised controlled trial. Because of the nature of 
the condition and its low prevalence, such a trial would require 
to be long term and would involve very large numbers; moreover 
there would be strong ethical objections. An alternative method 
of evaluation is through a retrospective review of the impact of 
antenatal screening. Selective screening of those pregnancies 
who have had previous children with neural tube defects or who 
have some family history could only reduce the prevalence by 10% 
(at most). To reduce the prevalence further the screening of all 
pregnancies is required and that is what was initiated in Glasgow 
and other cities in the United Kingdom in the 1970's. Antenatal 
screening for neural tube defects to residents of Greater Glasgow 
Health Board area avoided 286 (54.22%) of both anencephaly and 
spina bifida births out of a potential total of 527 births during 
the period 1976-1986.
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This finding, however, requires to be placed in the context of 
the changing epidemiological patterns of ASB and in particular 
the long term secular decline in pregnancy prevalence.
There was a statistically significant decline in both pregnancy 
prevalence and birth prevalence of anencephaly over the study 
period (Table 17, Figure 15). 93.4% of anencephaly fetuses were
"avoided" during 1982-19'86 (Table 19). Antenatal screening has 
clearly been highly effective in preventing anencephaly mainly 
due to high senstivity of maternal serum AFP (Ferguson-Smith,
1983) for this defect. Anencephaly can also be detected early by 
ultrasound examination (Roberts et al, 1983). There was a steady 
non-significant decline in spina bifida pregnancy prevalence 
(Table 18, Figure 16) during 1976-1986. 45.8% of spina bifida
pregnancies* were terminated (Table 20) during 1982-1986. The 
decline is however statistically significant in comparison with 
the earlier period (1976-1981). So analysis of the changes in 
pregnancy and birth prevalence of anencephaly and spina bifida is 
not only important for aetiological studies but also for 
evaluating the effectiveness of preventive programmes.
Antenatal screening has been responsible for part of the decline 
in the birth prevalence of anencephaly and spina bifida and 
undoubtedly has been instrumental in reducing the number of live 
births with spina bifida and the consequent burden of disability 
from this condition.
The effectiveness of antenatal screening for neural tube defects 
is influenced by these interacting factors:
1. the proportion of pregnancies with neural tube defects 
screened
2. the proportion of affected pregnancies detected, sensitivity 
of the screening procedures
3. the proportion of those terminated when detected 
Each will be considered in turn.
Antenatal screening for neural tube defects is available to all 
mothers in GGHB area on an entirely voluntary basis - screening 
can be a long process with a complex series of decision-making 
starting from referral to the ultimate decision to terminate the 
pregnancy. There are many opportunities for clinical and 
administrative events to occur which might deter some pregnant 
women from attending or undergoing further tests.
1. The Proportion of Pregnancies Screened:
The proportions of anencephaly pregnancies and spina bifida 
pregnancies screened was less than 50% (Figure 18, 22) during
1976 but started to increase gradually to more than 97% of 
anencephaly pregnancies being screened (Table 21) during
1982-1986 and more than 75% of spina bifida pregnancies were 
screened (Table 22) during the same period. There was an 
increasing trend in the proportion screened for both anencephaly 
and spina bifida and this was found to be significant (Figures 
17, 21; Tables 23, 24). The proportion of pregnant women opting
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in and staying in the screening procedure could be increased by 
ensuring that all pregnant women attending antenatal clinics are 
screened by ulatrasound and Ms AFP before 20 weeks gesdtation.
2. The Proportion of Pregnancies Screened and Detected:
Maternal serum AFP assay is more sensitive in detecting neural 
tube defects if measured between 16-20 weeks gestation. The 
interpretation of maternal seruma AFP in terms of normality and 
abnormality is influenced by gestational age. Some obstetricians 
tend to overestimate gestational age, thus placing a slightly 
raised maternal serum AFP just below the cut-off point. Thus one 
element in the effectiveness of antenatal screening depends on 
the accuracy of assessing gestational age. The increased use of 
obstetric ultrasound in antenatal screening has improved the 
precision of gestational age dating.
The proportions of anencephaly fetuses detected by antenatal 
screening procedures i.e. sensitivity was 95.6% during 1976-1986 
(Table 23, Figure 19). In the case of spina bifida the 
proportions detected by antenatal screening was 61.8% (Table 24, 
Figure 23). The more severe the neural tube defect the greater 
the likelihood of detection and so the procedure is highly 
sensitive for anencephaly. The sensitivity of Ms AFP depends 
on a cut-off point between positive and negative for the
laboratory concerned. Lowering the cut-off point would lead to 
more pregnancies with neural tube defects being detected and 
fewer cases missed but on the other hand would also lead to an 
increase in the number of false positive cases and hence an 
increase in the amniocentesis rate. But the skilled use of
ultrasound in identifying false positives may help avoid
unnecessary amniocentesis. The amniocentesis failure rate may 
also be reduced by simultaneous ultrasonography. Both
amniocentesis false positive and false negative rates can be 
reduced by the use of amniotic-fluid acetylcholinesterase (Smith 
et al, 1979).
3. Proportion Screened, Detcted and Terminated 
In cases of anencephaly, more than 96% of those detected were 
terminated (Table 23, Figure 20) during 1976-1986 and more than 
82% of those spina bifida detected were terminated during the 
same period. Some of the cases detected by antenatal screening 
procedures do not proceed to termination ; 3.1% of anencephaly
and about 17.4% of spina bifida. Aversion to abortion could be
due to religious or social reasons. Some may fear that a normal
pregnancy may be terminated, others may have declined for another 
reason.
The proportion of anencephaly pregnancies detected and proceeding 
to termination was much greater than that for spina bifida. This 
could be because anencephaly is detected early with confidence by 
ultrasound and also that the consequence for the child is well
known and the parents are therefore more likely to agree to 
termination. Spina bifida, on the other hand is detected later 
when the pregnancy is more advanced and there is uncertainty 
about the consequence of spina bifida and a lack of confidence 
regarding its diagnosis. The proportions of spina bifida
pregnancies screened during 1982 was low. This may have been due 
to the National Health Service strike that year and it may be 
that a proportion of affected pregnancies were not satisfactorily 
screened.
For these reasons, antenatal screening made less impact in the
case of spina bifida than is the case of anencephaly. From the 
public health perspective, if the health service personnel intend 
to improve the effectiveness of antenatal screening programmes 
further, especially for spina bifida, they might be able to 
tackle this problem by improving one or a combination of these 
three factors: the proportion with the defects screened; the
proportion with the defects detected; and the proportion with the 
defects terminated when detected.
Running an antenatal screening programme for neural tube defects 
requires a considerable degree of organisation and the
maintenance of good communication between the pregnant women and 
the obstetricians, the laboratory and obstetrician is essential. 
They may generate a considerable amount of anxiety among mothers 
whose maternal serum AFP value lies above the defined action
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point (Fearn et al, 1982) and thus demand expert forms of 
counselling and reassurance.
There have been several criticisms of the role of antenatal 
screening for the detection of neural tube defects. In East 
Anglia the programme was discontinued in the belief that AFP had 
a poor predictive value in detecting spina bifida (Standing et 
al, 1981).
Owens et al (1981) pointed to the declining prevalence of neural 
tube defects in the United Kingdom and the promising result of 
preconceptional vitamin supplementation in primary prevention 
(Smithells et al, 1981a). Edwards (1982) argued that a further 
substantial reduction in prevalence would make screening
uneconomic.
The prevalence of neural tube defects has declined in recent 
years, but it is not clear whether it is a temporary or permanent 
phenomenon Rates of pregnancy prevalence have not declined to 
the level where the experiments in the 1970s of setting up 
screening programmes are no longer valid. In general, these 
programmes have also achieved public acceptance. If the wide- 
scale use of preconceptional folic acid supplementation also 
contributes to a further decline, it may be necessary to 
reconsider the situation.
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7.3 Efficiency of Screening Service
Antenatal services in the United Kingdom can be general 
practitioner based, hospital/obstetric unit based or shared 
between both services. The patient initially attends her general 
practitioner for confirmation of pregnancy and is then referred 
to a booking clinic at a hospital, which is generally the time at 
which a complete history and examination are performed and a plan 
of care established.
Efficiency may be assessed in various ways but the response of 
pregnant women to the provision of antenatal care services is an 
important determinant of the outcome of screening services.
84.5% as a proportion of total births of pregnancies were 
screened in Glasgow during 1982-1986 (Table 26) but this figure 
drops to 75% when a denominator of total pregnancies (live and 
still and termination) is used (Table 25). This compared with 
77.4% of pregnancies screened as a proportion of total births 
during 1982-1986 in the west of Scotland (Heather and Stevenson, 
personal communication). These represent estimated percentages 
of pregnant women who accept antenatal screening for neural tube 
defects and utilise the service.
Another way of measuring the acceptability indirectly is by the 
number of normal fetuses aborted. In Glasgow no normal fetus 
has been aborted due to antenatal screening for neural tube
defects since 1981, the time at which AchE started to be used as 
a diagnostic test.
The acceptability of antenatal screening for neural tube defects 
may be expressed in terms of "losses" and "gains". The 
unnecessary exposure of normal pregnancies to diagnostic tests 
and the termination of normal fetuses represent "losses". The 
"gains" are those pregnancies with ASB detected by antenatal 
screening techniques.
Some might argue that a severe disease like anencephaly 
associated with death at birth causes little burden either to 
the family or to society. But since antenatal screening and 
induced abortion reduce the average duration of pregnancy, this 
is a substantial benefit to the parents. They can plan a 
subsequent pregnancy earlier and avoid the emotional consequences 
of giving birth to a full-term baby which dies. On the other 
hand, if affected fetuses with spina bifida survive they require 
continued care and treatment, thereby inflicting a severe and 
expensive burden on surviving individuals, their families and 
society.
There were 359 ASB pregnancies in Glasgow during 1979-1986 
(Figure 25); about 82.7% of those women were screened with an 
efficacy (the proportion of ASB detected and terminated out of 
the total ASB) of 63.2%. 13.6% of affected pregnancies screened
were missed. This may elicit a resentment among mothers who had
hoped for protection against the birth of an affected child 
despite the risk to the fetus which is implicit in the procedure.
17.3% of pregnancies with ASB were not screened because women 
declined screening, booked too late or were not screened for 
other reasons. The proportion of those who declined screening 
was 6.7%. These women were aware of antenatal screening for 
neural tube defects, but did not attend the appointment offered. 
Some refused to be screened for religious reasons or on 
principle. The proportion of pregnancies with ASB not screened 
because they attended antenatal clinic too late was 7.8%. 
Estimation of gestational age is improved by early attendance (by 
the use of ultrasonography) and so the potential benefit of 
antenatal screening is increased. Women who attend late for 
antenatal care experience a higher than average perinatal 
mortality and are less likely to benefit from antenatal screening 
not only for maternal serum AFP but for amniocentesis for 
chromosomal and other abnormalities, fetoscopy and fetal blood 
sampling (Pearson, 1982).
A high proportion of the women booked after 20 weeks gestation 
are more likely to be of immigrant origin and of high parity 
(Simpson and Walker, 1980). In the west of Scotland in 1981 
about 27% of pregnant women did not have MsAFP tested either 
because they attended before 16 weeks gestation (and were not 
recalled for screening) or attended after 20 weeks gestation 
(Ferguson-Smith, 1983). Most of those late attenders are found
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to be associated with maternal youth, high parity and poorer 
socio-economic status (McKinlay, 1970).
In the present study, 2.8% of the women with ASB babies were not 
screened either because they did not attend antenatal clinics at 
all or they attended the clinic only minimally. Others concealed 
their pregnancy because they were single women or had a 
prenuptial conception. _ This group also includes those women
attending antenatal clinic but without record of antenatal
screening for ASB in their case notes.
In order to reduce the proportion of pregnant women not screened, 
there is a need for an improvement in the administrative 
arrangements in antenatal clinic appointments such as lost 
letters or delay in sending appointments. It is also important 
to increase general practitioners’ awareness of the possibility 
of screening for NTD by measurement of Ms AFP at 16-20 weeks of
gestation; facilities could be made more widely available for
general practitioners to take blood at the desired stage of 
pregnancy. General practitioners also need to be reminded of the 
importance of early referral to hospital when anatenatal care is 
either to be shared or is to become the responsibility of the 
consultant.
Hospital antenatal clinics should be arranged so that the delay 
between receipt of the general practitioner's referral letter and 
an appointment for an antenatal clinic is kept to the minimum.
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Health education of the public at different levels through 
schools, the media and by community nursing and medical personnel 
might help to persuade women to contact services earlier. Unless 
a higher proportion of women contact antenatal services early the 
impact of the prenatal screening programme for NTD will fall 
short of its potential.
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7.4 Efficiency of the Screening Procedure
Maternal serum alphafetoprotein and ultrasound are the techniques 
which are used for the presumptive detection of neural tube 
defects, while for definitive diagnosis detailed ultrasound and 
amniocentesis for AFP and AchE are used.
Ultrasound is useful in determining the cause of an elevated Ms 
AFP. If there is no satisfactory explanation for the elevation 
of Ms AFP, Am AFP and AChE determination are usually carried out.
The use of ultrasound in the detection and diagnosis of NTD is 
increasing and some have suggested that screening for NTD by 
ultrasound has now become/ a serious alternative to screening by 
Ms AFP (Harris and Read, 1981; Christie, 1983).
In the present study the proportions of anencephaly terminations 
detected and diagnosed by ultrasound was increased from 20.2% in 
1976-1981 to 67.1% in 1982-1986 (Table 30). In 1982-1986 only 
8.2% of spina bifida terminations were detected and diagnosed by 
ultrasound (Table 30). Most of the terminations were diagnosed 
by amniocentesis. A possible explanation is that the anencephaly 
lesion is large, easily detected and diagnosed by ultrasound. 
The ability of ultrasound to demonstrate spina bifida is related 
to the resolution of the equipment used, the size of the defect 
and the experience of the operator. Defects involving more than
three vertebral segments can be easily diagnosed although if only 
one or two segments are involved the diagnosis is more difficult 
(Harrison, Golbus, Filly, 1984).
These findings suggest that a combined approach for screening of 
neural tube defects using both ultrasound and Ms AFP 
determination is probably worthwhile. This view is also 
supported by the finding of Persson et al (1983).
The sensitivity for neural tube defects in Glasgow was 
calculated in terms of both tests combined. For anencephaly 
sensitivity was 96.7% (Table 31) during 1982-1986 while for 
spina bifida the figure was 67.9% (Table 31). For ASB the 
sensitivity was 83.1% (Table 31),which is similar to the figure 
of Persson et al (1983) who found a sensitivity of 80.0% in 
Sweden.
The proportions of neural tube defects detected and terminated as 
a consequence of antenatal screening techniques were 67.7% for 
both anencephaly and spina bifida during 1982-1986 (93.4% for
anencephaly, 45.8% for spina bifida) (Table 32). Thus the 
efficacy of antenatal screening techniques improved during 
1982-1986 when compared with 1976-1981. This was due to an 
increase in the proportion of pregnancies screened, an 
improvement in the sensitivity of the screening techniques and an 
increase in the proportions of those terminated when detected.
7.5 The Economics of Screening
With the introduction of screening programmes during the early 
1960's the question was frequently asked "Is screening for NTD 
worthwhile in relation to its cost and the benefit it will 
yield?"
During the 1960's Wilson and Jungner (1968) and others set out 
criteria which required to be satisfied if any screening 
programme were to be justified. One of these is that the cost of 
contacting the population and carrying out the test must be 
reasonable.
In assessing a screening programme a decision has to be taken 
which requires some balance of costs and benefits. The costs and 
benefits of a screening programme are direct, indirect and 
intangible:
Direct costs include the direct medical costs (doctors, 
nurses, hospital treatment, inpatient and outpatient 
services, physiotherapy and rehabilitation services), cost 
of facilities, equipment, material, manpower and programme 
publicity.
Indirect costs include loss of productivity due to patient 
taking time off work, cost of travelling, loss of earnings 
and cost of special education.
Intangible costs include pain and anxiety experienced by the 
patient and their family, psychological effect on siblings 
and the child's own psychological problem.
Direct benefits include the reduction in the number of 
liveborn neural tube defect cases leading to a reduction in 
the care needed which leads to a change in the quality of 
life of the family'and change in the resources used.
Indirect benefits include the reduction in the number of 
live born neural tube defects and a reduction in the 
resources needed these resources can be used in other parts 
of the health service.
Intangible benefits include the reduction of suffering, pain 
and anxiety.
Cost benefit analysis involves establishing a relationship 
between the value of benefits generated and the cost that must be 
incurred to obtain these benefits.
The cost of screening procedures is ascertained and compared with 
the cost of not doing it in terms of the treatment and care that 
would be required if the disease were allowed to run its usual 
course. The screening procedures are judged to be worthwhile if 
their cost is less than that of treating and caring for the 
patient.
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An economic analysis based on the early years of the West of 
Scotland screening programme for spina bifida was conducted by 
Hagard, Carter and Milne in 1976. They took account of a wide 
range of direct and indirect costs and benefits to the families 
and the public services arising from screening. They concluded 
that on economic grounds screening may be worthwhile only in a 
population with a high prevalence of spina bifida.
Glass and Cove (1978) estimated that public sector costs of a 
group of spina bifida children would exceed the cost of a 
screening programme (with a test sensitivity of 45%) within four 
years.
Henderson (1982) carried out an economic analysis similar to that 
of Hagard, Carter and Milne (1976). He concluded that the 
tangible benefits of screening probably outweighed the tangible 
costs by a substantial amount. The intangible psychological 
costs and benefits are more difficult to estimate but the balance 
is likely to be greatly in favour of screening.
Two studies permit a comparison of economic benefits between low 
and high prevalence areas. Standing et al (1981) found that in 
a low prevalence area, Ms AFP values had a poor predictive value 
in detecting open neural tube defects and recommended abandoning 
the programme. An economic analysis carried out in a high 
prevalence area (Hibbard et al, 1985) based its analysis on the 
efficacy data of an earlier study (Roberts et al, 1983) and
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concluded that screening for neural tube defects in areas in 
which the prevalence falls below 5 per 1000 total births is not 
cost effective.
Spencer and Carpenter (1985) argued that the prevalence is not 
the only factor determining screening cost. In an area of low 
prevalence (1.95 per 1000 total births) a high detection rate, 
good patient compliance% good counselling, result in an efficacy 
of 75%; adding the psychological benefit of identifying non- 
viable pregnancies and the benefit from detecting other abnormal 
pregnancies, they concluded that antenatal screening programmes 
can be highly cost-effective in low prevalence areas; in other 
words, prevalence is not the only important factor in determing 
the screening cost. The detection rate, efficacy, proportion of 
pregnancies screened, and the provision of genetic counselling 
services are equally important.
If one accepts the conclusion of Hibbard et al (1985), their 
arguments are important in assessing the economic work of the 
Glasgow programme. The combined pregnancy prevalence in 1972- 
1978 was 5.22 per 1000 of total births but by 1979-1986 this had 
declined to 3.43 per 1000 total births. On strictly economic 
grounds, therefore, the benefits of the programame are likely to 
depend on the factors above and the balance is more likely to be 
in favour of the screening programme despite the falling 
prevalence. In addition, there may be other benefits. It is 
likely that the diagnosis of Trisomy 21, 18 and 13 is likely to
235
improve following the discovery of an association between these 
conditions and low Ms AFP. The screening for Down's Syndrome 
started in the West of Scotland in 1987 provided the possibility 
of screening all pregnant women with a combination of maternal 
age and early mid trimester Ms AFP concentration (Cuckle, Wald 
and Lindenbaum, 1984). This potential is currently being 
evaluated within the West of Scotland screening programme.
In addition, the introduction of antenatal screening for NTD also 
helped to improve obstetric services generally by promoting the 
wide-spread introduction of obstetric ultrasound which helps in 
dating the pregnancy with a consequent reduction in post­
maturity and unnecessary induction of a wide range of fetal 
abnormalities (Campbell and Pearce, 1983).
If maternal serum AFP testing is extended to later gestational 
ages to study the relationship between maternal serum AFP levels 
and intrauterine growth retardation this might lead to the 
earlier identification of more at risk pregnancies in whom the 
prognosis would be improved by more intensive obstetric care.
All these potential benefits will extend the usefulness of Ms AFP 
screening beyond the identification of NTD and add to the cost 
effectiveness of antenatal screening programmes. Therefore it is 
important to continue monitoring the pregnancy prevalence of 
anencephaly and spina bifida.
SECTION VIII - CONCLUSIONS
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SECTION VIII: CONCLUSION
8.1 Epidemiology and Natural History of 
Anencephaly and Spina Bifida
The findings confirm the view that Glasgow suffers a relatively 
high prevalence of NTD even in British terms. Birth and 
pregnancy prevalence fates of anencephaly declined significantly 
during the period 1976-1986. Birth and pregnancy prevalence of 
spina bifida declined over the same period. There is no evidence 
that the decline in prevalence has levelled off.
The decline in birth prevalence is partly attributable to 
antenatal screening, while the decline in pregnancy prevalence is 
unexplained.
There appeared to be a downward secular trend in prevalence in 
Glasgow which was independent of intervention during pregnancy. 
But antenatal screening and termination of affected fetuses have 
played an increasingly large part in reducing the birth
prevalence. The identification of the reasons for the decline in
pregnancy prevalence would be valuable for aetiological and 
preventive purposes. Even if this cannot be achieved, monitoring
the extent of the decline is important for health services
planning. Antenatal screening appears to have influenced the 
natural history of both anencephaly and spina bifida.
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8.2 The Effectiveness of Antenatal Screening
The effectiveness of an antenatal screening programme is judged 
by its ability to reduce the birth prevalence of NTD in the 
population.
Monitoring differences between pregnancy prevalence and birth 
prevalence is one means of estimating the effectiveness of 
antenatal screening. This difference also gives the proportion 
of births avoided which is reflected by the proportions of 
pregnancies terminated with NTD during the same period.
Antenatal screening for NTD made a considerable impact on the 
birth prevalence of anencephaly and spina bifida and was 
instrumental in reducing the number of live births with spina 
bifida and the consequent burden of disability from this 
condition.
The proportion of both anencephaly and spina bifida pregnancies 
screened showed a significantly increasing trend from 1976-1986. 
There was a significant trend in the proportion detected when 
screened for both anencephaly and spina bifida during 1976-1986.
In the case of anencephaly the proportion terminated when 
screened and detected was always high, while spina bifida showed 
a significant upward trend over the same period.
8.3 Efficiency of Screening Services
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The proportion of pregnant women who utilised the service of 
antenatal screening for NTD in Glasgow was higher than that for 
the west of Scotland during 1982-1986, suggesting that 
geographical proximity to services contributes to their uptake.
Less than one-fifth, of NTD pregnancies in Glasgow during 
1979-1986 were not screened, and these were mainly due to 
administrative reasons.
In order to reduce the proportion of those women not screened, 
general practitioners, obstetricians and health visitors need to 
put more emphasis on pregnant women under the age of twenty, 
multiparous women (IV and V) and those from social classes 
IV and V. - .
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8.4 Efficiency of the Procedures
The techniques used for the detection of NTD. were MsAFP and 
ultrasound, while for the diagnosis a detailed ultrasound 
scanning and/or amniocentesis for amniotic fluid AFP and AChE 
were employed.
The effectiveness of an* antenatal screening programme for NTD was 
improved by the combined use of Ms AFP and diagnostic ultrasound. 
Antenatal screening for NTD using combined ultrasound and AFP 
determination was carried out in Glasgow with a sensitivity of 
83.1%.
Due to an increase in the proportion of pregnancies screened, an 
improvement in the sensitivity of the screening techniques, and 
an increase in the proportion of those terminated when detected, 
the efficiency and effectiveness of the screening has improved 
over time.
The combined use of ultrasound and Ms AFP screening with its
high sensitivity, specificity and efficacy is worthwhile and will 
probably reduce the birth prevalence further.
It is clear that in Glasgow during 1986 Antenatal screening for 
NTD by MsAFP and ultrasound made a major contribution to the 
reduction in birth prevalence of children with ASB. Nonetheless 
such programmes are not without problems. They require a
iderable degree of organisation and communication.
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8 .5 Policy Implications
Policy implications will be discussed under three headings: 
public health monitoring; screening services and research.
Public health monitoring
Because of the epidemiology of ASB, continued monitoring of its 
prevalence is essential because changing exposure to an 
unidentified causative 'agent could lead to an upturn in the rate. 
The Glasgow Register of Congenital Anomalies is an example of a 
validated epidemiological surveillance system (Stone, 1986). 
Repeated searches for missed ASB births or induced abortions 
following prenatal diagnosis have failed to yield additional data 
and this permits a satisfactory monitoring of time trends, so any 
change in prevalence is unlikely to be due to varying case 
ascertainment. Monitoring in itself cannot improve health, and 
so measures to promote health and prevent disease are required.
The specific causes of ASB are unknown but the high risk group in 
the population are mothers under the age of 20 years and over 35 
years, primiparous or multiparous, and those from social classes 
IV and V (Stone, 1981) but improvements in unemployment and 
poverty, health education, diet and housing environment may 
assist the further decline in prevalence of ASB.
Recent evidence shows that there is a possibility of preventing 
NTD by preconceptional suppplementation with folic acid (MRC 
1991). But there is a need for continued monitoring of pregnancy
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prevalence of ASB in order to identify any acceleration in the 
declline which might be due to folic acid.
The impact of antenatal screening and therapeutic termination of 
the affected fetuses (discussed below) also requires continuous 
monitoring.
Screening services
The development of antenatal screening for the detection of ASB 
in utero represents a major scientific advance. It could assist 
the disappearance of neural tube defects as a major health 
problem but its limitations should be made clear to policy 
makers.
Antenatal screening for NTD requires a considerable degree of
organisation and good communication between the pregnant women
and the obstetricians and between the laboratory and the
obstetrician. Women should be told about the implications of 
antenatal screening and the limitations of the test since no
single test can exclude all fetal abnormalities. Women should 
always be given adequate information about the procedure and the 
meaning of false positive and false negative and any anxieties 
related to the procedure should be resolved. This may lead to a 
further increase in the proportion screened.
The proportion screened could presumably be increased further by 
health education and extensive publicity directed at encouraging 
antenatal screening for NTD. In particular, more emphasis needs
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to be placed on meeting the needs of women under 20 years, those 
who are multiparous and those from social classes IV and V by 
health services staff, since the success of screening is 
dependent on the attitude and behaviour of the target population 
toward the health service.
The use of reliable techniques and skilled staff in performing 
amniotic AFP and ultrasound with more careful counselling of 
parents before they enter the screening process would enhance the 
effectiveness and efficiency of the screening.
Preconception counselling and advice shoud be offered to all 
couples intending to have a baby rather than simply to those who 
seek genetic counselling due to a particular risk. The advice 
should include the importance of diet (especially folic acid) and 
nutrition not only in early pregancy but also before pregnancy. 
Antenatal screening for anencephaly and spina bifida must be 
subject to continuous medical audit in order that deficiencies 
can be identified and rectified promptly.
It would be premature to abandon antenatal screening for ASB 
given our current state of ignorance of the aetiology. At the 
same time, children born with NTD, despite anteantal screening, 
should continue to receive the highest standard of social and 
medical care.
Research
Although the birth prevalence is reduced by antenatal screening
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and despite the large number of epidemiological, clinical and 
laboratory studies, the cause of NTD is still unknown. 
Fundamental research into aetiology should remain a high priority 
and worthy of policy support and encouragement.
Antenatal screening for NTD makes a contribution to the reduction 
of both anencephaly and spina bifida birth prevalence, but there 
is substantial scope, for improving the efficiency and 
consequently the effectiveness of screening for spina bifida by 
identifying new methods. The present difficulty is the need for 
AFP testing within the 'window* of 16-20 weeks gestation and the 
limitations of ultrasound in the diagnosis of spina bifida.
Despite the falling prevalence of NTD, the benefit of Ms AFP 
screening may have increased after the discovery of the 
association of low MS AFP in pregnancies with Down's Syndrome. 
There is a need for an updated economic evaluation of antenatal 
screening programme which takes account of the epidemiological 
trends, the effectiveness and efficiency of screening and 
therapeutic advances in the care of handicapped children.
Examination of the distribution of maternal age parity and social 
class for the screened and not screened in total pregnancies is 
needed in order to help service planners to identify and target 
those least likely to be screened.
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APPENDIX I
The risk of having a fetus with NTD in those with positive test 
results.
The chance that those with positive results are affected is 
expressed as an odds ratio of the number of affected to the 
number unaffected among those with positive results (i.e 1:2 in 
every three positive results one is affected). Odds is used 
because it is easier to calculate and gives a better impression 
of the reliability of the test.
Odds of being affected for the group of individuals with positive 
results is necessary for planning a screening programme. It is 
critically dependant on the prevalence of the disorder in the 
screened population as well as on the detection rate and false 
positive rate of the test.
The birth prevalence is expressed as an odds ratio (i.e 
prevalence of 4 per 1000 is 4:996). The detection rate is 
applied to the left-hand side of the ratio and the false positive 
rate to the right-hand side of the ratio.
Example: Detection rate of 90%; False positive rate of 2.5%;
and Prevalence 4:996. The new odds ratio would be (90 x 4):(2.5x 
996) or 360:2490 which simplifies to 1:7 (i.e in every eight 
positive results one is affected).
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APPENDIX 2 
NOMOGRAM
Instructions for use
Always use the Maternal Serum AFP scale which corresponds to the 
appropriate Amniotic Fluid AFP scale (clear, any or blood-stained 
- regardless of source or extent of blood contamination- 
amniotic fluid sample). Join the appropriate AFP values on the 
serum and amniotic fluid scales using a straight edge, and read 
the odds ratio where the ruler intersects the centre (risk of
open spina bifida) scale. The odds indicated are those which
apply if birth prevalence in the absence of antenatal diagnosis 
and selective abortion is 1:1000. If necessary, adjust the odds
for different birth prevalences or for other factors as noted
below.
Adjustments to the left-hand side of the odds ratio 
For open spina bifida birth prevalences other than 1:1000: 
multiply by the number of times the prevalence is different from 
1:1000.
For women with one, two, or three previous infants with an NTD: 
multiply by 10, 20 or 40 respectively.
For positive amniotic fluid gel AChE result relating to 'clear1, 
'any' or 'blood-stained1 amniotic fluid: multiply by 62, 16 or 9
respectively.
For negative amniotic fluid gel AChE result: divide by 150.
APPENDIX 2 (cont.)
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Nomogram to es t i m a t e  risk of open spina b i f i d a  
from maternal s e r u m  and a m n iotic f l u i d  AFP 
values b e t ween 16 and 21 weeks of g e s t a t i o n  
(from Wald N.J. 19 8 4 )
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Example
Given an amniotic fluid AFP level of 3.6 MoM at 19 weeks1 
gestation in a clear sample, and a maternal serum level of 2.4 
MoM taken at 18 weeks' gestation, the straight line connecting 
the two values on the nomogram (using the clear amniotic fluid 
scales at 19-21 weeks' gestation for the amniotic fluid AFP and 
at 16-18 weeks' gestation for the maternal serum AFP) intersects 
the risk scale at 1:10. The woman lives in an area where the 
birth prevalence of open spina bifida is 0.5:1000, half that used 
to construct the central scale. Therefore the risk of her fetus 
having open spina bifida would be 1:20(0.5 x 1:10). However, she 
has already had an anencephalic fetus, so the odds now become 1:2 
(10 x 1:20). The gel AChE resuslt is positive, so her final risk 
of having a fetus with open spina bifida is 31:1 (62 x 1:2) or 97 
per cent (31/32).
Though mainly intended for use with women who have borderline 
amniotic fluid AFP results, the nomogram can also be used for a 
woman who has not yet had an amniocentesis. This is done, using 
the 'any amniotic fluid sample' scales, by joining the maternal 
serum AFP value to the point marked by the arrow.
APPENDIX 3
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MEDICAL IN CONFIDENCE
1. GENERAL IN FO RMATION 
Hospital Code 
Hospital Case 
Reference Num ber 
Surnam e
SCOTLAND M ATERNITY DISCHARGE SHEET
*
*
////I
/ / 
//'//
Forenam e 
Second 
Initial
J  I J_  L_ I I L
□
Maiden Name * j | |
Aqe Date of Birth * 1 9
Marital S tate
1 -5
6 -1 5  
16 -2 7  
28 
29 
30-41  
4 2 -4 9
□  »
Home Address
Post Code 
O ccupation 
— Patient _
5 1 -5 7
5 8 -6 0
Date of Marriage
-
6 4 -6 9 Apgar Score a t 5 m ins Baby 1 | I
Baby 2 E H
Sex Baby 1 | I
*
O bstetrician 7 0 -7 6
Family D octor I I 7 7 -8 3 Baby 2 | |
Type of A ntenatal Care □ 84
5. RECORD OF LABOUR 
M ethod of Induction of Labour
Presentation a t Delivery or" 
sta rt of Operative Delivery
Mode of Delivery_________
SMR2
Revised 1 .1 .87
  □ -
_Baby 1 □  13!
_B aby 2 E H
Baby 1 EH 
Baby 2 EH
131
13'
131
D uration of L abour (In Hours)
S terilisation after Delivery 
Date of Delivery
N um ber of Births this Pregnancy 
O utcom e of Pregnancy__________
1139.
]/il
□ 14
□  « 
Baby 1 E D  14 
Baby 2 I I 15
Birthw eight (GMS) Baby 1
151
16
2. PREVIOUS PREGNANCIES
^  , i oc Spontaneous A bortions I I oc
Total N um ber | _ |  85 (M iscarriages) [J 86
T herapeutic A bortions | | 87 Caesarean Sections | | 88
Perinatal Deaths [ | 89 Children now  Living I I 90
6. POSTNATAL RECORD OF IN FANT(S) 
Special Care Baby U n i t_____________ ;______
3. CU R REN T PREGNANCY 
Date of Admission 9 1 -9 6
A dm itted  F rom __________________________________
N um ber of Previous Admissions to  A ny Hospital in 
this Pregnancy
Type of A dm ission______________________________
Dats-of Booking
□ 97 
□ 9 
'□ 99
Baby Discharged To ___
Case Record No. Baby 1
in th is Hospital Baby 2
Baby 1 □ 16
Baby 2 □ 16
Baby 1 □ 16
Baby 2 □ 16
x m s z m
1'71
1100/
J / 1 0 5
Original Booking for Delivery_____
Blood G ro u p _ _ _________ Rh
H eight__________________f t _______
□  ™  
□ 107
To be specified by  Clinician
U nderlying Cause of S tillbirth  o r Baby 
Death
___________________________________ Baby 1
187 ^ /  
^190
1108/
J/flO 7. MAIN CONDITION
Type of A bortion .
Management of A bortion .
Sterilisation after A bortion  _
Principal C om plication of A b o rtio n ____
Last M enstrual Period 
Estim ated G estation a t A bortion  or Delivery 
Certainty o f G estation based on LM P________
□»» 
□ ,13 
□  "3 
□ 114
8. OTHER CONDITIONS
□
1 1 5 /
J / ' l  20 
I121/  
j/122
123
4. MATERNAL DISCHARGE DATA 
Date of Discharge
Condition on Discharge______________
Discharged T o ______________________
1124/
M29
Category of P a tie n t. 
Unit on Discharge _
.*□130
: □ ,3 t  
* | | 132
:*□<
Baby 2 
_ * □  
_ □  
_ □  
_ □  
_ □  
_□
191
194
19!
/I
201
201
21
22!
9. OPERATION
* THESE FIELDS MUST BE COMPLETED WHEN 
CONDITION ON DISCHARGE = 1 OR 4
National
Use
Local Use
EZEZ n m m m m u
231. 
CT 2
23'
ummnummnmz 1244/<
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Marital State [501
1 = Never married (Single)
2 = Married
3 = Widowed
4 = Divorced
5 = Separated
8 = Other
9 = Not Known
Type of Antenatal Care [84]
0 = None
1 = GP Onlv
2 = GP care with specialist consultation
3 = Hospital Only
4 = GP and Hospital Shared
8 = Other
9 = Not Known
Admitted from [97]
0 = Not admitted
1 = Home
2 = Other hospital
3 = GP unit outwith this hospital
4 = Other speciality in this hospital
Type of Admission [99]
0 = Domiciliary (Not Admitted)
1 = Abortion (includes threatened abortion and ectopic pregnancy)
2 = Pregnant but not in labour
3 = In Labour
4 = Born before arrival
5 = Admitted after delivery at home
6 = Admitted after delivery in any hospital
8 = Other (e.g. doubtfully pregnant)
Original Booking for Delivery [1061
0 = Not booked prior to this admission
1 = Booked for Home delivery
2 = This Hospital (Consultant Unit)
3 = This Hospital (GP Unit)
4 = Other Hospital (Consultant Unit)
5 = Other Hospital (GP Unit)
9 = Not Known
Blood Group [107)
1 = O Rh —ve
2 = 0  Rh +ve
3 = A Rh —ve
4 = A Rh +ve
5 = B Rh —ve
6 = B R h +ve
7 = AB Rh -ve
8 = AB Rh +ve
9 = Not Known
Type of Abortion [111]
0=  Threatened Abortion (still pregnant on discharge)
1 = Spontaneous or incomplete abortion
2 = Missed abortion
3 = Hydatidiform mole
4 = Therapeutic Abortion
5 = Suspected illegal abortion
6 = Failed therapeutic abortion
7 = Ectopic Pregnancy
8 = Unspecified abortion
Management of Abortion [112]
0 = Not operative (i.e. management of threatened or spontaneous
complete abortion)
1 = D+C
2 = Vacuum aspiration
3 = Hysterotomy
4 = Prostaglandin (all forms)
5 = Amniotic infusion (other than Prostaglandin)
8 = Other (including ectopic pregnancy)
9 = Not stated
Sterilisation after Abortion [1131
0 = None
1 = Laparoscopy
2 = Laparotomy
3 = Laparoscopy Other hospital
4 = Laparotomy Other hospital
8 = Other
9 = Not stated
Principal Complication of Abortion [114]
0 = None
1 = Haemorrhage
2 = Sepsis
3 = Trauma to Cervix or uterus
4 = Damage to bowel
5 = Retained products requiring re-evacuation
8 = Other
9 = Not stated
Certainty of Gestation (1231
0 = Not applicable
1 = Certain
2 = Uncertain 
9 = Not known
FULL INSTRUCTIONS FOR COMPLETING THIS FORM
KEY TO CODED ITEMS
Condition on Discharge [130]
0 = Domiciliary Delivery
1 = Still pregnant
2 = Aborted (all types of completed abortion)
3 = Delivered
4 = Post natal care only
5 = Pregnancy not confirmed 
8 = Other (e.g. known missed abortion)
Discharged to [ 131 ]
0 = Domiciliary Delivery
1 = Home Care
2 = Other hospital - GP maternity unit
3 = Other hospital - specialist maternity unit
4 = Other hospital or institution
5 = Other unit in this hospital
6 = Died (PM)
7 = Died (No PM)
8 = Other
Category of Patient [1321
1 = Amenity
2 = Paying
3 = NHS
7 = Special arrangement (see manual)
Unit on Discharge [1331
1 = Obstetric (Consultant)
2 = Obstetric (General Practitioner)
3 = Home or Other confinement not admitted to hospital
4 = Day Case (for definition see manual)
9 = Other or Not Known
Method of Induction of labour [1341
0 = None 6 = Prostaglandins + Oxytocics
1 = ARM 7 = Prostaglandins + ARM + Oxytocics
2 = Oxytocics 8 = Other
3 = ARM + Oxytocics 9 = Not Known
4 = Prostaglandins
5 = ARM + Prostaglandins
Presentation at Delivery or start
of Operative Delivery (Baby 1 and Baby 21 [1 3 5 ] , [136)
1 = Occipito - anterior
2 = Occipito - posterior
3 = Occipito - lateral
4 = Breech
5 = Face/brow
6 = Shoulder
7 = Cord
8 = Other
9 = Not Known
Mode of Delivery (Baby 1 and Baby 2) [1 3 7 ] . [138]
0 = Normal, spontaneous vertex, vaginal delivery, occipito - anterior.
1 = Cephalic vaginal delivery with abnormal presentation of head at delivery,
without instruments, with or without manipulation.
2 = Forceps, low application, without manipulation, forceps delivery NOS
3 = Other forceps delivery. Forceps with manipulation. High forceps. Mid forceps
4 = Vacuum extraction ventouse.
5 = Breech delivery, spontaneous assisted or unspecified partial breech extraction
6 = Breech extraction. Breech extraction: NOS or Total or Version with breech extrsdjon.
7 = Elective (p lanned) Caesarean Section .
8 = Em ergency, o th e r and unspecified C aesarean S ection
9 = Other and unspecified method of delivery 
Sterilisation after Delivery [141]
0 = None
1 = Laparoscopy
2 = Laparotomy
3 = Laparoscopy other hospital
4 = Laparotomy other hospital
8 = Other
9 = Not stated
Outcome of Pregnancy (Baby 1 and Baby 2) [1 4 9 ] , 1150]
1 = Live birth
2 = Still birth
3 = Live birth died< 7 days
4 = Live birth died 7-28 days
5 = Live birth died after 28 days
Sex (Baby 1 and Baby 2) (1 6 1 ) , [162]
1 = Male
2 = Female
8 = Other or Not Known
Special Care Baby Unit (Baby 1 and Baby 2) (1631 , (164 )
0 = Not Admitted
1 = Admitted for up to 48 hours
2 = Admitted for more than 48 hours
9 = Not known
Baby Discharged to (Baby 1 and Baby 2) [1651 . [16S]
1 = Home
2 = Remaining in Special Care Baby Unit
3 = Special Care Baby Unit but home with mother
4 = Transfer to  Other Hospital
5 = Other Unit in same hospital
6 -= Foster Home
7 = Local Authority Care
8 = Healthy baby remaining in unit after mother's discharge
9 = Dead
SMR2
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APPENDIX A
PLEASE PRESS FIRMLY WITH A FINE TIPPED BALL-POINT PEN 
NEONATAL RECORD (Revised 1 .1 .87 )
H ospital of Birth (N am e o r Code No.).
Case R eference No. 
M aternal Reference No. 
Surnam e
1
6
16
26
In fan t Forenam es.. 
Telephone N o........
H om e Address..
■ P ost Code
Ward..
Paediatrician 
o r G.P.
Fam ily D octor.. 
A ddress..............
.T elephone No.,
BIRTH RECORD
Specify Place
E.D .D ............................
G esta tion  (by dates).
N ot Sure
1. H ospital
2. Home
8. O ther
9. N/K
N/K
□
Time
Apgar S core
D ate of Birth
1 m ln ./5  mln.
(for 9 and 10 e n te r9 , N /K=0)
56
R esuscitation
1. Nil (w ith clear airw ay, funnel Oj) 5. In tuba tion , IPPV (w ith drugs)
2. Mask, IPPV (no drugs)
3. M ask, IPPV (w ith  drugs)
4. In tu b a tio n , IPPV (no drugs)
B irth W eight (g)
N um ber o f b irth s  th is  pregnancy 
Birth O rder
Sex 1. Male 2. Fem ale
O. F.C. cm.
6. Drugs only 
S pecify :
8. O ther
9. N/K
. N/K
'
70
71
75
76
77
78
Transfers w ith in  hospital (2 only)
0. N one
1. Post N atal Cot
N um ber o f days In SCBU
2. SCBU 
8. O ther
9. N/K 1st
2nd
90
91
92
Jaund ice
(b ilirubin  mg%; um o l/l)
1. A bsen t 3. M oderate
(1 2 .0 -1 9 .9 ; 2 0 5 -3 4 0 )
2. Mild ( 5 -1 1 .9 ;  8 6 -2 0 4 )  4. Severe
or n o t m easured (20.0+ ; 342+)
9. N/K
□
Significant H ypotonia
C onvulsions
R ecu rren t A pnoea
Assisted V en tila tion  after 30  mlns.
Feeding D ifficulty
A bsent Present N/K
1 2 9
116
118
121
122
123
124
SMR11 
(A BBREV IA TED )
TRANSFER BETWEEN HOSPITALS (Neonatal Only) 
TRANSFER 1
Receiving
Hospital C ode N o .
Case R eference No.
P aediatrician 
o r G.P.
I
•?ts>
top?
7* ;hm
D ate o f A dm ission...............................
A dm itted  to  1. P ost N atal C o t 2. SCBU 
N um ber o f  days in SCBU
127
132
142
149
15E
156
TRANSFER 2
Receiving 
H ospital Code No.
Case R eference No.
P aediatrician 
or G.P.
i SI
D ate o f Admission.,
A dm itted  to  1. P ost N atal C o t 2. SCBU 
N um ber o f days in SCBU L
156
162
18C
186
187
DISCHARGE RECORD
C ondition  1. N orm al 4 . Dead 8. O ther
2. D oub tfu l 5 . Dead P.M. 9. N /K
3. Cong. A bn. 6 . Cong. A bn.
& O ther
Discharge (Final)
1. H om e w ith  M other
2. H om e after M other
3. To care of relative
4. To o th e r w ard or 
H ospital (M edical o r 
Surgical).
Age (D ays)................................W eight a t  D ischarge
D ate of D ischarge
DIAGNOSIS
□ 19C
5. T ransfer to  
R esiden tia l/F oste r Care
6. Dead
8. O ther
9. N /K
— V 3
ii
■lr?J
j x a .
qk/.TUf
n r
M
$
Si. Mi 12
*8$
m
Mills
"if { v
IS IS II < f l,
* Y VT ■•V ..‘vVl o } H vr
(2 only)
FOLLOW  UP 
Local O ption
1 W
PT’ri :i ■ - \r1> : ' i .
N one 3. E lsew here 
This H ospital 4. M ultiple
.4 .
‘fct*
.-111. “iir’i
m m
y
191
192 
196
202
206
21/
22C
226
232
236
24/
256
256
262
266
276
271
281
PLEASE NOTE: COMPLETION OF SHADED ROXFS IS OPTIONAL
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NEONATAL RECORD—SM R 1 1 (ABBREVIATED) FOR FU R T H E R  D ETA ILS SEE M ANUAL
N otes to r com oletion  o t th is torm .
This form  should be com pleted  fo r every new born infant discharged or transferred  from  hosp ita l.
T he to p  coov should be sen t in m onth ly  batches to  R oom  BO20. Info rm ation  and S ta tis tic s  Division, 
T rin ity  Park House, S ou th  T rin ity  Road, Edinburgh EH5 3SQ. The second copy m ay be sen t to  
th e  G eneral P ractitioner and the  back copy  may be retained  in th e  Hospital Case R ecords.
Use leaible block capitals. A fine tipped  ball p o in t pen should be used.
In those  instances w here th e  key to  th e  code is n o t given on the fo rm , you may w rite  com m en ts  
in th e  spaces provided in add ition  to  codinq.
The use o f separate  tem pera tu re  and w eight charts  will be necessary.
Item s w hich do  n o t have num bered  coding boxes will n o t be included on th e  co m p u te r record . 
S haded boxes need n o t be filled.
Administrative and Clinical Data — Codinq Instructions
General 1.
2.
3.
4.
5.
Instructions
1 H ospital of Birth
6 Case R eference No. )
)
16 M aternal R eference No. )
26 Surnam e
38 P ostcode
47 Paediatric C onsu ltan t or G.P.
55 S pecify Place
56 G estation
58 D ate o f Birth
64  A pgar Scores (a t 1 and 5 m inutes)
70 R esuscitation
71 Birth W eight
75 N um ber o f B irths th is  Pregnancy
76 Birth O rder
77 Sex
78 O .F.C .
90-91 T ransfers w ith in  hospital
92 N um ber o f days in SCBU
1 Jaund ice
2 Findings — A ny Age
T ransfer betw een 
H ospitals
Transfer 1 and 2 (if appropriate) 
117 Receiving H ospital Code No.
122 Case R eference No.
132 Paediatric C onsu ltan t o r GP.
139 D ate of Adm ission
145 A dm itted  to
146 N um ber of days in SCBU
180 C ondition
181 Discharge (Final)
182 W eight on D ischarge or Death
186 D ate of Discharge o r Death
192-246 Diagnosis
E nter the 5-dioit o fficial code
E nter a un iau e  num ber. All num bers should have a m inim um  of 
6  digits. Preceeding zeros should be en tered  to  m ake th e  num ber up  to  
6  digits, e.g. 12345 = | 0  | 1 | 2 | 3 | 4 | 5 | | | | |
E nter the cu rren t surnam e, starting  w ith  th e  left-hand box . A postrophes  and hyp h en s 
should  be placed in separate  boxes. Names con tain ing  m ore than  12 le tte rs  shou ld  be  
en tered  as fo llo w ,: | D | u | R ) H | A |m~| - | R | 0  | B | E | R | T S 0  N
E nter postcode if available.
E nter app rop ria te  7-dlglt code.
E nter ap p rop ria te  code.
E nter th e  num ber of w eeks (m in. = 20, m ax. =45). If n o t know n, e n te r  " 9 9 " .
E n ter a 6-digit da te , e.g. 010 1 8 2  fo r 1st Jan u ary  1982.
Each box m ust con ta in  a num ber In th e  range 0-9, w here " 0 "  m eans n o t done!
F or scores of 9 or 10 en te r code " 9 " .
If resuscitation  is In progress a t  1 o r 5 m inu tes, en te r 'R '.
E n ter ap p rop ria te  code.
E n ter th e  w eigh t in gram s, e.g. '0 9 8 0 ' (m in. = 0200 , m ax. = 7500 ). If n o t know n e n te r  9999 . 
E n ter in box 74 if th e  child w as a singleton (1), a tw in  (2) o r a tr ip le t (3).
E n ter in box 75 th e  o rd er th is  ch ild  w as bo rn , e.g. th e  second ch ild  b o rn  in trlp!ets= 2 
E n ter ap p rop ria te  code.
E n ter th e  m easu rem en t in cm .(p referab ly  m easured on tKird day o f life).
Min. = 10.0, m ax. = 49.9 . If n o t know n en te r  " 9 9 .9 " .
Enter ap p rop ria te  code. B oth boxes should  be com pleted .
N um ber o f days  = day  of discharge m inus day of adm ission to  SCBU.
E nter ap p rop ria te  code.
E n ter app rop ria te  code.
(i.e. discharge from  one hospita l and adm ission to  ano ther) F o r fu r th e r  de ta ils  see m anual.
E n ter the 5-digit code if know n. O therw ise w rite  nam e of hosp ita l.
E nter a u n ia u e  10-diait code. All num bers should  have a m in im um  of 
6 digits. Preceeding zeros shou ld  be en te red  to  m ake the n um ber u p  to  
6 digits, e.g. 12345 = | 0 | l  h h U M  1 1 1 1
252-256 O perations
260 Follow  up
271 Local O ption
List o f  Abbreviations.
E nter ap p ro p ria te  7-dlglt code.
E n ter a 6-digit da te  e.g. 070282  fo r 7 th  F ebruary  1982.
E n ter app rop ria te  code.
N um ber of days = day of discharge m inus day  of adm ission to  SCBU.
E n ter ap p rop ria te  code.
This applies to  discharge from  th e  neona tal service. E n ter ap p ro p ria te  code.
E n ter th e  w eight in grams, e.g. '0 9 8 0 ' (m in. = 0200, m ax. = 7500). If g reater than  9 9 9 8  gm. 
en te r 9998 . If n o t know n en te r  9999 .
E n ter a 6-digit da te  e.g. 090282  fo r 9 th  F ebruary  1982.
The first diagnosis. C lassification of in fan t, Single tw in , e tc ., m u s t be com pleted .
The codes to  be used are in the range V 30 to  V39 with.O  .1 and 2 used to  indicate 
place of b irth . The I -  I V I 3 I have been p rep rin ted  leaving th e  rem aining  tw o 
digits to  be filled in. The o th e r diaqnoses m ay be left blank b u t if filled  in should  
be coded to  th e  BPA supplem ent.
E n ter code in accordance w ith  th e  O ffice of P opu la tion  Censuses and  S urveys C ode o f O perations.
E n ter ap p rop ria te  code.
These boxes are fo r local use only.
Unused boxes should  be left blank.
EDD
IPPV
SCBU
E stim ated  date  o f delivery Cong. A bn.
lnte>Tnittent positive pressure ven tila tion  N/K
Special Care Babv U nit
C ongenital A bnorm ality  
N ot know n
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Scotland — In-patient and Day-case Records Summary Sheet SMR1 —  MEDICAL —  IN CONFIDENCE
HOSPITAL
TIME OF ADMISSION/TRANSFER WARD
(w a r d )
147-
148
PREVIOUSLY ATTENDED THIS HOSPITAL? 
IF YES STATE YEAR
YES/NO
ADDRESS
(A00F1)
150-
209
TEL. No. POSTCODE
RELIGION
NEXT OF KIN (RELATIONSHIP) 
NAME
ADDRESS
TEL. No. POSTCODE
FAMILY DOCTOR 
NAME
ADDRESS
TEL.No. POSTCODE
GP CODE (G>o
210-
216
PROVISIONAL DIAGNOSIS ON ADMISSION
HOSPITAL CODE <hosp) 
HOSPITAL CASE REFERENCE
No. (CRN)
SURNAME
(SN)
FIRST (FN1) 
FORENAME
SECOND (FN2) 
FORENAME
MAIDEN 
NAME (VN)
ALTERNATIVE CASE 
REFERENCE No. ( a c r n )
1-5
6-15
16-35
3650
51-65
6665
8695
AGE........................ DATE OF BIRTH (0 0 9 )
SEX (SEX) □
POSTCODE (PC) f
I 96_
| [ I 103
MARITAL I I 105
STATE (Mest) |___ |
106
112
ADMITTED7TRANSFERRED FROM ( a d tf )
DATE PLACED ON WAITING LIST (OWL) 
DATE OF ADMISSION (DOA)
DATE OF DISCHARGE (DOD)
TIME OF
DISCHARGE ......................................
□  ',3 TYPE OF 
ADMISSION (TADM) □
116
120
121-
126
127-
132
CATEGORY OF 
PATIENT (CAT) □
DISCHARGE 
CODE (Oise)
TYPE OF 
FACILITY (TOF)
□
□ 136
SPECIALTY (s p e c )
CONSULTANTS 
SURNAME 
(CONS)
137-
140
CONSULTANTS! 
INITIALS
161- CONSULTANT 
162 CODE (CONC)
141-
160
163-
169
TO BE COMPLETED BY DOCTOR ON DISCHARGE OF PATIENT
(1)
(2)
(3)
(4)
(5)
(6)
(1)
(2)
(3)
(4)
MAIN CONDITION (DG1)
OTHER CONDITIONS (DG2)
(DG3)
(DG4)
(DG5)
(DG6)
(DG1C)
(DG2C)
(DG3C)
(DG4C)
(DG5C)
(DGSC)
MAIN OPERATION (0P1)
OTHER OPERATIONS (OP2)
(OP3)
(OP 4)
(OP1C)
(OP2C)
(OP3C)
(OP4C)
166
67-
132
133-
198
67-
132
133-
198
69-
136
137-
204
DATE OF MAIN OPERATION (DCp i ) DATE OF MAIN OPERATION (d o p i)
ERROR REPORT COMMENT: Dnta Items specified In boxes be'ow nre correct (COM)
Enter field 
Abbreviations u u I u u
Additional notes:
LOCAL
USE (LUSE)
NATIONAL
USE (NUSF) 
75 -134
136
140
MI-
146
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KEY TO CODED ITEMS
FULL INSTRUCTIONS FOR COMPLETING THIS FORM ARE CONTAINED IN THE SMR1 M A N U A L
SEX (SEX)
1. M a le
2.  F e m a l e
8.  O t h e r  or  NK
M AR ITAL STATE (MRST)
1. N e v e r  Ma r r i ed  — S ing le
2.  Mar r i ed  — ( Inc l ude s  S e p a r a t e d )
3 .  W i d o w e d
8.  O t h e r  — ( Inc l ude s  Di vo rced )
9.  NK
ADMITTED/TRANSFERRED FROM (ADTF)
1. H o m e  -  Us ua l  A d d r e s s
2.  O t h e r  N . H . S .  Hos pi t a l  ( In -pa t i en t .  S h o r t  S t a y  nr  D a y
Bed  Faci l i t ies  only)
3 .  O t h e r  Unit  in Th is  Hos p i t a l  ( In - pa t i en t  Faci l i t i es  or
D a y  Be d  Uni t s  only)
8.  O t h e r
TYPE OF ADM ISSIO N (TADM )
0 .  D e f e r r e d  A d m i s s i o n
1. W a i t i n g  Li sh ' Di ar y / Booked
2.  R e p e a t  A d m i s s i o n s
3 .  T r a n s f e r
4 .  E m e r g e n c y  — D e l i be r a t e  Se l f  Inf l i c ted Injury or
P o i s o n i n g
5.  E m e r g e n c y  — R o a d  Traf f i c  A c c i d e n t
6.  E m e r g e n c y  — H o m e  A c c i d e n t  ( In c l ud e s  A c c i d e n t a l
P o i so n i ng  in t h e  H o m e )
7.  E m e r g e n c y  — O t h e r  Injury ( i nc l ud es  A c c i d e n t a l
P o i s o n i ng  o t h e r  t h a n  in t h e  H o m e)
8.  E m e r g e n c y  — O t h e r  ( e x c l u d e s  A c c i d e n t a l  Po i son i ng )
DISCHARGE CODE (DISC)
0 .  ' I r r egu la r '  — e g  Se l f  D i s c h a r g e
1.  H o m e
2.  C o n v a l e s c e n t  Hos pi t a l  or  H o m e
3 .  O t h e r  h os p i t a l
4 .  Local  A u t h o r i t y  Ca r e
5.  T r a n s f e r  t o  o t h e r  s p e c i a l t y  in s a m e  h os p i t a l
6 .  Died  (P.M.)
7.  Died  (No P.M. )
8 .  O t h e r
SPECIALTY (SPEC)
(Road deta i led  in s t ruc t ions  in manual)
01 General Surgery
0 2  O rth o p aed ic  Surgery
0 3  ENT Surgery
0 4  O p h th a lm o lo g y
0 5  Urology
0 6  N eu ro su rg e ry
0 7  Thorac ic  Surgery  (incl. C ard iac  Surgery)
0 8  Plastic  Surgery  (incl. Maxillo-Facial S u rgery  and 
Burns)
11 O r th o d o n t ic s  and  Paedia tric  D ent is try  
1 2 Oral Surgery  and  Oral Medicine  
16  Genera! Medicine 
1 7 Card io logy  
18 M etabolic  D isease  
1 9 N euro logy
21 G a s t ro en te ro lo g y
2 2  Poisons  Unit
2 3  D e rm ato lo g y
2 4  Nephro logy
2 5  R h e u m a to lo g y
2 6  Rehabilitation Medicine
2 8  Respira tory  Medicine  (incl. R esp ira to ry  T.B.)
31 C om m u n icab le  D iseases
3 2  VD (STD)
3 3  D iagnost ic  Radiology
3 4  R ad io the rapy  (consu lta t ive)
3 6  H o m e o p a th y
3 7  Medical O ncology
3 8  Spinal Paralysis
3 9  Surgical Paed ia tr ics
4 0  Medical Paed ia tr ics
41 Pain Control (A n aes th e t is t)
4 2  G ynaeco lo g y
4 6  Specia l /In tens ive  Care  Baby Unit
4 8  In tens ive  T h erap y  Unit
4 9  A cc iden t  and  E m ergency
5 0  Geriatric  A s s e s s m e n t
51 Geriatric  Long S ta y
5 2  Y oung Chronic Sick 
6 2  H a em a to lo g y
7 3  GP (other  th an  O bs te t r ic s)
7 6  A cu te  Mixed 
9 8  O ther  A cu te
CATEGORY OF PATIENT (CAT)
1. A m e n i t y
2.  P a y i ng
3.  NHS
7.  S pe c i a l  A r r a n g e m e n t s
TYPES OF FACILITY (TOF)
1. I n - pa t i en t  A d m i s s i o n
5.  5 D a y  W a r d
6.  D a y  Bed  Uni t
7 .  D a y  C a s e  I n -pa t i e n t  Faci l i t ies
8 .  D a y  C a s e  O t h e r
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Greater Glasgow Health Board
Health Visitor Child Health Record
-t nn-i
B NO.CHILD'S SURNAME
Bp^TH DATEFORENAMES
OF DELIVERS 
BIRTH "WEIGHT
ADDRESS
MOTHER'S D .O .B .
DISTRICTEL. NO.
CHANGE OF ADDRESS
GENERAL PRACTITIONER
GUTHRIE TEST DATE________________ RESULT
HEALTH VISITOR SCREEN/EXAM. HEARING TESTS
AGE DATE
10-14 WEEKS
18-24 MONTHS
36-42 MONTHS
IM M U N IS A T IO N  R E C O R D
Antigen Date Antigen Date Antigen Date
DTP/DT 1 II Polio 1 /  / MMR / /
2 I / 2 / / / /
3 / / 3 /  / /  /
B.C.G. /  / / / / /
C ontraindications to Im m unisation
APPENDIX 6 (cont.)
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Antenatal Care________________
Post Natal Condition/Complications
DELIVERY
Type-----------------
Complications  __
NEONATAL DATA
Birth Weight----------   Kg Discharge Weight_________ Kg _ Date of Discharge / /
Gestation ("completed weeks')
YES NO
Not
Known
Asphyxia (Apgar below 5 at 5 minutes)
Assisted respiration required after 30 minutes
Low birth weight ( < 2,500 g)
Convulsions (any cause)
Jaundice (serum bilirubin > 200 ( jx mol) / L or 12 mg/100 ml)
Tube feeding
Profound Hypotonia
Recurrent apnoea or lapses of consciousness
CONGENITAL ABNORMALITIES & HANDICAPPING CONDITIONS (these factors 
should also be recorded on the reverse side of the consent form)
Other conditions
Feeding___
Examination
Remarks and Advice____________________
Date of First Visit_______________ H.V. Sig.
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DEATHS OF INFANTS RESIDENT IN GGHB
SURNAME . . .  
1 s t  name(s) 
Address . .
P la c e .o f  death: 1 -  home; 2 -  h o sp ita l;  
3 -  nursing home; 4 -  other
Cause o f death (words)
1.
2 .
3.
V STILLBIRTH
Category o f death
1. <24 hours ...........
2 . 24 hours -  6 days . .
3 . 7 days -  27 days . . .
4 . N28 days <1 year . . .
Age at death .............
Father* s occupation,
No. b ir th s: s in g le to n  -  1 
twin -  2 
t r ip le t  -  3
P ost mortem: yes . . .
no . . .  
expected . . .
d.o.b, m u No.
□Sex 
Postcode
Place o f B irth
D ate .o f death
Place o f  death
Cause o f death
1.
2 .
3 .
4 .
C ongenital d e fe c t  
Category
G estation  .J 54 P a rity
Birthw eight (grams)
S o c ia l c la s s
No. o f b ir th s
a
Ch
] Di„ □
10
16
23
□xn
□
29
30
□
□
50
51 
52
□
□
56
60
61
62
S in g le  parent L .J fia maternal- age I— L— J65
G estation  c e r ta in ty  □  Prev. p regs. I.. .1-—J 68
liv in g  i n  69 Prev SBs □  Prev IDs □  71
C odes:- Sex: male ■ 1; female * 2
C ongenital d efect: yes ■» 1 , no ■ 2 
s in g le  parent: yes * 1, no « 2
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ALPHAFETOPROTEIN ASSAY REPORT
From: DUNCAN GUTHRIE INST. OF MEDICAL GENETICS, 
YORKHILL, GLASGOW G3 8SJ 
Tel: 041-339 8888 ext 393
Date Sample Taken Lab.Ref. No.
Surname:
Forename:
Address:
Weight: Kg. Height: m.
Date of Birth:
Hospital:
Address:
Hospital No. 
Clinic/Ward: 
Consultant:
Previous Serum A.F.P. Report Number 
L.M.P.
Previous History of Neural Tube Defect 
Complication of this Pregnancy 
Remarks
Weeks Gestation:
By Dates ExamB Ultrasound
Serum A.F.P. Result kU/l
Comments
A.F.P.
kU/l
Please amend graph if gestation is corrected after sampling. 
Screening Period 16-20 Weeks
RECOMMENDED ACTION ON FIRST 
SERUM AFP LEVEL:
> 2 0 0
1 9 0
ABOVE 95th CENTILE:
CHECK GESTATION BY ULTRA­
SOUND, EXCLUDE TWINS. 
THREATENED AND MISSED 
ABORTION, REPEAT 
SERUM AFP
1 4 5
.6^
X
X
------ INTERVENTION LEVEL
BETWEEN 90-95thCENTILE: 
VALIDATE GESTATION
1 0 0
X
v ^ + BELOW 90th CENTILE:
NO ACTION INDICATED 
IF GESTATION VALID
a n d  DOB c o r r e c t
7 5
4 5
s o * '* * 1"*
2 5
s o * * * 1"*
StbCENTU-E _______________ — -
0 .5 * median
Date
< 1 0
14 15 16 17 18 19 20
Completed Weeks of Pregnancy
21 22 Signature
C
en
tr
e
EU
RO
CA
T 
RE
PO
RT
 
on 
CO
N
G
EN
IT
A
L 
M
A
LF
O
RM
A
TI
O
N
S 
G
L
A
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O
W
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APPENDIX 10
ANENCEPHALY AND SPINA BIFIDA SCREENING 
(i) Trends in Pregnancy & Birth Prevalence
Trends in birth and pregnancy prevalence where modeled using poisson regression models. 
Details of the significance of the regression slope and fit of the models are given below.
Poisson Regression
The form of the poisson model is
log(expected pregnancies or births) = intercept+log(pregnancies at risk) +slope*/
where i = 1,..., 11 represents the years 76-86 
log = natural logarithm
ANENCEPHALY
Pregnancy Prevalence
Trend X2 = 8.68 ldf p < 0.005
Fit of Model X2 = 13.10 9df p > 0.1
Parameter Estimates
intercept
slope
-6.006
-0.059
ese 0.127 
ese 0.020
Birth Prevalence
Trend X2 = 44.42 ldf p< 0.0005
Fit of Model X2 = 15.72 9df p > 0.05
Parameter Estimates
intercept
slope
-6.345
-0.306
ese 0.218 
ese 0.052
ese = estimated standard error
\
SPINA BIFIDA
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Pregnancy Prevalence
Trend X2 = 3.78 ldf 0.075 > p > 0.05
Fit of Model X2 = 8.87 9df p > 0.4
Parameter Estimates
intercept -6.037 ese 0.124
slope -0.037 ese 0.019
Birth Prevalence
Trend X2 = 20.9 ldf p < 0.0005
Fit of Model X2 = 17.6 9df p < 0.05
Parameter Estimates
intercept -6.071 ese 0.142
slope -0.110 ese 0.024
This regression has a poor fit (p < 0.05) and was redone excluding 1981 as this appears to be an 
‘outlier’ (ie an unusual observation with high sensitivity & terminated when detected in that 
year). The details of this new regression are give below.
Trend X2 = 19.95 ldf p < 0.0005
Fit of Model X2 = 12.18 8df p > 0.1
Parameter Estimates
intercept -6.049 ese 0.140
slope -0.105 ese 0.024
With this year removed the curve fits the data better. This is the curve which is shown on the 
prevalence graph. Please note - whether or not 1981 is removed would make no difference to the 
fact that there is a significant decline in birth prevalence, since using all years p < 0.0005. The 
fitting of these models is purely to document the fact that there are significant trends within the 
data.
APPENDIX 10 (c o n t .)
(ii) Trends in Screening, Sensitivity and Terminations when Detected
Trends in screening, sensitivity and terminations when detected provide insights into the effec­
tiveness of the screening process since -
proportion terminated = proportion screened ^proportion detected when screened (sensitivity)
*proportion terminated when screened & detected
Changes in the proportion terminated could be due to one or any combination of these three 
factors. Trends over time where modeled individualy for these three factors using logistic re­
gression. The details of the significance and fit of the regression curves are given below.
Logistic Regression
The form of the logistic regression model is
log(p/(l-p)) = intercept + slope*/
where i= l,..., 11 represents the years 76-86 
log = natural logarithm
p = expected proportion of whatever outcome (ie proportion screened, proportion detected when 
screened... etc)
The slope parameter can be thought of as the log odds ratio between successive years for what­
ever outcome.
ANENCEPHALY 
Proportion Screened
Fitted without intercept.
Trend z-score = 8.5 p < 0.0001
Fit of model X2= 15.62 lOdf p > 0.1
Parameter Estimate 
slope 0.3564 ese 0.042
Proportion Detected when Screened (sensitivity)
Trend X2 = 6.61 ldf p < 0.025
Fit of model X2 = 13.29 9df p > 0.2
Parameter Estimates 
intercept 1.487
slope 0.338
ese 0.650 
ese 0.151
APPENDIX 10 (c o n t . )
Proportion Terminated when Screened & Detected
Trend 0.042 ldf p> 0.8
Model fitted as a constant term
Fit of model X2 = 8.876 lOdf p > 0.5
Parameter Estimate
constant 3.45 ese 0.414
SPINA BIFIDA 
Proportion Screened
Fitted without intercept 
Trend z-score = 6.45 p < 0.05
Fit of model X2 = 13.09 lOdf p > 0.2
Parameter Estimate
slope 0.144 ese 0.022
Proportion Detected when Screened (sensitivity) 
Fitted without intercept 
Trend z-score = 4.16 p < 0.05
Fit of model X2 = 14.16 10 df p > 0.15
Parameter Estimate
slope 0.097 ese 0.023
Proportion Terminated when Screened & Detected
Fitted without intercept.
Trend z-score = 6.03 p < 0.05
Fit of model X2 = 14.92 lOdf p > 0.1
Parameter Estimate
slope 0.239 ese 0.040
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minations
dness of fit X 2 = 11.02 7df p > 0.1
NA BIFIDA 
minations
idness of fit X 2 = 20. 04 8df p < 0.05
_s produces a poor fit for jspina bifida. If, however, 1981 is removed 
i n ew f i t i s
X 2 = 11.43 7df p > 0.1
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